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Cystic Fibrosis (CF) lung disease is characterised by dysfunctional innate 
immunity.  Even before microbial colonisation is established, there is an 
accumulation of neutrophils within the airways.  Neutrophil extracellular traps 
(NETs) are an evolutionarily conserved antimicrobial defence mechanism of 
neutrophils.  However, NETs can also cause inflammation and damage when 
in excess and as such are implicated in the pathogenesis of CF lung disease.  
Within the airways, NETs are a source of proinflammatory proteins including 
myeloperoxidase, neutrophil elastase and calprotectin.  Treatment of CF 
patients with DNase reduces airway inflammation and sputum viscosity, which 
may be due to the drug increasing clearance and/or decreasing the production 
of NETs.  Our group has previously found that NETs are proinflammatory to 
monocyte-derived macrophages (MDM) in co-culture, and that this was more 
exaggerated in CF MDM, so it is likely that an interplay between the innate 
immune cells exacerbate airway damage.  Several defects have been reported 
in CF MDM previously, which may exacerbate airway infection and 
inflammation.  One such reported defect is failure of the macrophage 
phagolysosome to acidify, which impairs bacterial killing and may lead to more 
bacteria surviving in the airway as a driver of inflammation.   
 
Throughout this PhD, sputum samples from both CF and healthy control (HC) 
participants were collected and lung function measured to investigate whether 
iii 
NETs are associated with airways inflammation and increased severity of lung 
disease.  Using ELISA quantification of NETs (by an in-house ELISA which 
measures histone-bound calprotectin) and proinflammatory cytokines, CF 
participants were found to produce higher levels of sputum NETs than HC.  
Those CF participants taking DNase had significantly decreased levels of 
sputum NETs relative to those not on the drug.  Furthermore, positive 
associations were found between NETs and proinflammatory proteins, whilst 
negative correlations were demonstrated between these proteins and lung 
function.  Furthermore, when forced expiratory volume in one second (FEV1) 
was predicted by multi-variate linear regression, the level of sputum NETs was 
a significant independent indicator of FEV1.   
 
A murine model of lipopolysaccharide (LPS)-induced acute lung injury was 
used to characterise how CFTR alters NET formation and associated 
inflammation following a sterile inflammatory challenge and whether DNase 
affected this.  It was demonstrated that CFTR-/- mice have an exaggerated 
inflammatory response to LPS-induced acute lung injury relative to wild type 
(WT) littermates in terms of airway proinflammatory cytokine concentrations 
and histopathological scoring of acute lung inflammation.  This was despite no 
acute increase in airway neutrophil or macrophage numbers, suggesting 
intrinsic defects exist within these innate immune cells due to absence of 
CFTR.  The receptor for advanced glycation end-products (RAGE) had higher 
gene expression in CFTR-/- vs WT littermates, which leads us to speculate that 
iii 
up-regulation of NF-κB signalling could be responsible for increased 
inflammation in CF mice.  Importantly, airway NETs were not significantly 
different between genotypes and DNase had no effect on inflammation, 
suggesting the CF murine model is imprecise in mimicking human disease.  
This is perhaps unsurprising given that people with CF have non-resolving 
airways inflammation, rather than an acute injury. 
 
Final experiments investigated the role of CFTR in regulating macrophage 
phagolysosomal pH.  Using MDM from both HC and CF donors, we developed 
a novel technique compatible with real-time analysis of phagocytosis, which 
showed that surface-enhanced Raman spectroscopy-based nanosensors 
exhibit superiority over conventional fluorescence spectroscopy in measuring 
macrophage phagolysosomal pH in terms of sensitivity, ratiometric 
quantification, and both spatial and temporal resolution. Human MDM 
phagolysosomal acidification was found to be CFTR-independent and may not 
be critical in the pathophysiology of CF lung disease, although further 
experiments using alveolar macrophages would strengthen these conclusions. 
 
To summarise, NETs are associated with inflammation and disease severity in 
human CF lung disease. Our mouse work suggested that intrinsic defects of 
innate immune cells exist in CFTR-/- mice, manifest by an exaggerated 
response to sterile inflammation, possibly via RAGE-NFκB signalling 
pathways.  We also demonstrated that macrophage phagolysosomal 
iii 
acidification was not impaired in human CF MDM.  Further research 
investigating the underlying mechanisms causing innate immune cell 
dysfunction will help identify therapeutic targets for the treatment of 




Cystic Fibrosis (CF) is a genetic disease causing absence or malfunction of 
CFTR protein.  This can adversely affect many body systems, including the 
lungs and white blood cells (such as neutrophils and macrophages, which deal 
with infection and inflammation).  Neutrophil extracellular traps (NETs) are 
made by and released from neutrophils into the space surrounding these cells, 
and consist of DNA and inflammatory proteins.  NETs help kill invading 
microorganisms such as bacteria.  However, they may also be inflammatory 
and damaging to the airways.  NETs may interact with macrophages in the 
airways of CF patients to worsen inflammation.   
 
Sputum samples from CF and healthy control (HC) participants were 
processed and lung function measured.  We found higher levels of NETs in CF 
airway samples compared to HC samples and this was associated with 
increased levels of damaging inflammatory mediators and decline in lung 
function.  Sputum NET levels, alongside other factors such as age and sex, 
could help predict lung function in CF participants.  We also studied CF mice 
and found they had more inflammation in their lungs compared to non-CF 
mice.  Airway NETs were not significantly different between CF and non-CF 
mice.  This does not match the human data but all of our CF participants were 
adults with established lung damage and so this might explain the difference 




I also assessed the effects of NETs on macrophages and showed them to 
increase inflammatory signals released by these cells.  In addition, I studied 
whether CF macrophages were able to acidify their phagolysosomes (their 
“stomachs”, within which invading bacteria are digested).  Contrary to what has 
been suggested in published literature, CF macrophage phagolysosomal 
acidification was normal.  This suggests the faulty bacterial killing by CF 
macrophages is due to some other abnormality in function. 
 
These findings have important implications for CF patients.  Further research 
will help to develop targeted anti-inflammatory therapies against NET 
proinflammatory proteins.  Ultimately, we aim to help discover new treatments 
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Chapter 1: Introduction 
1 
 
Chapter 1: Introduction 
 
1.1 Epidemiology of Cystic Fibrosis 
Cystic Fibrosis (CF) is an autosomal recessive genetic disease occurring in 
people of all racial and ethnic backgrounds but is most common in Caucasians 
of northern European ancestry. In 2017, there were 10469 people with CF in 
the UK(1).  The reported incidence in the UK is one in 2500 live births(1).  
Worldwide, there are approximately 70,000-100,000 people living with the 
disease(2).  Due to advances in therapy over the past 50 years, the UK’s 
median predicted survival has increased from five to 47 years of age and the 
median age of people with CF is now 20 years of age(1).  It is therefore 
becoming more common to have CF patients within adult Respiratory Medicine 
services.     
 
1.2 Medical History of Cystic Fibrosis  
The medical history of CF, and the professionals responsible for its 
characterisation, is a fascinating topic in its own right and is reviewed more 
fully by Paul M. Quinton(3).  A disease thought most likely to be CF was first 
alluded to in European folklore from the Middle Ages: “woe is the child who 
tastes salty from a kiss on the brow, for he is cursed, and soon must die”(4).  
Indeed, such children were believed to be “hexed”(3).  It was not until 1595 
that Pieter Pauw, professor of botany and anatomy in Leiden, The 
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Netherlands, performed an autopsy on an 11-year-old girl and described her 
“swollen, hardened, gleaming white pancreas”(3).  Later case reports 
throughout the 19th and early 20th century described the gastrointestinal 
complications of the disease but it was not until the 1936 that Fanconi et al. 
published a brief report of two children who were thought to have Coeliac 
syndrome associated with congenital “cystic pancreatic fibromatosis and 
bronchiectasis”(5).  However, it was Dr. Dorothy Hansine Andersen (see 
Figure 1.1), an American physician, who first described CF as a disease.   
(6) 
Figure 1.1: Dr. Dorothy Hansine Andersen (1901-1963), of Columbia 
University College of Physicians and Surgeons, first described Cystic Fibrosis 
as a disease.   
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Dr. Andersen graduated from John Hopkins University School of Medicine in 
1926 then completed a surgical internship at Strong Memorial Hospital in 
Rochester, New York.  However, she was denied entry to the hospital’s 
surgical residency programme because she was a woman.  She therefore took 
up a post at Columbia University College of Physicians and Surgeons as an 
instructor of Pathology.  In her seminal paper, Andersen described a series of 
49 paediatric autopsies, all of which revealed extensive lesions of the acinar 
tissue of the pancreas – which she termed “cystic fibrosis of the pancreas” - 
despite the neonates/children having presented with different clinical 
syndromes(7).  Her careful review of the case notes determined that 
subdivisions in clinical phenotypes existed, with some children presenting with 
nutritional disturbances whilst others had mainly infections of the respiratory 
tract.  In the paper’s closing discussion, Andersen stated: “I do not know the 
cause of this disease…all the 44 patients had pulmonary lesions which were 
primary in the bronchi, and many had bronchiectasis”(7).  Her concluding 
hypothesis was that the pancreatic pathology prevented fat absorption and 
hence children developed vitamin A deficiency (since it is a fat-soluble 
vitamin), which was responsible for the bronchiectasis and 
bronchopneumonia(7).  It was interesting to note a quote from one of the 
children’s mothers: “"Whatever my first baby had, this baby has too”(7).  
 
It took Andersen and her colleague Dr. Richard G. Hodges another eight years 
to publish evidence that supported this mother’s intuition.  In their paper of 
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1946, Andersen and Hodges concluded: “Cystic fibrosis of the pancreas 
occurs among siblings, twins and more distant relatives with a distribution 
which is compatible with the hypothesis that it is carried as a relatively 
infrequent hereditary trait”(8).  In August 1948, a heat wave struck New York 
and several of Andersen’s patients developed vomiting as a result.  Those with 
cystic fibrosis of the pancreas had a quick response to medical treatment but 
the return of plasma chlorides to normal levels was more gradual compared to 
children with other conditions(9).  This observation prompted one of  
Andersen’s colleagues – Dr. Paul di Sant’Agnese – to discover the abnormal 
electrolyte composition of sweat in patients with cystic fibrosis of the 
pancreas(10).  This ultimately led to the development of the chloride sweat 
test, which remains to this day a key diagnostic test for CF(11). 
 
1.3 The genetic mutations responsible for Cystic Fibrosis 
Another 36 years of scientific endeavour resulted in the gene responsible for 
CF being successfully cloned and located to the long arm of chromosome 7.  
In 1989, Kerem et al. published their findings in Science, followed shortly after 
by confirmatory studies by other groups(3,12).  The gene within which 
mutations reside was named the Cystic Fibrosis Transmembrane conductance 
Regulator gene (CFTR).  Whilst there are now over 2000 known CFTR 
mutations known to cause CF, approximately 70% of those in Northern 
European CF patients are caused by the F508del mutation(1).  This is 
characterised by the specific deletion of three base pairs, with resultant loss of 
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a phenylalanine residue at amino acid position 508 of the resultant CFTR 
protein.  Indeed, this mutation accounts for 84.5-89.8% mutations in the UK 
CF cohort(1).   
CFTR Mutation Percentage of total mutations in the UK CF cohort 
(range indicating the different percentages by 
devolved nations)  
G542x 3.1 -7.2 
G551D 4.7 – 10.6 
R117H 3.0 – 13.8 
621+1G->T 1.4 – 11.2 
Table 1.1: The most common CFTR mutations in the UK Cystic Fibrosis 
population.  Modified from (1). 
 
Genotypes vary in frequency by devolved nation within the UK (see Table 1.1) 
and indeed vary geographically throughout Europe.  Looking at the wider CF 
population, Farrell et al. performed genetic analysis of 190 European CF 
patients and their parents to determine the age and origin of the F508del 
mutation.  Their age estimates put the mutation at 4600-4725 years old in 
northwestern populations and 1000 years old in southeastern populations(13).  
The authors propose that the ancient migrations of the early Bronze age 
people, known as the Bell Beaker folk (who were characterised by their 
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production and use of ceramic bell-shaped beakers, innovative metallurgy and 
great migrations(14)) were responsible for the mutation’s dissemination from 
northwest to southeast in prehistoric Europe(13). 
 
1.4 CFTR mutation classifications and the CFTR protein   
The CFTR genotype – whilst not necessarily predicting disease phenotype - 
has become clinically very important due to the development of drug therapies, 
such as Orkambi, which is indicated only in CF patients ≥ two years of age 
who are homozygous for the F508del mutation.  Mutations in the CFTR gene 
result in abnormalities in the CFTR protein.  This protein is an adenosine 
triphosphate (ATP)-binding cassette (ABC) transporter(15) (see Figure 1.2).  
Such ABC proteins hydrolyse ATP to generate energy, which drives the 
transport of substrates against a concentration gradient.  In the case of CFTR, 
it is a transmembrane ion channel responsible for the transport of chloride and 
bicarbonate ions across membranes.  It is expressed on the apical surface of 
airway, intestinal and exocrine epithelial cells where it functions to secrete 
chloride and bicarbonate into the lumens(16) and may regulate reabsorption 
of sodium ions and water molecules by the epithelial sodium channel (ENaC), 
although the latter point is contested within existing literature(17,18).   
 
More recently, immune cells have been shown to express CFTR messenger 
RNA (mRNA) at low levels(19) and express functional CFTR protein both 
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intracellularly(20) and at the cell membrane(21).  The protein’s expression 
varies between cell types, e.g. there is increased expression of CFTR on 
airway epithelial cells (AEC) compared to neutrophils.  With regard to CFTR 
activity, Plasschaert et al. described a novel cell type – the pulmonary ionocyte 
– as a major source of CFTR activity in the human airway(22).  They used 
single cell RNA sequencing to profile subpopulations of both human bronchial 
epithelial cells and mouse tracheal epithelial cells.  In doing so, they described 
the ionocyte, which accounted for 1-2% of airway epithelial cells.  These cells 
strongly co-expressed FOXI1, multiple subunits of vacuolar ATPase (see 
Chapter 5, section 5.9 for a description of this enzyme) and CFTR(22).  They 
conducted Ussing chamber experiments and cell-type quantification in human 
bronchial epithelial cell cultures derived from seven human donors to 
demonstrate that CFTR activity had a significant positive correlation with 
ionocyte but not ciliated cell number.  The authors suggested that ionocytes 
may have a role in airway luminal pH regulation, which could be of importance 
in the context of CF lung disease(22).   
 




Figure 1.2: Schematic representation of the structure of the Cystic 
fibrosis Transmembrane Conductance Regulator (CFTR) protein.  CFTR 
is a transmembrane protein, generating energy via the hydrolysis of adenosine 
triphosphate to transport chloride and bicarbonate ions via a membrane 
channel against concentration gradients.  
 
The CFTR protein has varying dysfunctions, depending upon the type of 
mutation affecting the gene.  Classification of these mutations in the CFTR 
gene results in six broad groups (see Table 1.2).  However, this is an over-
simplification of a complex process.  For example, some F508del mutations 
result in misfolded CFTR proteins, which are not degraded by the cells and so 
do reach the membrane.  However, once within the membrane, their misfolding 
causes a gating defect. 
 







Effect on CFTR Protein 
I: Often introduce 
premature stop 
codons, which are 
non-sense mutations 
G542x Resultant mRNA is truncated 
and unstable and usually results 
in non-functional CFTR. 
II: Base pair 
deletions 
F508del Results in abnormal folding of 
the CFTR protein, preventing 
efficient trafficking to the apical 
membrane because the cell 
recognises it as faulty and so 
degrades it. 
III: Gating mutations, 
the main target of 
ivacaftor drug 
treatment 
G551D CFTR protein is structurally 
normal but fails to open 
effectively such that ions do not 
have time to pass through.  
IV: As per III and 
include conductance 
and (some) gating 
defects 
R117H CFTR is structurally normal but 
inefficient ion transport occurs. 
V: Intron mutations 
affecting splicing 
A445E Reduced amount of CFTR is 
present on the cell membrane, 




432delTC CFTR is unstable with a 
decreased half-life and so there 
is a reduction in functional 
protein present at the 
membrane. 
Table 1.2: Classification of CFTR genotypes, example mutations and 
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1.5 The Clinical Manifestations of Cystic Fibrosis 
Mutations described in the last section result in CFTR protein dysfunction, 
reduction or absence, which underpin the pathophysiology of CF.  Due to the 
protein’s expression on epithelial cells and immune cells, CF is a multi-organ 
disease with varying phenotypes noted between patients, as was illustrated in 
Andersen’s original paper(7).  The morbidity and mortality related to CF 
principally relates to the chronic airway inflammation and infection, which 
causes respiratory failure, and will be the focus of this thesis.  However, other 
systems (e.g. the gastrointestinal, endocrine and reproductive systems) are 
also affected and this causes several modes of presentation that have 
important clinical implications (although precise pathophysiological 
mechanisms are out with the scope of this thesis).  Paediatric and adult CF 
patients have different modes of presentation.  Data in the UK CF Registry 
Annual report 2017 demonstrates that only 26.7% patients were diagnosed via 
the newborn screening programme; this is likely to be an historical anomaly, 
since newborn screening was only rolled out throughout the UK in 2007.  Of 
the remaining patients, 6308 were diagnosed with CF under the age of 16 (i.e. 
87%) whilst 848 were diagnosed once over the age of 16 (i.e. 11.7%)(1).  The 
most common mode of presentation in both adults and children is persistent 
or acute respiratory infection.  Thereafter, in the paediatric population, patients 
often present with features of pancreatic exocrine insufficiency such as failure 
to thrive/malnutrition and steatorrhea/malabsorption.  Neonates often present 
with meconium ileus (i.e. small bowel obstruction caused by thicker-than-
normal meconium).  In the adult cohort, the gastrointestinal manifestations are 
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not as common in the modes of presentation.  Instead, patients may present 
with a positive family history, genotyping, nasal polyps, bronchiectasis and 
infertility, as illustrated in Figure 1.3.  Other clinical manifestations of CF 
include cirrhosis of the liver and portal hypertension and pancreatic endocrine 
insufficiency causing CF-related diabetes (CFRD).  
 
Figure 1.3: Mode of presentation of Cystic Fibrosis patients ≥ 16 years of age, 
adapted from the UK CF Registry’s Annual Report 2017(1).  Adult patients most 
commonly present with persistent or acute respiratory infection (58.1%), followed by 
genotyping (19.5%), family history (15.9%), nasal polyps (8.5%), 
steatorrhea/malabsorption (6.5%), unknown (6.3%), bronchiectasis (4.6%), 
malnutrition (3.2%), infertility (2.5%), pancreatitis (0.9%), electrolyte imbalance (0.7%) 
and meconium ileus (0.6%).  Patients may present with one or more of these 
manifestations of CF.  These data illustrate that CF is a multi-organ disease and due 
to the rarity of the disease, clinicians need to have a high index of suspicion when 
reviewing a patient presenting with such features. 
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1.6 Cystic Fibrosis Lung Disease 
Not only is lung disease the most commonly occurring mode of presentation 
of CF but it also causes the most morbidity and mortality, with 85% of deaths 
being attributable to respiratory complications(24).  Chronic inflammation and 
infection ultimately leads to respiratory failure and one third of CF patients on 
the transplant list die whilst awaiting transplantation(25).  The CF lung has 
dysfunctional immunity exacerbated by chronic bacterial infection.  In infants 
with CF, Staphylococcus aureus (S.aureus) and Haemophilus influenzae 
(H.influenzae) are the most common infections(1).  Patients then accrue 
further chronic microbial infections with increasing age (e.g. with 
Pseudomonas aeruginosa (P.aeruginosa), Burkholderia cepacia (B.cepacia) 
and Aspergillus fumigatus (A.fumigatus)).  Failure to resolve these microbial 
infections is due to multiple abnormalities within the CF lung environment 
caused by absence, reduction or dysfunction of CFTR protein.   
 
The pathophysiology of CF lung disease is therefore multi-factorial.  In recent 
years, the CF pig model has been used to study CF lung disease because 
unlike CF mice, CF pigs develop spontaneous post-natal lung disease, 
mimicking human disease.  Studies have shown that foetal lung development 
is abnormal in CF pigs(26).  CFTR is thought to be responsible for anion 
transport/liquid secretion during branching morphogenesis of the proximal 
airways and so CF airways have smaller, hypo-distended lumens compared to 
non-CF airways(26).  Furthermore, submucosal gland functioning is impaired 
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(they do not release the mucous strands effectively in the CF pig model(27)) 
which may contribute to the mucous burden seen in paediatric patients’ 
airways, evident even before infection has occurred(28).   
 
The AEC are also dysfunctional in CF lung disease.  AEC provide a physical 
barrier against pathogens, regulate transport of ions that maintain airway 
hydration and are central in the innate immune response to pathogens(29).  
The cell membranes of AEC contain pattern recognition receptors (PRR), 
including the toll-like receptors (TLR), which recognise microbial pathogen-
associated molecular patterns (PAMPs, e.g. LPS) and “self” damage-
associated molecular patterns (DAMPs), which include nucleic acids.  Through 
these constitutively expressed PRR, AEC can respond to numerous 
pathogens by producing proinflammatory cytokines including IL-6, IL-8 and 
IFN-β(29).  In CF, AEC produce excessive amounts of these cytokines, 
especially IL-8, which is a neutrophil chemokine(30).  This contributes to the 
excessive accumulation of neutrophils within the CF airways (see section 1.9).   
 
In addition to their key role in innate immunity, AEC together with submucosal 
glands produce the airway surface liquid (ASL).  ASL comprises an upper 
mucous layer – within which microorganisms, cellular debris and foreign 
materials are trapped – and a lower periciliary liquid layer, which bathes the 
AEC cilia and lubricates their beating movements(25,29).  The cilia beat to 
move the mucous layer upwards and out of the airways – this is termed the 
mucociliary clearance escalator - ultimately moving unwanted material towards 
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the pharynx for elimination from the airway via either expectoration or 
swallowing into the gastrointestinal system.  In addition to this physical removal 
of pathogens, the ASL also contains antimicrobial peptides (e.g. lactoferrin, 
LL-37 and the human β-defensins) and antiproteases (e.g. alpha 1 anti-trypsin 
and secretory leucoprotease inhibitor) which function to sequester and 
degrade microorganisms(29).  However, in the CF lung, degranulation of 
neutrophils releases excessive amounts of the serine protease neutrophil 
elastase (NE), which cleaves and inactivates these antimicrobial peptides and 
antiproteases, contributing to the dysfunctional immune response.  
Furthermore, in CF lung disease, the ASL is dehydrated and acidic, which 
impairs bacterial killing and clearance and contributes to mucopurulent 
secretions(31).  The reduced pH of the ASL is thought to be due to loss of 
CFTR, which reduces bicarbonate secretion and hence hydrogen ions 
secreted by the non-gastric hydrogen/potassium ATP12A are not buffered(32).  
The fact that ATP12A is expressed at low levels in the mouse airways may be 
why they do not develop spontaneous, post-natal lung disease(32).  Indeed, 
ATP12A expression in CF mouse airways acidified the ASL, impaired host 
defenses and increased bacteria within the airways, conversely inhibition of 
ATP12A in the CF pig model abrogated host defence abnormalities(32).  The 
acidic ASL has been demonstrated in vitro in cultured human CF airway 
epithelial cells(33), in the CF pig model(34), and in a study measuring the nasal 
ASL pH in infants with CF(35).  Moreover, the recently described pulmonary 
ionocyte (described in section 1.4) may play an important role in ASL pH 
regulation(22).   
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Finally, inflammation is present in the CF airways shortly after birth and before 
microbial infection occurs(21,36,37).  Sly et al. reported a study of  127 infants 
diagnosed with CF by newborn screening in which they used chest computed 
tomography and bronchoalveolar lavage (BAL) assays to monitor clinically 
stable children up until 3 years of age(38).  In doing so, they found that BAL 
NE activity at 3 months of age was associated with persistent bronchiectasis 
at both 12 months and 3 years of age(38).  This suggests that a dysfunctional 
innate immune response involving neutrophils is key to the inflammation seen 
in CF lung disease.  The roles of neutrophils and macrophages within the 
context of both health and CF lung disease will be discussed in detail in 
sections 1.7-1.15.   
 
Whilst neutrophils predominate within the airway lumens of CF patients, there 
is evidence to show that the adaptive immune system also plays a role in CF 
lung disease.  Endobronchial biopsies performed on children with CF and 
healthy controls show that subepithelial bronchial mucosa has a lymphocytic 
infiltration (comprising mainly CD3+ T lymphocytes) in CF patients, the 
numbers of which were increased in patients with P.aeruginosa colonisation 
and during exacerbations(39).  There is also cross talk between the innate and 
adaptive immune systems.  For example, Th17 lymphocytes are CD4+ T cells 
that secrete IL-17 cytokines(40) in response to stimulation by IL-23, IL-6 and 
TGF-β from innate immune cells.  IL-17 is elevated in BAL and sputum of CF 
patients(40), especially when colonised with P.aeruginosa.  This cytokine 
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activates innate immune cells, stimulates antimicrobial peptide production by 
epithelial cells, and recruits neutrophils and so exacerbates CF lung 
pathology(41).   
 
1.7 The role of the neutrophil in health 
Despite there being emerging evidence that the adaptive immune system 
plays an important role in CF, it remains a disease characterised by neutrophil-
dominant airways inflammation.  Neutrophils account for 80% of the total cells 
present in CF sputum, even when patients are clinically stable(42).  In order to 
understand this phenomenon, exploration of physiological neutrophil function 
and homeostasis mechanisms is first required.   
 
Neutrophils form in the bone marrow from granulocyte/macrophage precursor 
cells and are released into the circulation once terminally differentiated, 
accounting for 40-60% peripheral blood leucocytes in humans(43).  In health, 
they have a relatively short half-life, on average six to eight hours(44).  
Recruitment of neutrophils from the bloodstream into the lungs increases in 
response to inflammation/infection.  Neutrophil recruitment consists of three 
stages: 1) adherence to activated endothelial cells and subsequent rolling 
under vascular flow; 2) neutrophils arrest and firm attachment to the 
endothelial cells; and 3) migration across the endothelium to the 
inflamed/infected airways(45).  The first step relies upon the interaction 
between the glycoprotein P-selectin glycoprotein ligand-1 (PSGL-1) and P-
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selectin/E-selectin expressed on the plasma membrane of activated 
endothelial cells(46).  Firm attachment is then achieved by the interaction 
between β2-integrins and up-regulated endothelial cell-surface adhesion 
molecules such as intercellular adhesion molecule 1 (ICAM-1)(47).  The final 
migratory stage is dependent upon several factors including cytokine 
production (i.e. cell signalling proteins such as IL-8 and TNF-α) and the 
production of chemokines (i.e. cell signalling proteins released by cytokine-
activated endothelial, epithelial and immune cells to stimulate directed cellular 
chemotaxis).  The release of such cytokines, chemokines, and presence of 
microbial products such as lipopolysaccharide (LPS, present on the outer 
membrane of gram-negative bacteria) primes recruited neutrophils.  That is, 
they have an enhanced response to activating stimuli due to an upregulation 
in enzymatic and transcriptional processes that results in activation and 
production of proinflammatory mediators and enzymes that regulate 
downstream phenotypic and functional alterations(48).  Primed neutrophils 
have altered shape and a more rigid cytoskeleton, which serve to trap them in 
the capillary microvasculature of the inflamed lung tissue (49).   
 
Once at a site of inflammation and/or infection, such as the CF lung 
environment, a neutrophil is a key effector cell in the innate immune response.  
Neutrophils express PRR, including the TLR, which recognise PAMPs and 
DAMPs.  Through these constitutively expressed PRR, neutrophils can 
respond to numerous pathogens by employing their antimicrobial defence 
mechanisms.   
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Neutrophils’ antimicrobial defence repertoire consists of phagocytosis, 
degranulation, generation of reactive oxygen species (ROS), and NET 
formation(50).  Phagocytosis is the process whereby the neutrophils uptake 
microbes, foreign material and cellular debris to degrade them safely within 
designated organelles called phagolysosomes.  Neutrophils contain 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, an enzyme 
that generates superoxide (O2-), which acts as a precursor of hydrogen 
peroxide (H2O2).  This hydrogen peroxide is used by myeloperoxidase (MPO) 
to produce other oxidants such as hypochlorous acid, which are highly 
microbiocidal(51).  Most of these reactions occur within 
phagosomes/phagolysosomes containing microbes, but ROS can also be 
released by neutrophils and act as signalling molecules, which drive 
inflammation.  Degranulation results in release of granule contents including 
NE, which alongside degrading microbial structures, also damages lung 
parenchyma if not held in check by protease inhibitors such as alpha-1 anti-
trypsin.  NET formation, the final antimicrobial defence mechanism of 
neutrophils, will be discussed independent of the others in section 1.8.   
 
To maintain appropriate neutrophil numbers in tissues, they undergo cell death 
once they have deployed their antimicrobial defence mechanisms.  After 
neutrophils have died, they are cleared from sites of inflammation and infection 
by phagocytes, or are lost from the body after trans-epithelial migration into 
fluids such as sputum(43).    Neutrophil death occurs via the processes of 
apoptosis, necrosis, necroptosis, autophagy and NETosis.  Apoptosis, derived 
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from the Greek “apo” for separation and “ptosis” for falling off, was a term used 
to describe leaves falling from a tree(52).  It is a term adopted by the field of 
cell biology to describe programmed cell death and reminds us that death is 
an essential part of healthy life.  Apoptosis is tightly regulated and neutrophils 
“shut down” their cytotoxic machinery but maintain cell membrane integrity to 
avoid release of harmful contents into the tissues.  Such apoptotic neutrophils 
have altered morphology(53), including cytoplasmic vacuolation, retention of 
membrane integrity (particularly plasma membrane), changes in membrane 
phospholipid (i.e. exposure of phosphatidylserine), nuclear degradation, 
especially due to the activation of endonucleases, which catalyse 
intranucleasomal DNA cleavage.  The nuclear changes also include 
condensation of chromatin, which results in the characteristic appearance of 
nuclei of apoptotic cells.  Activation of caspases (especially caspase 3) is also 
a feature of apoptosis, which performs proteolysis of cell proteins such as 
actin.  Apoptotic bodies may occasionally form, i.e. small membrane-bound 
vesicles released by the dying cell(52).  These apoptotic bodies are taken up 
by nearby phagocytes including macrophages, and this is protective and is a 
critical step in resolution of inflammation and infection(54).  Necrosis, on the 
other hand, is an unprogrammed and chaotic form of cell death resulting from 
inflammatory insults including infection, which can release the cells’ toxic 
contents, which act as DAMPs, into the site of infection.  It is characterised by 
cytoplasmic swelling, disorganisation of organelles, ruptured plasma 
membrane, and nuclear lysis(55).  Necroptosis is a programmed form of 
necrosis characterised by rapid plasma membrane permeabilisation and 
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release of DAMPs into the extracellular environment(56).  It is therefore a 
proinflammatory form of cell death.  Autophagy is a cell death process 
employed by cells under excessive stress(57).  Autophagic neutrophils display 
vacuolation of their cytoplasm (autophagosome formation), degradation of 
organelles within autophagosomes, and lack the chromatin condensation step 
that is typical for apoptotic cells.  Autophagic neutrophils are phagocytosed by 
neighbouring innate immune cells and so autophagy is a non-inflammatory 
form of cell death(58).   
 
1.8 NET formation  
NETosis, first described by Brinkmann et al. in 2004, is a distinct form of cell 
death, which results in the production of neutrophil extracellular traps (NETs).  
NETs are extracellular, web-like structures composed of decondensed 
deoxyribonucleic acid (DNA), histones and an array of proinflammatory 
cytosolic and granule proteins including NE, MPO, LL-37 and 
calprotectin(59,60).  Once within the extracellular space, NETs function to 
ensnare and degrade microbes.  Due to these key antimicrobial effects, NETs 
have been conserved throughout evolution.  For example, extracellular trap 
formation has been shown to be critical for encapsulation of microbes by 
haemocytes of the invertebrate shore crab Carcinus maenas(61), the 
extracellular traps of which contain histone 2A and peroxinectin, the 
crustacean homologue of MPO(61), and NETs (or equivalent) have been 
described in fish(62), chickens(63), dogs(64) and pigs(25).  Studies in humans 
have also demonstrated NETs to be antimicrobial(65).   
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The cellular mechanisms understood to be involved in PMA- or bacteria-
induced NET formation are summarised in Figure 1.4 and involve NADPH 
oxidase 2 (NOX2)-dependent mechanisms.   
 
 










Figure 1.4: Neutrophil extracellular trap (NET) production via the NADPH oxidase 2 (NOX2)-dependent mechanisms(66).  
Neutrophils undergo NET formation when triggered by microbial (bacterial, viral and fungal), inflammatory (e.g. IL-8, TNF-α) and 
sterile endogenous triggers (e.g. platelets and monosodium urate crystals)(66).  When these ligands bind their respective 
receptors on neutrophils, it triggers increased calcium release from the endoplasmic reticulum, which activates Protein Kinase 
C (PKC).  This leads to activation of NAPDH oxidase on both the cell membrane and lysosomes, forming O2-, which reacts with 
chloride and water to form hypochlorite.  This activates peptidyl arginine deiminase 4 (PAD4) which translocates to the nucleus 
where it catalyses hypercitrullination of histones 3 and 4(67).  This causes the histones to lose their positive charge, weakening 
their binding to negatively charged DNA, leading to decondensation of chromatin.  NOX-2-mediates release of neutrophil 
elastase (NE) and myeloperoxidase (MPO) from azurophilic granules, which function as co-factors for decondensation of 
chromatin.  The neutrophil’s plasma membrane loses integrity then decondensed chromatin and histones are expelled into the 
extracellular space where they form complexes with granule and cytoplasmic proteins such as MPO (= pink ovals), NE (= purple 
squares), lactoferrin (= red triangles) and calprotectin (=green squares).  Recent research suggests that NETs are an end 
product of numerous, independent cell signalling pathways, not all of which require all of the above steps(68).   




However, since the original description of NETosis, mounting evidence 
suggests that neutrophils may also release NETS in vivo without cell death in 
a process called “vital” NETosis, which may involves the release of 
mitochondrial DNA(69) and this does not require the presence of citrullinated 
histones on the DNA backbone(70).  Indeed, authors of a recently published 
consensus document advise that the term “NETosis” only be used in situations 
where death of the neutrophil is obvious and “NET formation” should otherwise 
be the preferred terminology(71).   
 
NET formation is triggered by bacterial, fungal and viral infections, 
inflammatory mediators including IL-8 and TNF-α, and sterile endogenous 
triggers such as sodium urate crystals and platelets(66).  In NOX-2-dependent 
NET formation, NE and MPO were shown to be essential co-factors for the 
decondensation of chromatin but evidence now shows that NET formation can 
be independent of NOX-2 and MPO(68).  Furthermore, there now exists a 
debate about whether peptidyl arginine deiminase 4 (PAD4) is essential for 
NET formation.  PAD4 is an enzyme that translocates to the nucleus and 
catalyses hypercitrullination of histones, which results in the loss of positive 
charge of histones and consequently decondensation of chromatin.  
Pharmacological PAD4 inhibition and PAD4 knock-out mouse model 
experiments have suggested that this enzyme is critical for NET formation(72–
74).  Conversely, more recent investigations reveal that NET formation can 
occur independent of PAD4 in response to microbes such as Candida albicans 




and Group B streptococcus(68).  We can conclude that a diverse range of cell 
signalling pathways ultimately result in NET formation.   
 
Moreover, there are emerging links between autophagy and NET 
formation(75,76).  Remijsen et al. used wortmannin (a phosphatidylinositol 3-
kinase (PI3K) inhibitor often used to inhibit autophagy) to inhibit PMA-induced 
NET formation in human neutrophils(75).  Similarly, synovial fluid neutrophils 
from gout patients did not produce NETs ex vivo when phagolysosomal fusion 
was inhibited, implicating autophagy in NET formation(77).  However, 
treatment with late-autophagy inhibitors such as Bafilomycin A1 and 
chloroquine had no impact on NET formation(78) and so whether a relationship 
exists between the two pathways remains equivocal.   
 
 
1.9 Neutrophil homeostasis is dysregulated in CF lung disease 
In CF lung disease, neutrophils accumulate within the airways from an early 
stage, before infection has occurred.  Impaired apoptosis may contribute to 
neutrophil accumulation(79,80) and our group has recently shown that CF 
neutrophils survive longer due to delayed apoptosis and this is associated with 
the absence of CFTR function and results in enhanced NET formation(70).  
Furthermore, this apoptosis delay is reversed in patients treated with ivacaftor 
(a CFTR potentiator drug), which alludes to CFTR’s key role in apoptosis 
pathways(70).  Our group’s previous in vitro studies demonstrated that NETs 
are proinflammatory to macrophages, causing the release of proinflammatory 




cytokines and chemokines including IL-8 and TNF-α(70).  Within the CF 
airways, chemokine release would recruit more neutrophils and so a cycle of 
inflammation ensues, summarised in Figure 1.5.  Indeed, infants diagnosed 
with CF at newborn screening or with early modes of presentation such as 
meconium ileus have increasing levels of IL-8 in their BAL fluid with increasing 
age, despite there being no bacterial infection or impairment in their lung 
function(81).  The inflammatory response heightens once bacterial infection 
occurs.  For reasons that will be discussed in sections 1.10, 1.11 and 1.15, the 
host inflammatory response is unable to eradicate such infections and this 
leads to persistent release of proinflammatory mediators, chemoattractants 
and recruitment of more neutrophils and macrophages(82).    
  






Figure 1.5:  Cystic Fibrosis (CF) lung disease is characterised by a cycle 
of inflammation, in which innate immune cells play a key role.  
Inflammation occurs in CF infants before bacterial infection has occurred.  
Neutrophils and macrophages release proinflammatory mediators, which 
cause destruction of lung tissue and impaired mucociliary clearance within the 
airways.  This leads to accumulation of DNA – much of which is NET-derived 
– and protease release.  This contributes to the viscosity of lung secretions 
and so mucous plugs form.  These are ineffectively cleared, contributing to 
microbial colonisation/infection, which further drives this vicious cycle of 









1.10 Intrinsic defects exist within CF neutrophils 
Not only do neutrophils excessively accumulate in the CF airway environment 
but also their function is abnormal due to CFTR dysfunction.  The 
aforementioned antimicrobial defence mechanisms of degranulation, 
phagocytosis, ROS generation and NET formation are all abnormal in the 
context of CFTR dysfunction.  Previous studies have confirmed CFTR 
expression within neutrophils.  For example, Painter et al. used reverse 
transcriptase-polymerase chain reaction (RT-PCR), immunofluorescence 
staining, and immunoblotting to demonstrate low level expression of CFTR in 
neutrophils at both mRNA and protein levels, with CFTR protein expression on 
secretory vesicles and phagolysosomes(83).  This suggests CFTR could have 
multiple roles in neutrophil function.  For example, CFTR is responsible for ion 
exchange between the cytoplasm and phagolysosome.  CF neutrophils have 
impaired transport of chloride into the phagolysosome from the cytoplasm and 
accordingly have increased cytosolic concentrations of sodium and chloride 
ions and reduced chloride concentrations in their phagolysosome(83).  This 
has two detrimental effects to neutrophil function.  Firstly, the formation of 
hypochlorite (a potent microbiocidal ROS formed from hydrogen peroxide and 
chloride) within the phagolysosome is impaired due to a reduction in chloride 
availability(84).  Secondly, the increased cytosolic sodium and chloride 
concentrations decreases cytosolic pH, which leads to excessive 
degranulation of azurophilic granules, thus increasing the release of 
antimicrobial enzymes such as peroxidases (e.g. MPO), proteases (e.g. NE) 
and antimicrobial peptides (e.g. calprotectin)(85).  The resulting high 




extracellular levels of NE overwhelms the binding capacity of the anti-protease 
alpha-1 antitrypsin(86), and degradation of elastin within lung parenchyma 
contributes to lung destruction and bronchiectasis seen in CF(38).  Pohl et al. 
also demonstrated that human CF peripheral blood neutrophils have abnormal 
cytosolic ion concentrations that result in the inactivation of Rab27a, an 
intracellular protein involved in granule trafficking.  This led to impaired 
degranulation of secondary and tertiary neutrophil granules with resultant 
impaired bacterial killing(87).  Treatment of CF patients with the G551D CFTR 
mutation with the ion channel potentiator Ivacaftor abrogated these defects in 
CF neutrophils(87).  
 
Whether CFTR dysfunction directly causes abnormalities in NET formation 
remains to be determined.  Gray et al. showed that aged CF neutrophils have 
higher levels of NET formation compared to HC neutrophils(70).  Whilst this 
observation does not implicate CFTR directly in regulation of NET formation 
pathways, it demonstrates that CF neutrophils form more NETs compared to 
HC neutrophils, which was abrogated by blocking apoptosis(70), suggesting 
an indirect mechanism linking CFTR to NET formation.  Akong-Moore et al. 
performed in vitro experiments stimulating neutrophils with PMA to induce NET 
formation in the presence and absence of chloride in the culture media.  They 
found NET formation was significantly decreased in the absence of 
extracellular chloride(88), which may be of relevance in the context of CF.  The 
potential role of CFTR in NET formation certainly merits further investigation. 
 




1.11 NETs are an ineffective antimicrobial defence mechanism within 
CF airways 
Within the context of CF, non-resolving neutrophilic inflammation has negative 
consequences for patients’ respiratory systems.  In spite of there being high 
numbers of neutrophils present in their airways, patients suffer recurrent lower 
respiratory tract infections and colonisation with organisms such as S.aureus, 
P.aeruginosa and A.fumigatus as defence mechanisms are overwhelmed.  It 
has been demonstrated that NETs are an ineffective defence against bacteria 
in CF airways.  For example, laboratory strains and CF clinical isolates of 
P.aeruginosa strongly trigger NET release(89), however P.aeruginosa isolates 
from patients with established airways colonisation acquire resistance against 
NETs(90,91).  Furthermore, Fuchs et al. showed that only 25% of neutrophils 
form NETs to kill S.aureus in vitro; the majority of bacterial killing was by 
phagocytosis(92).  NET formation appears better suited to tackling large 
microbes, such as fungal hyphae, which are too large to be phagocytosed(93).  
In line with this suggestion, Marcos et al. found NETs in airway samples of CF 
patients were associated with fungal colonisation with A.fumigatus but not with 
bacterial infection(94).  Furthermore, a recent study elegantly showed that 
NETs are crucial in preventing central nervous system dissemination of 
P.aeruginosa bacterial keratitis in a mouse model of acute keratitis(95).  Thus, 
NETs are likely to be bacteriostatic rather than bactericidal.  With these studies 
in mind, we hypothesise that in the context of CF, NETs play only a minor 
antimicrobial role, as despite the presence of large numbers of activated 




neutrophils and extracellular DNA in their airways, patients suffer microbial 
colonisation and recurrent infections.   
 
This introduces the concept of NETs acting as the Jekyll and Hyde of 
immunity(66).  In lower order species, NETs ensnare and kill microbes(61) but 
in higher order species, due to the presence of an adaptive immune system, 
NET constituents may function as auto-antigens and so drive autoimmune 
disease. 
 
1.12 NETs contribute to autoimmune disease and sterile inflammation 
There are a number of diseases characterised by NET-mediated sterile 
inflammation including Systemic Lupus Erythematosus (SLE), psoriasis, small 
vessel vasculitis, rheumatoid arthritis, gout, venous thrombosis and 
cardiovascular disease(96–100).  The autoantibodies present in autoimmune 
diseases target NET-bound proteins, which act as auto-antigens, e.g. anti-
MPO, anti-Proteinase 3, extractable nuclear antibodies (ENA), anti-nuclear 
antibodies (ANA) and anti-dsDNA antibodies.  The autoantibodies bind to their 
respective auto-antigen and form immune complexes that are pathogenic.  
Hakkim et al. demonstrated that serum endonuclease DNase1 is critical for 
degradation of NETs in the sera of SLE patients(97).  A sub-set of their patient 
cohort had impaired NET degradation, due to either the presence of DNase1 
inhibitors in their sera or anti-NET antibodies, which prevented the enzyme’s 
access to the NETs.  These patients suffered renal impairment secondary to 
resultant lupus nephritis(97).  Similarly, during the pathophysiology of 




atherosclerosis, NETs activate macrophages to release proinflammatory 
cytokines which interact with the adaptive innate immune system by activating 
T helper 17 cells, driving further immune cell recruitment and exacerbating 
inflammation(100).  In the context of venous thrombosis, NETs act as a third 
scaffold of the blood clot, alongside fibrin and von Willebrand Factor(99).  In 
psoriasis, an autoimmune skin condition, NET formation is increased in 
peripheral blood and the skin plaques and correlates with disease severity(98).  
Intact NETs were shown to induce human β-defensin-2 production by plaque 
keratinocytes, partly explaining the decreased susceptibility of psoriasis 
plaques to microbial infections.  However, the fact that NET levels correlate 
with disease severity suggests that they are also a driver of inflammation.   
 
1.13 The pathophysiological role of NETs in Cystic Fibrosis 
In view of this evidence that NETs are involved in the pathophysiology of 
autoimmune and sterile inflammatory diseases, it is likely that NETs are an 
important proinflammatory component in the CF airway, where inflammation is 
driven by chronic infection.  Higher levels of free DNA are present in BAL 
samples of CF patients compared to healthy controls(101).  Originally, it was 
thought this DNA was derived from apoptotic and necrotic cell debris.  
However, more recent studies have suggested most DNA present in the 
airways arises from NETs, levels of which are increased in airway samples 
from CF patients compared to healthy controls and are associated with poorer 
lung function(94,102).  However, these studies used the PicoGreen® assay as 
a measure of NETs, which only measures dsDNA and so may not be specific 




for NETs(103).  In order to quantify NETs in vitro, a recent expert review article 
recommended that assays demonstrate co-localisation between the DNA 
backbone alongside constituent proteins(103).  Numerous studies have 
previously focussed only on NET proteins in isolation and although indirect, 
these studies still add to the evidence that NETs are proinflammatory.   
 
1.14 NET constituent proteins are associated with lung injury and 
inflammation 
Histones 
Chromatin is a complex of negatively charged DNA wound around positively 
charged histones that functions to efficiently package DNA within the nuclei of 
eukaryotic cells.  This means that when the chromatin unravels in the process 
of NET formation (see Figure 1.4) histones are extruded into the extracellular 
space along with the nuclear DNA.  Indeed, histones are the most abundant 
NET protein.  In a study where neutrophils were stimulated to form NETs using 
PMA, resultant NETs were digested then analysed by nano-scale liquid 
chromatography coupled matrix-assisted laser desorption/ionization mass 
spectrometry (nano LC-MALDI-MS); histones H2A, H2B and H3 together 
accounted for ~ 64% total NET protein content(104).  Histones have been 
studied extensively in the context of acute lung injury in mice(105–108) in 
which their positive charge binds to and disrupts the phosphodiester bonds 
within cell membranes, thus causing toxic calcium influx(105).  They also bind 
TLR-2 and TLR-4 and induce proinflammatory cytokine production in 
macrophages(107).  Histone sub-types - H1, H2A, H2B, H3 - have defined 




effects upon murine and human phagocytes; they can lead to cell swelling, 
lactate dehydrogenase release, cytokine and chemokine release to varying 
degrees(107).  Interestingly, the treatment of mice with DNase has been 
shown to reduce citrullinated H3 levels in BAL fluid and protect from LPS-




NE is another key NET constituent, accounting for 5.8% total NET protein 
content(104) in PMA-induced NETs, and implicated in the pathophysiology of 
CF.  It is an azurophilic granule protein, which functions in an antimicrobial 
capacity to degrade phagocytosed proteins.  It can also be released into the 
extracellular space in the process of degranulation and as an adverse effect 
within the airways, NE degrades protein structures including elastin and 
collagen(109).  It is found in high concentrations in CF sputum and BAL 
samples and levels correlate with lung function decline in CF(38,85).  Dubois 
and co-workers demonstrated that in vitro DNase treatment of NETs 
significantly increased NE activity(102).  They concluded that negatively 
charged DNA binds to cationic NE and protects it from inhibition by anti-
proteases in the lungs. This interaction likely contributes to the protease-anti-
protease imbalance seen in CF lung disease, which leads to parenchymal 
destruction.  These findings suggest that combining protease inhibitors with 
DNA-degrading treatments may represent an effective therapeutic strategy for 
preventing lung damage.  





MPO, a peroxidase enzyme involved in innate immune responses, is another 
NET constituent protein used as a biomarker in CF.  MPO helps degrade 
phagocytosed material within lysosomes and is released from azurophilic 
granules into the extracellular space during neutrophil degranulation.  This 
enzyme is also an essential mediator of PMA- and some bacterial-induced 
NET formation(110).  Serum MPO levels decrease significantly during 
antibiotic treatment of a CF lung exacerbation(111).  Elevated sputum MPO 
levels are associated with increased mortality in CF patients infected with 
B.cepacia complex(112) and are associated with albumin/g sputum (a 
measure of protein leakage into the airways) and radiographic evidence of lung 
damage, as well as reduced lung function in CF patients(113).  However, this 
has not been a consistent finding in all studies.   Gray et al. did not find a 
significant reduction in sputum MPO levels following antibiotic treatment of a 
CF exacerbation(114), possibly because baseline levels are high due to the 
chronic airway neutrophilia.   Calprotectin may be a more sensitive biomarker 
of CF lung disease, because its levels did significantly fall in sputum following 
treatment of an exacerbation(114).       
 
Calprotectin 
Calprotectin is a neutrophil cytosolic protein (accounting for 40-60% of the 
cytoplasmic protein load(115) and 5% total protein load(116)), incorporated 
onto NETs during NET formation.  It is a heterodimer formed from S100A8 and 
S100A9, which account for 4% and 1.41% total NET protein content, 




respectively(104).  S100A8 was identified as a protein abnormally elevated in 
the serum from CF homozygotes and obligate heterozygotes in 1982 by 
Bullock et al. using quantitative immunoprecipitation and immunoradiometric 
assays(117).  Following on from this discovery of the “CF antigen”, its gene 
was cloned and located to chromosome 1 by Dorin et al. in 1987(118), 
although its involvement in the pathophysiology of CF was unknown.  Since 
then, calprotectin has been studied extensively and is associated with 
inflammatory and infectious diseases, including inflammatory bowel disease 
and arthritis.  It has numerous functions including chelation of micronutrient 
metals like zinc and manganese, which limits their availability to microbes in a 
process called nutritional immunity(119).  Calprotectin on NETs has been 
shown to be crucial as an anti-fungal defence in mice(104).  It also induces 
apoptosis(120) and promotes chemotaxis of neutrophils and macrophages to 
sites of inflammation(121).  In addition, calprotectin acts as a TLR-4 agonist,  
contributing to proinflammatory cytokine production through NF-κB 
activation(122).  Our group has also studied calprotectin in the context of CF 
lung disease.  Gray et al. previously demonstrated that it could be used as a 
biomarker for CF(114).  Both sputum and serum calprotectin levels 
significantly decrease following treatment of an exacerbation, and serum 
calprotectin levels were negatively correlated with forced expiratory volume in 
one second (FEV1) (a measure of patient lung function) and predicted time to 
next exacerbation(114,123).   
 




In summary, histones, NE, MPO and calprotectin are all found to be associated 
with NETs, cause inflammation and correlate with lung function decline in CF.  
Free DNA has similarly been shown to correlate with airflow obstruction in 
CF(94).  The available evidence therefore suggests that NETs are critically 
involved in the pathophysiology of CF, although the precise mechanisms 
require further elucidation.  Mutation of the CFTR causes abnormal function of 
innate immune system cells, including decreased apoptosis that may 
contribute to excessive production and/or impaired clearance of NETs. 
 
1.15 Intrinsic defects also exist within CF macrophages  
NETotic and apoptotic neutrophils are cleared from the airways partly by 
phagocytosis by macrophages - the professional phagocytes of the innate 
immune system, integral to an effective antimicrobial response.  Macrophages 
clear dead cells, microorganisms and foreign material from the airways.  In 
common with neutrophils, macrophages express PRR that recognise microbial 
PAMPs and self-DAMPs (e.g. NETs).  In addition, macrophages initiate the 
inflammatory response through production of cytokines, ROS and 
antimicrobial peptides, to target microbes and resolve inflammation(124).  
Hence, exposure of macrophages to NETs may amplify proinflammatory 
responses and tissue damage caused directly by the accumulated neutrophils. 
 
Macrophages specialise in the phagocytosis of pathogens and dead cell 
debris.  The ultrastructure of these cells is beautifully adapted to such a role, 
with a cytoskeleton that rapidly alters its structure to permit efficient 




chemotaxis.  Macrophages express PRR, complement Fc, and scavenger 
receptors, which aid phagocytosis of target material(124).  Ligation and 
activation of these receptors results in intracellular signalling cascades 
involving PI3Ks and phospholipase C(125), which lead to actin cytoskeletal 
reorganisation and alteration of the plasma membrane to permit engulfment of 
the target material into assembled phagosomes.  These membrane-bound 
organelles in turn fuse with lysosomes (i.e. another type of membrane bound 
organelle containing degradative enzymes) to form a phagolysosome which 
has an acidic environment, with a pH of around 4.5-5.0 at full 
maturity(126,127). The phagolysosome functions to break down ingested 
substances via the activity of lysosomal enzymes together with proton-pump 
acidification.  The mechanisms by which phagolysosomes are acidified are 
described more fully in Chapter 5.   
 
Numerous intrinsic abnormalities of the CF macrophage have been reported 
in the literature.  Recent work by our group demonstrated that when human 
monocyte-derived macrophages (MDM) were co-cultured with NETs and 
control neutrophils, NETs induced an exaggerated proinflammatory response 
from the MDM and this effect was enhanced in CF MDM(70).  Associations 
between human alveolar macrophage numbers and airway proinflammatory 
cytokine levels have been shown to exist, adding support to the hypothesis 
that CF macrophages have an exaggerated response to inflammatory 
stimuli(128).  Indeed, the macrolide antibiotic Azithromycin functions in an 
immunomodulatory capacity to reduce proinflammatory cytokine production 




from alveolar macrophages and is known to reduce pulmonary exacerbation 
rates and promote weight gain in CF(129,130).   In the context of 
atherosclerosis, circulating CD14-purified monocytes have been shown to 
increase IL-1β and IL-6 production when pre-treated with NETs prior to culture 
with cholesterol crystals(100).  This effect was abrogated with DNase 
treatment, suggesting DNA is crucial for the proinflammatory response(100).  
In newborn CF pigs, CF macrophages also have a hyper-responsive 
phenotype, which is independent of the inflammatory milieu of the CF lung 
(since lung inflammation is not present in the newborn animals)(131).  Ex vivo 
experiments using MDM from newborn CF pigs demonstrate that CF MDM 
produce more IL-8 and TNF-α compared to WT MDM in response to LPS(21).  
 
The MDM hyper-responsiveness to LPS seen in the CF pig model may be due 
to aberrant trafficking of its PRR, TLR-4.  Bruscia et al. demonstrated that CF 
murine macrophages have prolonged TLR-4 retention in the early endosome 
and reduced translocation into the lysosomal compartment.  Consequently, 
TLR-4 had reduced degradation and so more remained available on the 
plasma membrane.  When stimulated with LPS, murine CF macrophages had 
increased activation of the NF-κB, MAPK, and IFN regulatory factor-3 
pathways and hence increased proinflammatory cytokine production(132), 
including IL-8, which acts as potent chemokine for neutrophils.  CFTR 
inhibition of murine WT macrophages resulted in similar hyper-responsive 
phenotype.  This demonstrates that CFTR plays a key role in spatial and 
temporal resolution of TLR-4. 




As well as this exaggerated response to PAMPs and DAMPs, CFTR 
dysfunction may adversely affect macrophage phagocytosis.  This is both in 
terms of the cells’ ability to uptake bacteria(124,133) and in the degradation of 
internalised microbes.  In a recent ex vivo study, Barnaby et al. demonstrated 
that the CFTR modulator Lumacaftor (which increases export of F508del 
CFTR from the endoplasmic reticulum to the plasma membrane) restored the 
ability of CF MDM to phagocytose and kill P. aeruginosa to levels seen in non-
CF MDM(134).  This suggests CFTR plays a key role in macrophage 
phagocytosis pathways, although precise mechanisms of action are unknown.  
Furthermore, CFTR function may contribute to the regulation of macrophage 
organelle acidification.  The debate surrounding this topic is described more 
fully in Chapter 5.  Some groups have reported failure of phagolysosomal 
acidification in CF macrophages which led to impaired bacterial killing of the 
pathogenic organism P.aeruginosa, although this was contended by 
others(20,135).  Discrepancies in reported results may relate to potential 
insensitivity of fluorescence microscopy techniques used to quantify 
phagolysosomal pH. 
 
Lastly, recruitment of monocytes into the inflamed lung environment may be 
compromised in CF due to intrinsic defects in mononuclear cells.  The 
chemoattractant-induced activation of β1 and β2-integrins and subsequent 
chemotaxis (via Rho family GTPases) is defective in human CF mononuclear 
cells(136).  This abnormality was reproduced when healthy mononuclear cells 
were treated a pharmacological inhibitor of CFTR (CFTR-inh172).  Moreover, 




when CF monocytes were treated with CFTR-correcting drugs, integrin 
functionality was restored(136).  Hisert et al. studied peripheral blood 
monocytes from CF patients commencing treatment with the CFTR potentiator 
ivacaftor.  They measured the plasma membrane proteome and found that 
proteins involved in the inflammatory response and monocyte migration were 
altered significantly by 7 days’ ivacaftor treatment, perhaps due to decreased 
IFN-ɣ responses(137).  These studies suggest that the non-resolving 
neutrophilia of CF lung disease may be in part due to failure of mononuclear 
cell recruitment, which would help resolve the inflammation. 
   
1.15 Anti-inflammatory treatments for Cystic Fibrosis lung disease 
Despite the unrelenting neutrophilic inflammation of the airways in CF lung 
disease, there remains no effective, targeted anti-inflammatory treatment for 
CF.  The drugs that do have anti-inflammatory actions such as Azithromycin 
exert these as additional, off-target effects or with unknown mechanisms of 
action.  Non-resolving inflammation, including NET formation represents a key 
response to chronic microbial infection, preventing microbial dissemination. 
Treating inflammation in CF lung disease is therefore likely to require a balance 
between maintaining host defence and preventing excessive inflammation.  
For example, a randomised double-blind, placebo-controlled phase 2 trial of 
an LTB4 receptor antagonist in adults and children with CF had to be 
terminated early after interim analysis revealed significant increases in 
pulmonary related serious adverse events in the adult cohort(138).  LTB4 is 
produced by macrophages and neutrophils and is a potent chemoattractant 




and activator of neutrophils(139).  In the group receiving the LTB4 antagonist 
drug, there were significant increases in respiratory symptoms necessitating 
intravenous antibiotics and hospitalisation, as well as impaired lung function 
and increased peripheral blood neutrophil counts(139).  These data suggest 
that reducing neutrophil recruitment and activation actually worsened 
inflammation and so any inhibition of host defence mechanisms must be 
measured to avoid unintentional harm to patients.  Given the evidence that an 
excessive innate immune response is key to the pathophysiology of CF, it is 
likely that moderated immunomodulation would be of benefit to most patients.   
  






Figure 1.6:  Anti-inflammatory treatments targeting the causes of 
inflammation that lead to damage in Cystic Fibrosis lung disease.  
Clinicians prescribe only a handful of anti-inflammatory medications in CF, 
shown in blue text.  Anti-inflammatory drugs include ibuprofen and 
Azithromycin, which modulate innate immune cell functions.  Nebulised 
recombinant human DNase targets the excessive DNA within the airways to 
reduce sputum viscosity.  Hypertonic saline similarly reduces sputum viscosity.  
Antibiotics are prescribed to target colonisation and recurrent infections.  
CFTR potentiators and correctors are also emerging as modulators of immune 
cell function.   
 
Anti-inflammatory Medications 
With regard to anti-inflammatory medications, inhaled and oral corticosteroids 
are indicated in CF patients only if they suffer from asthma or Allergic 
Bronchopulmonary Aspergillosis (ABPA)(140).  Non-steroidal anti-




inflammatory drugs (NSAIDs) have also been evaluated in the context of CF.  
A Cochrane review reports three trials studying the effects of ibuprofen in 
CF(141).  One of those, by Konstan et al., demonstrated that patients assigned 
to four years’ treatment with high-dose ibuprofen had a slower annual rate of 
change in FEV1 and weight(142).  These effects were greatest when ibuprofen 
was started in paediatric patients(141).  It is therefore recommended that in 
patients with CF six years of age and older, and with FEV1 > 60% predicted, 
oral ibuprofen is used to slow lung function decline.  However, the bleeding 
diathesis may limit ibuprofen’s use. 
 
Recombinant Human DNase 
DNase I is a human enzyme present in the blood, saliva, pancreatic secretions 
and urine, which functions to digest extracellular DNA(143).  Recombinant 
human DNase (Pulmozyme®, known generically as dornase alfa) is classed as 
a mucoactive agent and as such, is offered to patients with evidence of lung 
disease(144).  It functions to degrade the excessive DNA that accumulates in 
CF sputum, reducing sputum viscosity and aiding clearance(140).  It improves 
lung function in both paediatric and adult CF patients(145–147).  In a 
randomised placebo-controlled trial, Fuchs et al. demonstrated that the 
administration of once or twice daily rhDNase improved FEV1 over the 24 
weeks’ follow up by an average of 5.8% and 5.6%, respectively(146).  This 
was a statistically significant improvement in lung function as compared to the 
placebo group, whose FEV1 remained static.  Furthermore, rhDNase improved 
quality of life in terms of reduced dyspnoea and improved overall well-




being(146).  In addition to slowing the rate of lung function decline(148), the 
BEAT study demonstrated that rhDNase has direct anti-inflammatory effects.  
In this placebo-controlled study, which followed patients over three years after 
initiation of treatment, those untreated had significant increases in BAL median 
neutrophil percentage, IL-8 and elastase levels, whereas those treated with 
DNase did not(149).  Furthermore, a sub-study showed that the matrix 
metalloproteinases 8 and 9 (MMP-8 and -9), enzymes implicated in lung tissue 
destruction in CF, had increased levels in the untreated group but decreased 
levels in the rhDNase treated group(150).  With these anti-inflammatory 
actions in mind, we hypothesise that DNase may reduce inflammation in CF 
through decreased NET formation or increased degradation of NETs.  If this 
were to be the case, there could be an argument for commencing DNase 
treatment at an earlier stage of disease. 
 
Nebulised Hypertonic Saline 
Nebulised hypertonic saline is another mucoactive drug treatment indicated in 
CF lung disease.  It improves hydration of the ASL to improve airway 
clearance(151).  Studies have shown that hypertonic saline treatment 
improves lung function and reduce exacerbation rates, but not to the same 
extent as rhDNase(140).  If patients cannot tolerate rhDNase due to side 
effects, hypertonic saline can be prescribed as a monotherapy.  Similarly, 
these two mucoactive drugs can be given in combination in patients who have 
an inadequate response to rhDNase alone.  Antibiotics 




When CF patients experience lower respiratory tract infections, treatment is 
with antibiotics as per local formulary guidelines.  However, there is also a role 
in prescribing antibiotics for the prevention of infection.  In some regions, 
paediatric patients receive prophylactic Flucloxacillin to protect against 
S.aureus infection from the point of diagnosis up to the age of 3 or 6(144).  In 
patients newly infected with P.aeruginosa, eradication is attempted by 
treatment with at least two oral/IV antibiotics coupled with an inhaled antibiotic, 
followed by a prolonged course of oral an  inhaled antibiotics(144).  However, 
if patients are chronically infected with P.aeruginosa, the first-line inhaled 
antibiotic is Colistimethate sodium, a polymyxin antibiotic, which degrades the 
bacterial cell membrane(144) (polymyxin is also used in vitro as an LPS 
blocker because it binds LPS).  If this is ineffective, inhaled Tobramycin is 
indicated in patients over the age of 6 years who are symptomatic or with mild 
lung disease(140).  Tobramycin is an aminoglycoside antibiotic, which inhibits 
bacterial protein synthesis through binding their cytoplasmic ribosomes(152).  
This treatment reduces exacerbation rates and improves pulmonary 
function(140,153–155).   
 
Azithromycin 
Another antibiotic used in CF is Azithromycin, a macrolide antibiotic which has 
been shown to improve lung function and reduce exacerbation rates in 
patients(140).  It is indicated in patients with deteriorating lung function or 
repeated pulmonary exacerbations who are chronically infected with 
P.aeruginosa(144).  It reduces mucin secretion and biofilm formation by 




P.aeruginosa and increases the bacterium’s susceptibility to other 
antibiotics(156).  Of relevance to this PhD, Azithromycin also has marked 
immunomodulatory mechanisms of action.  It works to inhibit the acute phase 
of the innate immune response, by reducing proinflammatory cytokine 
production from neutrophils, macrophages and AEC, thereby reducing 
recruitment of immune cells to the inflamed lung environment(129,157–159).  
It also acts upon the resolution stages of the immune response, by increasing 
neutrophil apoptosis and reducing neutrophil oxidative burst(160).  
Azithromycin might decrease NET formation in CF airways, perhaps indirectly 
by increasing apoptosis rates, a question that will be addressed in Chapter 3, 
section 3.3.       
 
CFTR Modulators 
Finally, we will review the role of the recently introduced CFTR modulators 
because abnormalities in immune cell function are reversed with ivacaftor 
treatment (see sections 1.8, 1.9 and 1.10).  Ivacaftor (trade name, Kalydeco) 
was the first precision medicine available on the NHS for CF patients.  It is 
indicated in those with at least one gating mutation in the CFTR gene (e.g. 
G551D), which accounts for ~ 5% UK CF patients(1).  Ivacaftor is a CFTR 
potentiator because it increases the open probability of the CFTR channel (i.e. 
the fraction of time the channel is open, to aid ion transport)(161).  Treatment 
with this drug significantly improves lung function, with median FEV1pp 
increasing from 55.4 to 64.1%(1).  Ivacaftor was shown to decrease 
significantly CF patient sputum inflammatory measures from the first week of 




treatment and this effect is maintained over two years’ follow up(162).  
Furthermore, chest CT scan studies before and one year after commencement 
of ivacaftor revealed that the drug decreased airway mucous plugging(162).  
Taken together, these findings suggest CFTR function is indeed related to 
airways inflammation.   
 
Orkambi was the second precision medicine available in the UK and it is a 
combination therapy made up of ivacaftor and lumacaftor.  Lumacaftor is a 
CFTR corrector, which increases export of F508del CFTR from the 
endoplasmic reticulum to the plasma membrane(134).  It is indicated in 
patients with at least one F508del mutation, accounting for half of the UK’s CF 
population(1), but the cost of the drug currently precludes its prescription, 
asides apart from on compassionate use.  The TRAFFIC and TRANSPORT 
studies report that lumacaftor/ivacaftor improved FEV1 and reduced 
exacerbation rates in patients with CF homozygous for the F508del CFTR 
mutation(163).   
 
Moreover, Symkevi is another combination therapy consisting of ivacaftor and 
tezacaftor (the latter functioning like lumacaftor to move CFTR to the cell 
membrane) but is only licensed in patients ≥12 years of age.  This combination 
drug has been evaluated in the recently published EVOLVE and EXPAND 
studies.  The EVOLVE study, was a phase 3, randomised, double-blind, 
multicenter, placebo-controlled, parallel-group trial which studied tezacaftor 
and ivacaftor combination therapy for CF patients ≥ 12 years of age and 




homozygous for F508del mutation.  It demonstrated a statistically significant 
absolute change in the FEV1pp of 4 percentage points in favour of the 
tezacaftor-ivacaftor over placebo and exacerbation rates were 35% lower in 
the treatment group(164).  The EXPAND study evaluated tezacaftor-ivacaftor 
in CF patients with one F508del and one (out of a possible 14) residual function 
mutation.  It found a significant absolute improvement in FEV1pp of 6.8% in the 
treatment group compared with the placebo(165).  This drug was given 
marketing authorisation by the European Medicines Agency in November 2018 
and is now available in Scotland and soon to be available in England.    
 
Finally, several next generation correctors have been trialed(166,167).  One 
such corrector, VX-659 combined with tezacaftor and ivacaftor (VX-659-
tezacaftor-ivacaftor) was shown to improve CF508del protein processing and 
trafficking and restore chloride transport in human bronchial epithelial cells in 
vitro(166).  When trialed in CF patients with one or two F508del alleles, VX-
659-tezacaftor-ivacaftor resulted in a significant mean increases in the 
percentage predicted FEV1 at 29 days’ follow up of up to 13.3% in patients with 
F508del-minimal function genotypes(166).  In patients homozygous for 
F508del already on tezacaftor-ivacaftor, adding VX-659 resulted in a further 
9.7% increase in percentage predicted FEV1(166).    VX-445-tezacaftor-
ivacaftor treatment resulted in an 11-point increase in the percentage of 
predicted FEV1 and improved quality of life in CF patients(167). These studies’ 
conclusions are immensely exciting finding because triple combination 
correction-potentiation regimens could be indicated in 90% CF patients.   




To summarise, CFTR modulators offer an exciting new group of drugs, which 
are likely to revolutionise the treatment of patients with CF.  Emerging evidence 
highlights positive effects on neutrophil, macrophage and monocyte 
functioning and suggest that these drugs have important anti-inflammatory 
actions.  For example,   Pohl et al. demonstrated that human CF peripheral 
blood neutrophils have inactivation of Rab27a, a granule trafficking protein.  
This inactivation led to impaired degranulation with resultant impaired bacterial 
killing(87).  Treatment of CF patients with the G551D CFTR mutation with 
ivacaftor corrected this defect in CF neutrophils(87). Furthermore, our group 
found that ivacaftor treatment corrected the propensity for human CF 
neutrophils to live longer due to delayed apoptosis(70).  Abnormalities in CF 
peripheral blood monocyte protein expression are also restored by ivacaftor 
treatment, e.g. proteins affecting cell migration were increased and those 
involved in inflammation, including S100A9, were decreased(137).  Future 
studies should focus on underlying mechanisms by which correction and 
potentiation of CFTR abrogates dysfunctional innate immune cells.     
 
1.16 Summary 
Innate immune cells play a vital role in the regulation of inflammation and 
infection.  If unregulated, the functions of neutrophils and macrophages may 
become pathogenic, particularly in the context of the CF lung.  The underlying 
mechanisms through which CFTR function affects NET formation and 
macrophage function require further investigation.  Despite there being 
advances in CF therapy over the past 50 years, the median age of death of 




UK CF patients is still only 31 years of age.  Therefore, there is a real clinical 
need to design new anti-inflammatory drugs for CF to prevent the respiratory 
failure that causes premature death.  A better understanding of the intrinsic 
defects of the CF innate immune cells and their interactions with one another 
will contribute towards this ultimate goal.   
 
  




1.18 Hypotheses and Aims 
 
The overarching hypothesis for the project was that NETs are central to 
inflammation and play only a minor antimicrobial role in CF lung disease.  We 
also hypothesise that DNase therapy may reduce inflammation in CF through 
decreased production and/or increased clearance of airway NETs.  We predict 
that CF macrophages will have a hyper-responsive phenotype in response to 
NETs in vitro and that CF NETs are hyper-inflammatory.  We also set out to 
study a NET-independent defect in CF macrophages; we hypothesised that 
there would be a difference in macrophage phagolysosomal pH between CF 
and non-CF cells. 
 
The principal aim of this PhD is to understand better the innate immune cell 
dysfunction in the context of Cystic Fibrosis airways disease.  Specifically, the 
project aims: 
 
1) To establish whether the presence of NETs in the sputum of CF 
participants was associated with more severe lung disease and 
inflammation. 
2) To investigate responses of macrophages to NETs in culture, 
comparing macrophages from HC to those from CF participants. 
3) To determine whether NET formation and associated inflammation are 
increased in a CF mouse model in comparison to WT mice following a 
sterile inflammatory challenge.   




4) To investigate whether clearing NETs using DNase can reduce 
inflammation in a CF mouse model. 
5) To develop a new, sensitive in vitro experimental technique using 
optical nanosensors to quantify phagolysosomal pH within living 
systems - comparing this method to conventional fluorescence 
spectroscopy – to address the hypothesis that there is a difference in 
pH between CF and non-CF cells. 
  




Chapter 2: Materials and Methods 
2.1 Common Buffer Solutions and Reagents 
Buffer Solution Description and Source 
DPBS Dulbecco’s phosphate buffered saline without 
Mg2+/Ca2+ (DPBS) (Gibco, UK) 
HBSS Hank’s Balanced Salt Solution, without Mg2+/Ca2+ 
(Gibco, UK). 
1X TAE 1X Tris-acetate-EDTA (TAE), 0.05% PBS-
Tween® (Sigma) 
10% NBF Neutral-buffered formalin (Thermo Fisher 
Scientific) 
TBST Tris-buffered Saline and 0.05% Tween 20 
MACS buffer for 
Monocyte negative 
isolation 
PBS without Mg2+/Ca2+, Bovine Serum Albumin 
(BSA) at 0.5g per 100 mL (Sigma) and 2mM 
EDTA. 
Table 2.1.1: Common Buffer Solutions  
  




Reagent Description and Source 
Phorbol 12-myristate 13-acetate 
(PMA) 
10 nM, 50 nM and 100 nM.  Phorbol 
12-myristate 13-acetate (PMA) 
(Sigma) 
Ionomycin 1 µM, 5 µM and 10 µM (Sigma) 
Diphenyleneiodonium chloride (DPI) 2µM DPI (Sigma) 




DNase 100 U/mL DNase (Roche, UK)   
SYTOX® green Invitrogen, Thermo Fisher Scientific, 
UK 
Cytochalasin D 5 µg/mL (Sigma, UK) 
CFTRinh-172 10 µM (R&D Systems, UK) 
Bafilomycin A1 100 nM (Abcam, UK) 
Table 2.1.2: Reagents 
 
  




2.2 Human Participants 
Experiments were performed on blood and/or sputum from CF adult patients 
attending the Edinburgh Adult CF Service at the Western General Hospital, 
Edinburgh.  Age- and sex-matched HC were recruited from the Centre for 
Inflammation Research Blood Resource.   
 
2.2.1 Inclusion and Exclusion Criteria 
Participants included were over the age of 16, without any respiratory tract 
infection within two weeks’ prior to donation, no immunosuppressant use, no 
past medical history of lung transplant, and were non-smokers by reporting 
(including the use of electronic cigarettes and vaporisers).  HC participants 
included had no past medical history of respiratory disease whilst CF 
participants had a formal diagnosis of CF by clinical and genetic parameters.   
 
2.2.2 Ethics Approval 
The West of Scotland Research Ethics Committee 3 granted approval for this 
study (REC reference number: 16/WS/0239).  HC participants were recruited 
from the Centre for Inflammation Research Blood Resource, ethical approval 
for which was granted by the Centre for Inflammation Research Blood 
Resource Management Committee (AMREC), 15/HV/013.  All participants 
provided informed written informed consent.  




2.2.3 Statistical analysis 
Statistical analysis was performed using GraphPad Prism software (Version 
8.0.2, USA).  To verify that data were normally distributed, Shapiro Wilk 
normality tests were performed.  Data were assumed to follow a non-
parametric distribution where sample sizes were insufficient to test for 
normality.  Summary data were expressed as the mean ± SD or median ± 95% 
confidence intervals (CI), with the number of experiments in parentheses.  
Significance testing was performed using an unpaired, two-tailed Student’s t-
test or Mann Whitney test when comparing two groups, or one-way/two-way 
ANOVA or Kruskal Wallis test when comparing three or more experimental 
groups with appropriate post-hoc tests.  Multi-variate linear regression 
modelling to predict FEV1 was performed using R software with the help of Dr 
Alastair Rushworth.  Results were considered significantly different when 
p<0.05.  Correlations were determined using Pearson Rank or Spearman 
Correlation Co-efficient, depending on the normality of data distribution.   
 
2.2.4 Spirometry 
FEV1 and forced vital capacity (FVC) were measured according to ERS/ATS 
guidelines(169) using an EasyOne® Spirometer (New Diagnostic Design, 
Zurich, Switzerland) which was calibrated twice weekly.   
 
2.2.5 Sputum Induction for Healthy Control Participants 




All sputum and blood samples from HC participants were obtained at the 
Wellcome Clinical Research Facility at the Royal Infirmary of Edinburgh.  HC 
participants had baseline FEV1 measured in triplicate, after which they were 
treated with 2.5 mg nebulised Salbutamol then post-bronchodilator FEV1 was 
measured after 10 min.  Participants were subsequently given hypertonic 
saline nebulisers, the concentration of which increased incrementally at 10 min 
intervals (3%, 4%, 5%; 3% sourced from Tayside Pharmaceuticals and 4% 
and 5% from Stockport NHS Foundation Trust), similar to a method previously 
described(170).  After each hypertonic saline nebulisation, participants were 
asked to blow their nose and rinse their mouth out with water (to avoid 
contamination of sputum with saliva) then were asked to cough and 
expectorate sputum into a sterile container.  If FEV1 fell by > 10% from the 
post-bronchodilator value, the hypertonic saline concentration was not 
increased.  If FEV1 fell by >20% or distressing symptoms occurred, the 
nebulisation was stopped.  These complications did not occur in any 
participants.   
 
2.2.6 Sputum collection from CF participants 
All sputum and blood samples from CF participants were obtained at the 
Edinburgh Adult CF Service at the Western General Hospital, Edinburgh.  CF 
participants were all able to expectorate sputum spontaneously so did not 
undergo the above induced sputum protocol.   




2.2.7 Sputum Processing 
Sputum was collected in sterile polypropylene tubes, which were transported 
on ice then samples processed within two hours of collection as described 
previously(170).  In brief, sputum was transferred to a sterile petri dish then 
plugs (i.e. dense portions of sputum) were harvested from the expectorated 
sample using forceps and transferred to a petri dish.  Forceps were used to 
gather plugs together using circular motions, to expel residual saliva.  The 
resultant plug was transferred to a 15 mL BD Falcon tube.  Sputum was 
homogenised using 0.1% dithiothreitol (DTT) (Sputolysin; Calbiochem Corp., 
San Diego, CA, USA), added to the sputum in equal volume to weight of 
sputum (e.g. 1mL DTT to 1g sputum).  The sputum/DTT mixture was rotated 
at room temperature for 15 min.  DPBS was subsequently added (in equal 
volume to that of the DTT) to stop further digestion.  Samples were filtered 
through 48 μm nylon mesh (pre-soaked in DPBS) set in a funnel into a 50 mL 
BD Falcon tube, then centrifuged at 300g for 10 min at 4°C.  The resulting cell 
pellet was re-suspended in DPBS. Cell-free supernatant was aliquoted and 
stored at -80°C until analysis.   
 
2.2.8 Sputum Cell Pellet Cytocentrifuge Preparation and analysis 
Sputum cell pellets were re-suspended in DBPS supplemented with BSA at 1g 
per 100 mL, and then 150 µL cell suspension was used per cytocentrifuge 
preparation, which permit visual assessment of cell morphology.  Two 




cytocentrifuge preparations were made per sample.  Cell suspensions were 
pipetted into reusable Shandon™ Single Cytofunnel™ cell concentrators, 
apposed to disposable filter cards (Shandon™, Thermo Fisher, UK) in turn 
apposed to glass slides, all fixed together with metallic slide holders.  Samples 
were centrifuged for three min in Thermo Scientific™ Cytospin™ 4 
Cytocentrifuge (Thermo Fisher Scientific), at 300 revolutions per minute (rpm), 
on medium acceleration.  All slides were air-dried, fixed with 100% methanol 
then stained with Shandon™ Kwik-Diff™ (Thermo Fisher Scientific, UK) to 
visualise acidic and nuclear structures.  Lastly, slides were mounted with DPX 
Mountant (Sigma, MO 63146, USA) and glass coverslips. 
 
Light microscopy of the above cytocentrifuge preparations was performed on 
EVOS™ XL Core light microscope at 20X magnification.  Images were saved 
as TIF files and differential cell counts were performed using a cell counter 
function of ImageJ software (National Institutes of Health, USA, 
http://imagej.nih.gov/ij/download.html); 300 consecutive nucleated cells were 
counted and assessed for cell morphology.  Sputum samples were adequate 
for further analysis if there were <40% squamous epithelial cells, indicating 








2.2.9 Collection and Preparation of Serum Samples  
Whole blood was obtained from participants by venepuncture and collected 
into 3mL tubes containing sodium citrate (Coagulation 9 NC/3mL tubes, 
Sarstedt monovette, Sarstedt AG and Co., Germany) to prevent clotting, then 
gently inverted.  Samples were centrifuged at 350g for 20 min at 20°C.  
Platelet-rich plasma (PRP) was aspirated and transferred to a glass vial, to 
which 1M CaCl2 was added (22µL per 1mL PRP).  The vial was gently inverted 
then incubated in a 37°C waterbath for one hour.  Resultant autologous re-
calcified “serum” was aliquoted and stored at -80°C until analysis.   
 
2.2.10 Sputum Supernatant and Serum Analysis by Enzyme-linked 
Immunosorbent Assays (ELISAs) 
PBS containing 1% BSA (i.e.1g in 100mL (Sigma)) was used to dilute sputum 
samples for all ELISA experiments, unless otherwise stated.  All samples were 
plated in duplicate.  The sputum cytokines measured were IL-8, IL-6 and TNF-
α.  The optimal dilution of samples was elucidated for each analyte in a series 
of preliminary experiments.  Details of dilutions and ELISA kit sources can be 
found in Table 2.2.1. 
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Table 2.2.1: ELISA kits used for sputum ELISAs and dilution of sputum 
samples in PBS with 1% BSA. 




ELISAs were performed according to the manufacturers’ protocols, 
summarised below for R&D Systems DuoSet.  Plates (96-well EIA/RIA plate 
(Corning™ Costar™, NY, USA)) were coated with 100 µL capture antibody 
(Ab) per well that was diluted in DPBS without carrier protein and incubated at 
room temperature overnight.  All antibodies and cytokine standards were 
prepared in reagent diluent (RD, i.e. PBS with BSA at 1g per 100mL).  Wells 
were then washed 3x with 0.05% Tween-20 in PBS then blocked with 300 µL 
per well of RD at room temperature for one hour.  After washing 3x, 100 µL 
sample and standards were added per well.  Serial two-fold dilutions of 
cytokine standards were prepared to yield a standard curve to determine 
cytokine concentrations in unknown samples.  Plates containing samples and 
standards were incubated at room temperature for two hours.  Plates were 
washed 3x then 100 µL per well of the biotinylated detection Ab was added 
per well and incubated at room temperature for two hours.  The plates were 
washed 3x before addition of 100 µL 1:40 Streptavidin-horseradish peroxidase 
(S-HRP) at room temperature in the dark for 20 min.  Plates were washed 3x 
and then 100 µL of substrate solution (1:1 ratio of colour reagents A and B) 
was added per well and incubated at room temperature in the dark for 20 min.  
The reaction as stopped by adding 50 µL per well of Stop solution.  Absorbance 
was read at 450 nm – 630 nm using a BioTek Synergy™ HT plate reader 
(BioTek Instruments Inc., VT, USA).  Data were analysed using software 
available at elisaanalysis.com. 
 




2.2.11 Sputum NET ELISA 
An in-house, double-sandwich ELISA was developed to measure histone-
bound calprotectin, as an estimate of NET formation.   This ELISA is illustrated 
in Figure 2.2.1.   
 
Figure 2.2.1: A schematic of the in-house NET ELISA in which the primary 
antibody captures histones, ensuring eukaryotic DNA is specifically targeted 
and the secondary antibody binds calprotectin.  The ELISA therefore 
specifically measures calprotectin associated with DNA as an estimate of the 
presence of NETs. 
 
The in-house NET ELISA used antibodies from two different ELISA kits, the 
anti-histone capture antibody from the Cell Death Detection ELISA (Roche) 
and S100A9/calprotectin detection antibody from Hycult Biotech.  A modified 




protocol was developed based on the respective protocols from each 
manufacturer.  Briefly, the primary anti-histone Ab was diluted 1:10 using the 
kit’s coating buffer, then added to the plate at 100µL/well.  The plates were 
sealed then incubated in a fridge overnight.  The following day, the anti-histone 
Ab was removed from plate by inversion and tapping then the plates were 
blocked with incubation buffer at 200µL/well for one hour.  The plates were 
then washed three times.  Sputum samples were diluted 1:10 with incubation 
buffer then 100 µL/well added and incubated at room temperature for 90 min.  
At this point, the Hycult Biotech’s kit was used.  The reconstituted 
S100A9/calprotectin detection Ab was diluted 1:12.  The plates were washed 
four times, after which diluted detection antibody at 100 µL/well was added to 
the plates, incubated at room temperature for one hour.  Plates were then 
washed four times after which S-HRP (diluted 1:200) was added to the plates 
at 100 µL/well.  The plates were incubated at room temperature for one hour, 
after which plates were washed four times.   TMB 100 µL/well was added to 
the plates, which were incubated under aluminium foil for 30 min.  Finally, 100 
µL/well Stop solution was added before the plates were read on 450 nm – 630 
nm on the digital kinetic plate reader as before.  Although it was not possible 
to generate a standard curve to quantify NET formation directly, fluorescence 
optical density (OD) (excitation 450 nm, emission 630 nm) was measured then 
fold-change in OD from mean HC values calculated.   
 
 




2.2.12 Sputum and Serum Calprotectin ELISA 
See Table 2.2.1 for sputum dilutions.  HC serum samples diluted 1:200 whilst 
CF serum samples diluted 1:10000 for the Calprotectin ELISA, performed 
using the Human Calprotectin ELISA kit (Hycult Biotech), performed following 
manufacturer’s instructions and absorption measured at 450 nm.   
 
2.2.13 Sputum MPO Assay 
All assays were performed in duplicate in flat-bottomed, 96-well EIA/RIA plates 
(Corning™ Costar™, NY, USA).  Sputum samples were combined with 0.3 
mM H2O2 (Sigma) and 1X TMB solution (Thermo Fisher Scientific).  Plates 
were incubated at 37°C, 5% CO2 for 5 min. The reaction was stopped by 
adding Stop solution and absorption was measured at 450 nm to estimate 
MPO activity. 
 
2.2.14 Sputum Human Neutrophil Elastase Assay 
Human Neutrophil Elastase (HNE) was measured using a NE Assay Kit 
(Cayman Chemical, MI, USA) following manufacturer’s instructions.  Briefly, 
the cell-based assay buffer (AB) was diluted: one tablet in 100 mL dH2O.  Two-
fold dilutions of the HNE assay reagent were prepared in diluted AB to 
determine HNE using a standard curve.  Sputum samples were  diluted - 1:10 
for HC sputum and 1:1000 for CF sputum - in AB then 100 µL per well of 




samples and HNE standards (range 0 – 10 u/mL) were added to flat-bottomed, 
96-well, black-sided plates (Thermo Fisher Scientific) in duplicate.  10 µL per 
well of the (Z-Ala-Ala-Ala-Ala)2Rh110 substrate solution was added then 
plates were incubated in the dark at 37°C, 5% CO2 for 1.5 hours.   
Fluorescence  (excitation 485 nm/emission 525 nm) was recorded and data 
analysed using software available at elisaanalysis.com for standard curve 
acquisition and corrected fluorescence calculation.  The HNE activity was then 
calculated using the formula:   
 





2.2.15 Sputum PicoGreen® Assay  
The Quant-iT™ PicoGreen® dsDNA Reagent Kit (Thermo Fisher Scientific) 
was used to quantify dsDNA in sputum samples according to the 
manufacturer’s protocol.  Briefly, 1X TE assay buffer was prepared by diluting 
the concentrated buffer 20-fold in sterile, distilled DNase-free water.  100 µL 
Quant-iT™ PicoGreen® dsDNA reagent was added to 19.9mL assay buffer in 
a polypropylene tube then protected from light using aluminium foil.  Double-
stranded DNA standard curves were made ranging 25 pg/mL - 1µg/mL by 
dilution of calf thymus DNA (Thermo Fisher Scientific) in AB.  In the wells of 
flat-bottomed, 96-well black-sided plates, 150 µL of DNA standards/samples 




and 150 µL diluted Quant-iT™ PicoGreen® dsDNA reagent were mixed.  The 
plates were incubated at room temperature in the dark for five min then 
fluorescence at 480 excitation/520 emission was measured.  Standard curves 
were made then sample fluorescence readings multiplied by the line formulae 
to obtain DNA concentrations.    
 
2.3 Cell Isolation and Co-culture  
2.3.1 Isolation of PMN and PBMC from whole blood 
Blood collected by venepuncture from HC and CF participants was anti-
coagulated with 0.38% sodium citrate and centrifuged at 350g for 20 min to 
separate PRP and cells.  Autologous re-calcified serum was generated as 
described in section 2.2.9.  Erythrocytes were separated from leucocytes by 
differential sedimentation in 0.9% sodium chloride (NaCl) containing 0.72% 
Dextran-500 for 30 min at 37°C.  Thereafter, the leucocyte-rich upper layer 
was aspirated and diluted in 0.9% NaCl then centrifuged at 350g for 6 min to 
pellet the leucocytes.  PMN and PBMC were separated by discontinuous 
Percoll® (81%, 70% and 55%) gradient, centrifuged at 720g for 20 min 
(acceleration 1, deceleration 0).  PBMC were removed from the 55%/70% 
interface and the PMN removed from the 70%/81% interface.  Isolated cells 
were washed twice in DPBS, within which they were subsequently re-
suspended to permit a cell count performed using a C-chip haemocytometer 
(NanoEnTek, SK).   




2.3.2 Culture of Monocyte-derived Macrophages from adherent 
Monocytes 
Monocytes were isolated from PBMC using a negative selection pan-monocyte 
isolation kit (Miltenyi Biotec Ltd., UK) according to the manufacturer’s protocol.  
In brief, PBMC were re-suspended in MACS buffer (see Table 2.1.1) (40 µL 
per 107 cells) and FcR were blocked (10 µL of FcR Blocking Reagent per 107 
cells).  Cells were incubated with Biotin-Antibody cocktail (10µL per 107 cells) 
on ice for 5 min prior to adding MACS buffer (30 µL per 107 cells) and Anti-
Biotin MicroBeads (20 µL per 107  cells) and incubation on ice for 10 min.  A 
washed (3 mL of MACS buffer) LS column (Miltenyi Biotec Ltd., UK)  was 
mounted in the magnetic field of a MidiMACS™ Separator (Miltenyi Biotec Ltd., 
UK) and the cell suspension was then applied, collecting the flow-through and 
3 x 3mL washes of enriched monocytes in a polypropylene tube.  Monocytes 
were centrifuged at 300g for 5 min at 20°C, re-suspended in DPBS and 
counted using a C-chip haemocytometer.  The cell suspension was centrifuged 
as before and finally re-suspended in IMDM supplemented with 2mM L-
Glutamine and 25 mM HEPES, 10% Autologous Serum, 1% 
Penicillin/Streptomycin (i.e. 10,000 U/mL of penicillin and 10,000 µg/mL 
streptomycin) and plated at 2.5x105 per well in 48-well plates (Corning™ 
Costar™, Life Sciences, UK).  Adherent monocytes were cultured at 37°C, 5% 
CO2 for seven days to generate MDM, with media changes on days one and 
five. 
 




2.3.3 NET formation from Neutrophils in Rolling Culture with PMA 
Isolated neutrophils were re-suspended in HBSS to 1x106/mL in a 15 mL BD 
Falcon tube.  Neutrophils were stimulated with 100 nM PMA (Sigma) or HBSS-
only control for 15 min at room temperature on a rolling platform set at 35 
rotations/minute (Scientific Laboratory Supplies Lab Basics Hexiroll, UK).  
Neutrophils treated with PMA were deemed “NETs”, whilst non-PMA-treated 
neutrophils represented “control” neutrophils.  In vitro experiments described 
in section 2.3.5 were employed to elucidate that PMA and DNase were the 
most efficient stimulator and inhibitor of NETosis, respectively. 
 
2.3.4 Cytocentrifuge Preparations of blood cells  
As per section 2.2.8.  Samples with ≥ 95% PMN were deemed satisfactory for 
use in neutrophil assays.  Cytocentrifuge preparation analysis was used to 
confirm that the negative isolation technique had effectively isolated 
monocytes from PBMCs.  See Figures 2.3.1 and 2.3.2 for representative 
images of cytocentrifuge preparations.  
 




   
Figure 2.3.1: Cytocentrifuge preparation of polymorphonuclear 
leukocytes following isolation from whole blood using dextran sedimentation 
and Percoll® gradient centrifugation.   Contaminating eosinophils highlighted 
(white arrows). 
 






Figure 2.3.2: Cytocentrifuge preparation of peripheral blood 
mononuclear cells (top) and monocytes (bottom) following negative 
magnetic isolation using Miltenyi Biotech Pan-Monocyte Isolation Kit 
(Human).  Top image at 20X, bottom image at 10X magnification.   
 




2.3.5 In Vitro NET Formation and Inhibition 
Preliminary experiments were performed prior to the co-culture experiment to 
optimise in vitro NET formation and inhibition.  Two techniques were performed 
– microscopic detection of NETs and NET DNA release kinetic assay – based 
on published methodology (61,70,171).  Immunofluorescence was also used 
to provide detailed images of the morphological appearances of NETs.     
 
2.3.6 Microscopic Detection of NETS 
Following isolation of PMN, neutrophils were plated at 5x104 per well in RPMI 
supplemented with 10% FCS, 1% L-Glutamine (Gibco, UK), 1% 
Penicillin/Streptomycin into 24-well flat-bottomed plates (Corning™ Costar™, 
Life Sciences, UK) in duplicate.  PMA was added at 10 nM, 50 nM and 100 nM 
whilst ionomycin was added at 1 µM, 5 µM and 10 µM, to allow fine-tuning of 
optimal concentration.  Adherent neutrophils were incubated for four hours at 
37°C, 5% CO2 to permit NET formation prior to addition of 0.15 µM SYTOX® 
green (Invitrogen, Thermo Fisher Scientific). Plates were then imaged using 
bright field and fluorescent (470/22 nm excitation; 510/42 nm emission) 
microscopy using an EVOS™ FL cell imaging system (Thermo Fisher 
Scientific).  Images were saved as TIF files and NET formation was quantified 
as a percentage of total cells by counting a minimum of 300 cells from a 
minimum of two 10X fields-of-view from duplicate wells using a cell counter 
function of ImageJ software, then averages calculated(61).  Neutrophils were 




classified as NETed if they had diffuse or spreading characteristics (see Figure 
3.20).  In some experiments, cells were incubated with 2 µM DPI, 1 µM Ro-31-
8220 or 100U/mL DNase (see Table 2.1.2) to inhibit NET formation.   
 
 
Figure 2.3.3: Fluorescence microscopy image of NETs in vitro stained 
with SYTOX® Green.  “Diffuse” NETs, which have a characteristic fluffy 
outline, are shown by solid white arrows.  “Spreading” NETs, with strands of 









2.3.7 Immunocytochemistry of NETs 
Immunofluorescence was used to obtain detailed images of in vitro NETs.  
Isolated neutrophils were re-suspended 1x106/mL in RPMI and seeded onto 
sterile, glass coverslips placed in flat-bottomed 12-well plates.  Neutrophils 
were incubated for 30 min at 37°C, 5% CO2 to allow cells to adhere to the 
coverslips.  Cells were then incubated with 100 nM PMA for four hours to 
permit NET formation.  Thereafter, the RPMI was gently aspirated and 
replaced with 1mL 2% paraformaldehyde (PFA) overnight at 4-8˚C to fix cells.  
After aspiration of PFA, cells were permeabilised using 1% Triton™-X-100 
(Thermo Fisher Scientific).  Cells were washed 3x with DPBS then blocked 
with 3% BSA in DPBS for 30 min at room temperature.  The blocking solution 
was aspirated then cells were stained with primary rabbit anti-human MPO 
(Abcam, 1:200) for one hour.  Cells were washed 3x with DPBS then incubated 
with the fluorochrome-tagged secondary antibody (goat anti- rabbit IgG Cy2® 
(Abcam, 1: 300) for one hour at room temperature under aluminium foil.  
Hoechst (Invitrogen™, Thermo Fisher Scientific, 1:10000 dilution) was used 
for DNA counterstaining.  All antibodies/Hoechst were diluted in DPBS.  Cells 
were washed 3x in DPBS then ProLong™ Diamond Antifade Mountant 
(Thermo Fisher Scientific) was used to mount coverslips onto microscope 
slides.  Slides were imaged on the EVOS™ FL cell imaging system (470/22 
nm excitation; 510/42 nm emission). 
 
 




2.3.8 NET DNA release Kinetic Assay 
Following isolation of PMN, neutrophils were plated at 5x104 per well in RPMI 
into 96-well flat-bottomed plates (Corning™ Costar™, Life Sciences) in 
triplicate.  NET formation was induced by addition of PMA added at 10 nM, 50 
nM and 100 nM or ionomycin added at 1 µM, 5 µM and 10 then 0.15 µM 
SYTOX® green was added.  The plate was inserted into a digital kinetic plate 
reader (BioTek® Synergy™ HT) with the set up: excitation 485/20 nm, emission 
530/25 nm, bottom optics, sensitivity 35 and 50 nm, and temperature 37°C.  
Measurements were taken at 30 min intervals for six hours.  Data were 
exported to Microsoft Excel and averages of each time point calculated to 
permit dose-response curve formulation.  In some experiments, cells were 
incubated with 2 µM Diphenyleneiodonium chloride (DPI), 1 µM Ro-31-8220 
or 100U/mL DNase (see Table 2.1.2) to inhibit NET formation. 
 
2.3.9 Co-culture between MDM and NETed/control Neutrophils 
A co-culture experiment was performed between MDM and neutrophils – either 
control or NETing – from different participants.  There were four combinations 
of cells in the co-culture experiment, as shown in Figure 2.3.4: 




Figure 2.3.4: Schematic of co-culture experiment, illustrating the four 
combinations of cells.  Neutrophils were either control or NETing (“NETs”) and 
in some experiments in which NETs were present, DNase was added to 
determine if it affected parameters measured.  
 
On day seven of MDM culture (section 2.3.2), whole blood was obtained from 
a different participant (either HC or CF) then PMN were isolated and half were 
made to NET, as described in section 2.3.3.  Neutrophils were then washed 
3x in HBSS to remove any residual PMA before seeding 5x105/well onto MDM 
(2:1 neutrophil to MDM ratio)(70) in 500 µL IMDM supplemented with 2mM L-
Glutamine and 25 mM HEPES, 5% foetal calf serum (FCS) (Gibco, UK) and 
1% Penicillin/Streptomycin.  Plates were incubated at 37°C, 5% CO2 for 24 
hours.  Negative control wells were also plated – a co-culture between MDM 
and NETs with the addition of 100U/mL DNase (Roche, UK) - to inhibit NET 
formation.   




2.3.10 Co-culture Supernatant Harvest and ELISAs 
Cells were co-cultured for 24 hours, after which supernatants were collected, 
centrifuged at 300g for 5 min at 20°C to remove cell debris, and then frozen at 
-80°C.  Following collection of all samples, quantification of the cytokines IL-6, 
IL-8, TNF-α and IL-10 in the co-culture supernatants was carried out using 
commercially available ELISAs (R&D Systems, UK) as per section 2.2.10 with 





ELISA Kit Supernatant 
Dilution 
















Table 2.3.1: ELISA kits used for co-culture supernatant ELISAs and 
dilution of samples in PBS with 1% BSA. 
 
2.3.11 Scanning Electron Microscopy of Co-Culture Experiment 
Scanning electron microscopy was performed to provide detailed microscopic 
evaluation of the morphological features of co-cultured cells.  The experiments 




were performed as described in section 2.3.9 but before monocyte adherence, 
Nunc™ Thermanox™ Coverslips (Thermo Fisher Scientific) were placed in the 
wells, onto which monocytes then adhered.  After the seven days culture to 
permit differentiation of monocytes to MDM and subsequent 24 hours’ 
MDM/NET or control neutrophil co-culture, cell samples were fixed in a solution 
of 3% glutaraldehyde (Sigma) in 0.1 M sodium cacodylate (CAC) buffer (pH 
7.3) for two hours.  They were then washed in 3x 10 min changes of 0.1 M 
CAC.  Samples were then transported to Steven Mitchell at the King’s 
Buildings, The University of Edinburgh, who performed the remainder of the 
steps in the protocol.  Briefly, samples were post-fixed in 1% osmium tetroxide 
in 0.1 M CAC for 45 min then washed three times as before.  Dehydration in 
graded concentrations of acetone (50%, 70%, 90% and 3 x 100%) for 10 min 
each was followed by critical point drying using liquid carbon dioxide.  Samples 
were mounted on aluminium stubs with carbon tabs attached, then sputter-
coated with 20 nm gold palladium, viewed and imaged using a Hitachi S-4700 
scanning electron microscope with assistance from Steven Mitchell.  Images 
were false-coloured using GNU Image Manipulation Program (GIMP) Version 
2.8 software.        
 
  




2.4 Cystic Fibrosis Mouse Model of Acute, Sterile Lung 
Inflammation 
 
2.4.1  Use of Animals and Animal Facilities 
All experiments were approved under a Project License (license number 70-
8884) granted by the Home Office (UK) and conducted in accordance with 
local ethics approval from the Veterinary Scientific Services of The University 
of Edinburgh.   
2.4.2  Strains of Animals Used 
C57/BL6 littermate mice (Charles River Laboratories Ltd., UK) were used for 
the preliminary DPBS/LPS time course experiment. 
 
The LPS and DNase nebulisation experiments were carried out using 
Cftrtm1UncTg(FABPCFTR)1Jaw/J mice (Charles River Laboratories Ltd., UK) 
(referred to as CFTR-/- mice henceforth), which have been described 
previously(172).  See Chapter 4 for a description of the genotype.  CFTR-/- 
mice were bred with C57BL/6 mice to create a mixed background under 
specific pathogen-free conditions at the University of Edinburgh Animal 
Facilities.  CFTR-/- mice were genotyped using qPCR by Lauren Melrose (see 
Appendix 1).  The DNase activity assay experiments were carried out using 
CFTR-/+ mice.   




Mice had free access to chow and water.  Mice were age- and sex-matched 
within experiments and used at 9-16 weeks of age.  WT and heterozygote mice 
were from the same mixed background as the CFTR-/- mice because they were 
littermate controls.  Experiments were designed to use the minimum number 
of animals possible, whilst attaining statistically meaningful results.  
 
2.4.3 In vivo manipulations 
Administration of PBS 
Where indicated, mice received 3mL oxygen-driven nebulised DPBS on day 
zero. 
Administration of LPS 
Where indicated, mice received 3 mL oxygen-driven nebulised LPS 1mg/mL 
in DPBS (P. aeruginosa 10, Sigma) on day zero. 
Administration of DNase 
Where indicated, mice received oxygen-driven nebulised DNase 
(Pulmozyme®) 2500U in 2.5 mL (Roche, UK) at 12, 36 and 60 h post-LPS. 
Administration of Euthatal 
All mice were culled by intraperitoneal (i.p.) injection of 300 µL Euthatal 
(Pentobarbital Sodium, Henry Schein, UK).   




2.4.4 Time course experiment to determine Peak and Resolution of 
Inflammation post-LPS Lung Injury 
A nebuliser system was developed with local expertise (Figure 2.4.1).   
Figure 2.4.1: Mouse nebuliser system.  For all the animal experiments, 
compounds were administered to the mice via nebulisation using a sealed 
system in a fume hood – one sealed system per compound.  Upon completion 
of nebulisation, animals were placed in standard cages – separated depending 
upon whether they received LPS only or LPS and DNase.  
 
With regard to the time course experiment, there were 48 female, 10-week old 
C57BL/6 mice.  Half of the group received nebulised control DPBS whilst the 
other half received nebulised LPS (see Figure 2.4.1) on day zero.  Groups 
were culled at 0, 24, 48 and 72 h by overdose of i.p. Euthatal.  Mice were 
observed each day to ensure well-being using an established scoring system.  




No mice became unwell to warrant euthanasia throughout any of the 
experiments.   
 
Figure 2.4.2: Overview of the mouse time course experiment to determine 
the time of peak and subsequent resolution of inflammation following LPS-
mediated lung injury.  There were 48 C57BL/6 mice, half of which received 
3mL DPBS, the other half received 1mg/mL LPS (P.aeruginosa 10 (Sigma)).  
Groups were culled at 0, 24, 48, and 72 hours and bronchoalveolar lavage and 
lung tissue harvest was subsequently performed.  Samples frozen at -80°C for 
later analysis. 
 
2.4.5  Bronchoalveolar Lavage and Excision of Lung Tissue 
Following i.p. Euthatal, death was confirmed by exsanguination: the axillary 
artery was severed by an incision at the axilla.  Following an incision across 




the abdominal wall and thoracic area, the diaphragm was dissected and 
anterior chest wall removed to gain access to the thoracic cavity.  An 
elasticated string was tied around the left hilum then a left pneumonectomy 
was performed.  Half of the tissue was placed in 250 µL RNAlater (Qiagen, 
Netherlands) for RNA extraction (for 24 hours, then RNAlater was removed 
and lungs were frozen at -80°C) and half was snap frozen on dry ice.  
Thereafter, the trachea was exposed by dissection through the anterior neck 
tissues then cannulated with Jelco® IV catheter Radiopaque (Smith Medical 
International Ltd, UK).  This permitted bronchoalveolar lavage (BAL) of the 
right lung using HBSS supplemented with 3 mM Ethylenediaminetetraacetic 
acid (EDTA), which functioned to preserve cell morphology.  An initial 500 µL 
was lavaged, providing a cytokine-rich sample used for later assays to 
measure cytokines.  A further 1.5 mL was lavaged, which was for 
cytocentrifuge preparation.   
 
Resultant BAL fluid (BALF) was stored on ice until centrifugation at 350g for 5 
min at 4°C, and then supernatant from the cytokine-rich samples were 
aspirated and frozen at -80°C until analysis.  BALF cell pellets from both the 
cytokine-rich lavage and cytocentrifuge preparation samples were re-
suspended in DPBS and combined.  Cells were counted using 
NucleoCounter® NC-200™ (Chemometec, USA), centrifuged as before then 
re-suspended at 1x106/mL for cytocentrifuge preparation, as per section 2.2.8. 
 




2.4.6 Lung Excision for Histological Examination 
Some animals from each group were reserved for histological examination of 
lung tissue.  In such cases, the right lung was not lavaged with HBSS; rather 
it was lavaged with 10% NBF, the trachea tied off with elasticated string, then 
the lung was dissected and placed in a sterile universal container containing 
10% NBF for 24 hours.  After this, the 10% NBF was replaced with 70% 
ethanol.  These samples were paraffin-embedded, sectioned in the coronal 
plane and stained with Haematoxylin and Eosin (H&E) by the Histology 
Department of the Shared University Research Facilities (SuRF) at the Centre 
for Inflammation Research, Edinburgh.         
 
2.4.7 Light Microscopy of BALF Cytocentrifuge Preparations for 
Differential Cell Counts 
As per section 2.2.8. 
 
2.4.8 Determination of Peak and Resolution of Inflammation post-LPS  
In order to determine when peak and resolution of inflammation occurred 
following LPS administration, two parameters were used.  Firstly, BALF 
differential cell counts were analysed and secondly, an IL-6 ELISA was carried 
out using the DuoSet ELISA Mouse IL-6 (R&D Systems).  BALF supernatants 




were diluted 1:5 in PBS with 1% BSA and ELISA methodology is described in 
section 2.2.10.   
 
2.4.9 LPS-mediated Acute Lung Inflammation experiments 
The time course experiment established that peak inflammation occurred 24 
hours’ post-LPS administration and resolution had occurred within 72 hours 
(Chapter 4, section 4.1).  The experiment modelling acute lung inflammation 
in CFTR-/- and WT littermate mice was therefore conducted with culls at 24 and 
72 hours post-LPS administration (see Figure 2.4.3).  Mice were nebulised with 
3 mL 1mg/mL LPS, then half the group received nebulised Pulmozyme® 12 
hours post-LPS administration in a separate sealed system.  All mice were 
culled and BALF and lung tissue harvested, as described in sections 2.4.5 and 
2.4.6.  The 24- and 72-hour time point experiments were performed over n=3 
and n=4 separate experiments, respectively.   
 





Figure 2.4.3:  Overview of the mouse model of LPS-mediated acute lung 
inflammation.  CFTR-/- and WT littermate mice were received 3 mL 1mg/mL 
LPS (P. aeruginosa 10 (Sigma) in DPBS), then half the group received 
nebulised 2.5 mL 2500iU Pulmozyme® (Roche, UK) 12 hours’ post-LPS 
administration in a separate sealed system.  Thirty-seven animals were culled 
at the 24-hour time point (n=3 separate experiments).  Forty-four animals were 
culled at the 72-hour time point (n=4 separate experiments) and these received 
2.5 mL 2500iU Pulmozyme® treatment once daily.   
 
 
2.4.10 Cytokine U-PLEX® Biomarker Group 1 (Mouse) Assay  
The commercially available U-PLEX® Biomarker Group 1 (Mouse) Assays 
(Meso Scale Diagnostics (MSD®), Maryland, USA) was used to measure the 
concentrations of 10 cytokines in murine BALF supernatant samples: IL-6, IL-
10, IL-17A, IL-23, IL-1β, IFN-ɣ, KC, MCP-1, MIP-2 and TNF-α.  This assay is 




similar to an ELISA but biotinylated capture antibodies are coupled to U-PLEX 
Linkers, which self-assemble onto unique positions (“spots”) on the U-PLEX 
plate, permitting up to ten cytokines to be quantified concomitantly in one 
assay.  In the assay described here, there was cross-reactivity between some 
of the analytes and so the assay was performed over two U-PLEX plates, see 
Figure 2.4.4 according to the manufacturer’s protocol. 
 
 
Figure 2.4.4: U-PLEX immunoassay on U-PLEX 8-assay and 2-assay plates from 
Meso Scale Diagnostics (MSD®) was used to quantify proinflammatory cytokines in 
murine BALF.  Quantification of numerous cytokines is possible in one assay because 
the biotinylated capture antibodies are coupled to U-PLEX linkers, which attach onto 
the designated positions on the U-PLEX plate.  Figure adapted from page 5 of MSD® 
U-PLEX Platform U-PLEX® Biomarker Group 1 (Mouse) Multiplex Assays product 
insert (18164-v3-2016Nov) (https://www.mesoscale.com/en/products/u-plex-
biomarker-group-1-mouse-assays-k15069l/).   




Briefly, 200 µL of each biotinylated capture antibody was coupled to 300 µL of 
a unique linker, identified on a spot map, and then incubated for 30 min at room 
temperature.  The reaction was stopped by adding 200 µL Stop Solution, 
incubated for 30 min at room temperature.  All of the U-PLEX®-coupled 
antibodies were combined – two solutions were made such that none of them 
shared the same linker – and the volume brought up to 6 mL with Stop 
Solution.  The two black-sided 96-well plates were coated with 50 µL per well 
multiplex coating solution then incubated for one hour at room temperature on 
a plate shaker set at 500 rpm with a 1.5 mm stroke (Heidolph, Titramax 1000, 
Germany).  Meanwhile, calibrator standard solutions were prepared from a 5X 
concentrated stock diluted five-fold to generate the highest point on the 
standard curve.  BALF supernatants were diluted 1:2 in Diluent 41.  The 
assay’s detection antibodies are conjugated with electrochemiluminescent 
labels (MSD GOLD™ SULFO-TAG).  These detection antibodies were diluted 
1:100 with Diluent 45 and combined.  Plates were washed 3x with wash buffer 
then incubated with samples and calibrators 25 µL per well for one hour at 
room temperature.  The plates were washed 3x with 150 µL per well wash 
buffer after which 50 µL per well of detection antibody solution was added and 
incubated for one hour at room temperature on the plate shaker.  Plates were 
washed 3x as above then 150 µL per well 2X Read Butter T was added before 
plates were analysed on a Mesoscale Quickplex sq120 instrument (MSD®).  
For details of analytes and calibrators, please see Appendix 2. 
  




2.4.11 Quantification of Murine NETs by NET, Histone and S100A9 
ELISAs 
NET ELISAs were performed with BALF diluted 1:10 as described 2.2.11.  The 
histone ELISA was performed using the Cell Death Detection ELISA (Roche) 
with BALF samples diluted 1:50.  The S100A9 ELISA was performed using the 
Mouse S100A9 ELISA (Hycult Biotech) with BALF samples diluted 1:50.  
Manufacturer’s protocols were followed in each case, with ELISA methodology 
described fully in section 2.2.10. 
 
2.4.12 Pierce™ Bicinchoninic Acid (BCA) Assay  
A protein analysis kit (Pierce™ Microplate BCA Protein Assay Kit, Thermo 
Fisher Scientific) was used to measure the total protein content of murine 
BALF.  Two-fold dilutions of 2 mg/mL albumin standard was prepared in HBSS 
to determine protein concentration using a standard curve.  BCA reagent was 
made by mixing BCA Reagent A with BCA Reagent B in a 1:1 ratio.   Ten µL 
standard/sample and 200 μL of the BCA reagent was mixed in wells of a 96-
well, round-bottomed plate (Corning™ Costar™) in duplicate and incubated at 
37 °C for 30 min.  Absorbance was read on the plate reader 450 nm – 630 nm 
using the BioTek Synergy™ HT plate reader. 
 
 




2.4.13 Quantification of NETs by Immunohistochemistry on Murine Lung 
Tissue 
De-paraffinisation and rehydration of paraffin-embedded murine lung sections 
was performed by moving them through the following wash steps: 
Solutions Number and Duration of Washes 
Xylene 2 x 3 min  
Xylene: 100% Ethanol at 1:1 ratio 2 x 3 min  
100% Ethanol 2 x 3 min  
95% Ethanol 1 x 3 min 
70% Ethanol 1 x 3 min 
50% Ethanol 1 x 3 min 
Rinse in running tap water Until antigen retrieval step 
 
Antigen retrieval was then performed by heating slides to 110°C for 5 min in 
sodium citrate buffer (see Appendix 3) in a pressure cooker.  Slides were then 
washed twice in DPBS and loaded onto a Sequenza® Slide Rack (Thermo 
Fisher Scientific) then 150 µL DPBS applied to each slide.  Slides were blocked 
with 150 µL 25% goat serum in DPBS for one hour at room temperature.  
Primary antibodies were then applied and incubated at 37°C for one hour.  
Slides were washed twice in DPBS then secondary antibodies were applied 
and incubated at room temperature for one hour.  Details of primary and 
secondary antibodies used can be found in Appendix 3.  Slides were washed 
twice in DPBS then Hoechst (1:10000 dilution) was applied and incubated for 




5 min at room temperature.  Slides were lastly washed in tap water before 
being air-dried then ProLong™ Diamond Antifade Mountant (Thermo Fisher 
Scientific) was used to mount coverslips onto slides.  Slides were covered in 
aluminium foil and left to dry for at least 24 hours.  Confocal microscopy images 
were acquired using a Leica SP5 confocal laser scanning microscope with 
Leica Application Suite Software.  Six images at 40X magnification were 
obtained per animal and images were saved as TIF files.  These were analysed 
on ImageJ software by opening merged RBG channels and using the cell 
counter and grid functions.  Cells positive for all three colours were counted 
first (i.e. suggestive of neutrophils due to morphology and the presence of 
DNA, MPO and S100A9) then cells positive for yellow pixilation were counted 
(i.e. suggestive of NETs due to co-localisation of S100A9 and MPO, see 
Introduction).  The percentage of NETed neutrophils was subsequently 
calculated.   
 
2.4.14 Murine Bronchoalveolar Lavage DNase Activity Assays 
In order to confirm that the DNase being administered to the mice was active 
in its DNA-cleaving activity, two assays were used.  The first was an in vitro 
DNA gel electrophoresis, in which the Pulmozyme® drug was mixed with calf 
thymus DNA.  The second assay involved administering heterozygote mice 
(CFTR-/+) with nebulised control DPBS or DNase, then immediately culling the 
animals and performing BAL, after which the Quant-iT™ PicoGreen® dsDNA 
Reagent Kit was used to quantify BALF dsDNA. 




2.4.15 DNA Gel Electrophoresis using Pulmozyme® and Calf Thymus 
DNA 
DNA was resolved using 1% agarose gels (containing GelRed® (Cambridge 
Bioscience, UK) at 1:10000 dilution) in 1X TAE buffer using a horizontal gel 
electrophoresis tank.  Calf thymus DNA was diluted in DPBS to 1 µg/mL.  This 
DNA was mixed in equal volumes with graded concentrations of Pulmozyme® 
(100%, 75%, 50%, 25% - diluted in DPBS), then incubated at 37°C, 5% CO2 
for 30 min to permit DNA digestion.  A 6X DNA Loading Dye (Thermo Fisher 
Scientific) was added to each sample.  The gel was then loaded with a 1kb 
Plus DNA ladder (Invitrogen, Thermo Fisher Scientific), a positive control well 
containing DNA at 1mg/mL, then samples.  The gel was run at 70V for 70 min 
then imaged on Analytikjena UVP GelDoc-lte Imaging System with 
VisionWorks® Software.    
 
2.4.16 Murine Bronchoalveolar Lavage PicoGreen® Assay to quantify 
DNase activity 
CFTR-/+ mice received either nebulised 2.5mL DPBS or 2500iU Pulmozyme®, 
as per section 2.4.3.  Animals were immediately culled then BAL performed as 
in section 2.4.5.  BALF was stored on ice and transported immediately to the 
laboratory, where it was used in the Quant-iT™ PicoGreen® dsDNA Reagent 
Kit, being mixed with the PicoGreen® reagent with the assay performed as per 
section 2.2.15. 




2.4.17 Semi-quantitative scoring of Acute Lung Inflammation on H&E 
stained lung sections 
Two methodologies for assessment of acute inflammation following LPS 
administration were employed: a semi-quantitative score of lung histology and 
a quantitative translocator protein (TSPO) radiotracer assay.  Taking the 
former method, following paraffin-embedding, sectioning and H&E staining, 
sections were imaged on the EVOS™ XL Core Imaging System: two images 
per animal were taken at 20X and 40X magnification (to permit mean 
calculations).  Images were saved as TIF files then analysed on ImageJ 
software using the grid tool and cell counter function.  Images were analysed 
using a semi-quantitative score of acute lung inflammation, modified from 
published, validated scores(173,174).  The investigator was blinded to 
genotype and treatment group during analysis and parameters assessed were 
vascular congestion, thickness of the interalveolar septa (indicative of 
oedema), inflammatory cell infiltration, and haemorrhage (see Figure 2.4.5).  
The score is between zero and 16; zero suggested no inflammation whilst 16 
indicated maximal acute inflammation.   




Figure 2.4.5: Semi-quantitative scoring method employed for H&E stained 
sections of murine lung tissue to assess acute lung inflammation.  Each animal 
had two sections analysed and mean scores were calculated based on the 
extent of any vascular congestion, oedema, inflammatory cell infiltration and 
haemorrhage.      
 
2.4.18 [3H]-PK11195 Autoradiography on 24 hour Murine Lung Sections 
To provide a quantitative method for scoring lung inflammation, a [3H]-PK 
11195 radiotracer, which binds TSPO (a protein demonstrating increased 
expression in immune cells during inflammatory responses(175) was used 
together with autoradiography.  Performed in collaboration with Dr. Adriana 
Tavares of the Centre for Cardiovascular Science, University of Edinburgh.   
 




For details of reagents used, please see Appendix 4.  Two consecutive 
paraffin-embedded sections per animal were de-paraffinised and rehydrated 
as per section 2.4.13.  Slides were pre-washed in 50mM Tris-Base buffer (pH 
7.4) for 3x 5 min then incubated in 1.87nM [3H]-PK11195 for one hour at room 
temperature.  The reaction was terminated by two 5 min washes in buffer and 
one immersion in dH2O.  Slides for non-specific binding were pre-washed as 
before then incubated in 1.87 nM [3H]-PK11195 and 10µM PK11195 for one 
hour at room temperature.  The reaction terminated as before.  Both the total 
and non-specific binding slides and ART0123A [3H]-microscales (American 
Radiolabelled Chemicals) were placed into the autoradiography cassettes, 
apposed to autoradiographic films (Fuji imaging plates), and incubated for five 
weeks.  Films were exposed using a Fujifilm FLA-S100 phosphorimager with 
Image Reader FIA 5000 software.  Images were saved as TIF files then 
analysed using ImageJ software.  Calibration curves were generated from 
regions of interest (ROI) of standards of known tritium ([3H]) concentrations.  
ROI were then drawn around lung sections for both total binding and non-
specific binding, then mean ROI pixel intensities were extracted.  Non-specific 
binding was subtracted from total binding to obtain specific binding in nCi/mg 
and data was also expressed as % specific binding. 
 
2.4.19 RT-PCR for Toll-like Receptors and Receptor for Advanced 
Glycation End Products (RAGE) on murine cDNA 




Frozen lung sections were thawed, then homogenised in 600 µL TRIzol® (Life 
Technologies) in Precellys Lysing Kit tubes (CK28), shaken using the Precellys 
24, Lysis and Homogenisation Machine (PeqLab, Bertin Technologies) for 1 x 
20 s at 5000 rpm, then transferred to 1.5 mL Eppendorf tubes and centrifuged 
at 4000 rpm for 5 min to remove particulate debris.   
 
The Direct-zol™ RNA MiniPrep kit (Zymo Research) was used to extract RNA.    
Supernatants were transferred to new tubes, to which ethanol was added, 
which functions to separate RNA.  The samples were transferred into a Zymo-
Spin™ IIC Column in a collection tube and centrifuged at 14000g for 30 sec.  
Flow-through was discarded then the column re-filled with remaining sample 
and centrifuged as before.  Flow-through was once again discarded then a 
DNase I treatment was performed to guarantee removal of any contaminating 
genomic DNA: RNA wash buffer was added to the column, which was 
centrifuged as before, then DNase I and DNA digestion buffer were mixed in 
an RNase-free tube.  This mix was added to each column and incubated at 
room temperature for 15 min.  Samples were thoroughly washed by sequential 
centrifugation then columns were transferred to an RNase-free tube.  To elute 
RNA, DNase/RNase-free water was added directly to the column matrix then 
centrifuged as before.  The quantity and purity of RNA was analysed using a 
Nanodrop 100 spectrophotometer.  Samples were stored at -80°C until use.  
 




Complementary DNA (cDNA) was made using a Multiscribe™ cDNA/RT Kit 
(Applied Biosciences), details of the master mix and primers used are in 
Appendix 5.  Samples were run on a C1000 Touch Thermal Cycler as follows: 
 25°C for 10 min; 
 42°C for 120 min; 
 85°C for 5 min; 
 then 4°C until samples removed and samples stored at -20°C until use. 
Gene expression was analysed using commercially available RT-PCR 
primer/probe assays (see Appendix 5) and PrimeTime® Gene Expression 
Master Mix 2X (Integrated DNA Technologies, Leuven).  Samples were run in 
duplicate and the gene of interest expressed relative to expression of a house-
keeping gene (β-actin).  Negative controls included no RT and no cDNA.  
Assays were run on a StepOne™ machine with the cycling protocol as follows: 





Polymerase activation 1 95 3:0 
Amplification: 
                      Denaturation 
          Annealing/Extension 
35-45   
 95 0:15 
 60 1:0 
Hold, if needed 1 4 Up to 24 hours 
 
Data was analysed using SDS 2.0 software (Thermo Fisher Scientific). 
 
 




2.4.20 Murine Lung Homogenisation for immunoblot lysates  
Details of buffers used are in Appendix 7.  The left lung segments snap frozen 
following the dissection in section 2.4.6 had been stored at -80°C.  These 
samples were thawed then homogenised in Laemmli Buffer (see Appendix 7) 
using the Precellys Lysing Kit tubes (CD14), shaken using the Precellys 24, 
Lysis and Homogenisation Machine for 1 x 25 s at 5500 rpm, then centrifuged 
at 12000 g for 10 min at 4°C.  Pierce® BCA Protein Assay Kit was used to 
quantify protein concentrations of resultant lysates, as described in section 
2.4.12.  Subsequent dilutions in Laemmli buffer and 2xSDS in a 1:1 ratio 
ensured all lysates had a protein concentration of 1 µg/µL.  Lysates were then 
boiled at 95°C for 5 min then stored at -80°C until use. 
 
2.4.21 Immunoblot for RAGE Protein Expression in Murine Lung Lysates 
Murine lung lysates were analysed for RAGE protein expression by western 
blot.  Details of the gels and buffers used are in Appendix 7. Proteins were 
separated by SDS-polyacrylamide gel electrophoresis using the BioRad mini-
protean system (run at 70-150V until the dye front runs off the end of the gel) 
prior to electrophoretic transfer to polyvinylidene difluoride (PVDF) membranes 
(Merck Millipore), run at 100V for 90 min.  Membranes were blocked with 5% 
skimmed milk powder in Tris-buffered saline and 0.05% Tween 20 (TBST) 
solution for a minimum of one hour.  Membranes were incubated with primary 
antibodies (prepared in 5% skimmed milk in TBST) at 4°C overnight on a rolling 




platform.  Details of the primary antibodies are found in Appendix 7.  
Membranes were washed 3x in TBST for 10 min per wash.  This was followed 
by incubation with anti-rabbit IgG horseradish peroxidase-conjugated 
secondary antibody (1:2000) (Dako) for one hour at room temperature on a 
rotating platform.  Membranes washed 3x in TBST for 10 min per wash then 
developed in enhanced chemiluminescence (ECL) detection reagent as per 
manufacturer’s instructions (ECL Select™ Western Blotting Detection 
Reagent, GE Healthcare, Buckinghamshire, UK).  Chemiluminescence was 
assessed using the Odyssey® Fc Imaging System (LI-COR® Bio-sciences, NE, 
USA) and quantified using ImageStudioLite software.  To allow semi-
quantitative analysis of protein expression, membranes were stripped using 
Restore Western Blot stripping buffer (Thermo Fisher Scientific) for 15 min, 
washed in dH2O and then re-probed for GAPDH as described above.  
 
  




2.5 Surface-enhanced Raman Spectroscopy-based 
Nanosensors Quantify Phagolysosomal pH in Healthy Control 
and Cystic Fibrosis Macrophages 
2.5.1 MDM Culture  
For Raman spectroscopy experiments, PBMC were differentiated into MDM 
by plating at 1x106/mL onto MgF2 discs (Crystran, UK) in 12-well plates 
(Corning™ Costar™, Life Sciences, UK) in IMDM supplemented with 10% 
autologous serum, 1% Penicillin and Streptomycin, 1% L-glutamine and 25 
mM HEPES at 37°C, 5% CO2.  Adherent monocytes were cultured for seven 
days with media changes on days one and five.  For fluorescence 
spectroscopy experiments, PBMC were differentiated as above in six-well 
UpCell™ plates (Nunc™, SLS, UK).  MDM differentiated in this manner have 
previously been shown to express CD14 and CD64, which are macrophage 
markers(176,177).   
 
2.5.2 Optical nanosensor preparation and incubation with MDM 
The Raman spectroscopy experiments were a collaborative study with Samuel 
J. Stanfield (studying for a PhD in Chemistry, supervised by Dr Colin J. 
Campbell of the Department of Chemistry, the University of Edinburgh) and 
myself. 
 




Gold nanoparticles (~150nm diameter, Sigma, UK) were functionalised with p-
MBA (termed MBA-NP) by S.J. Stanfield as previously described(178).  On 
day seven of MDM culture, IMDM was removed and MBA-NP at 5x106/mL in 
fresh IMDM were added (in a 5:1 ratio between MBA-NP and MDM) and 
incubated at 37ºC/5% CO2 for one hour to permit phagocytosis of the MBA-NP 
by MDM.  In some experiments, cells were treated with inhibitors as one-hour 
pre-treatments and throughout MBA-NP/Zymosan Bioparticles™’ incubation 
with MDM. 
 
2.5.3 Calibrating the pH response of MBA-NP 
IMDM solutions with pH values ranging from 4.0 - 9.5 (increments of 0.5 pH 
units) were made by adding either sodium hydroxide or hydrochloric acid (0.1 
M, aqueous) accordingly.  The pH of these solutions were measured firstly 
using a Mettler-Toledo InLab Ultra-Micro-ISM pH electrode and secondly using 
our pH-responsive MBA-NP.  For each pH, spectra from the MBA-NP were 
collected using the Renishaw inVia™ Raman microscope as described in the 
next section.  
 
2.5.4 Measurement of phagolysosomal pH using Raman spectroscopy 
Following incubation of MBA-NP with MDM, the MgF2 discs, upon which MDM 
had adhered, were transferred to a petri dish containing IMDM pre-warmed to 
37ºC.  MDM were then imaged on the Renishaw inVia™ Raman microscope 




using a 60X immersion objective (Olympus).  To permit mean calculations, 
spectral acquisition was performed on MBA-NP within three individual MDM 
per sample and three spectra were collected from each of the MBA-NP.  
Spectral acquisition times were 30 sec with a laser power of 0.875 mW.   
 
2.5.5 Acquisition of Raman Maps 
Raman maps were also collected with a Renishaw streamline 785 nm laser at 
0.0875 mW and a 30 sec acquisition time.  Data were processed using WIRE™ 
2.0, producing heat maps of Raman intensity based on the spectral peak at 
1580cm-1.   
 
2.5.6 Raman Data Analysis using MATLAB® Software 
Using MATLAB® software, the spectra were baseline corrected and normalised 
to a reference Raman-shift position (1580 cm-1), the intensity of which was 
invariant to pH.  The 1420 cm-1 peak intensity was used as the spectral metric 
for change in H+ concentration, and its value was calculated and plotted 
against the pH of the IMDM solutions.  The resultant scatter plot had a 
Boltzmann curve, the equation of which was: 
𝑦 𝐴2  , 




where y is pH, x is the intensity of the peak at 1420 cm-1, and A1, A2, x0, and 
dx are coefficients with values 0.003551, 0.224, 6.669 and 0.8053, 
respectively.  The calibration curve R2 = 0.9895 (see Chapter 5, section 5.4). 
 
2.5.7 Temporal measurement of pH as the MBA-NP progresses through 
MDM Phagocytosis Compartments 
In some experiments, single MBA-NP that looked to be adhered to the outside 
of an MDM (but not yet phagocytosed) on microscopy were imaged, as 
previously described, from 10 min to two hours’ post-incubation with MDM at 
least every 5 min, to assess the acidification rate of the MDM phagocytosis 
compartments.   
 
2.5.8 MDM MBA-NP phagocytosis quantification 
To determine whether MBA-NP uptake differed between genotypes, light 
microscopy on the Renishaw inVia™ Raman microscope at X60 magnification 
was used to quantify the percentage of MDM performing MBA-NP 
phagocytosis, counting at least 100 consecutive cells from at least three fields-
of-view and noting the presence of intracellular MBA-NP.  Representative 
images were taken using a digital camera focussed down the eyepiece.   
 




2.5.9 Quantification of Phagocytosis of pHrodo™ Green Zymosan 
Bioparticles™ by MDM 
Fluorescent pHrodo™ Green Zymosan BioParticles® conjugates were re-
suspended to 0.5 mg/mL in Live Cell imaging Solution (Thermo Fisher 
Scientific, UK) then sonicated for 5 min.  MDM differentiated in  UpCell™ 6 
well plates, see section 2.3.2, were detached  with cold DPBS supplemented 
with 0.5% BSA and 0.5 M EDTA and resuspended in IMDM at 1x106/mL and 
105 cells plated per well of a 96-well plate.  After allowing the MDM to adhere 
for one hour (37ºC/5% CO2), the culture medium was aspirated and replaced 
with BioParticles® suspension at 0.5mg/mL, incubated at 37ºC, 5% CO2 for one 
hour.  In some experiments, MDM were pre-treated with the inhibitors 
cytochalasin D or bafilomycin A1 for one hour.  The no-cell and BioParticles® 
suspension-free controls were also plated (to determine cellular auto-
fluorescence and reagent background fluorescence, respectively).  Each 
sample was plated in triplicate.  Plates were read on a BioTek Synergy™ HT 
microplate reader (excitation 509 nm and emission 533 nm).        
 
2.5.10 Transmission Electron Microscopy to confirm MBA-NP 
Localisation to Phagolysosomes    
In some experiments, following incubation with MBA-NP (one cell: eight MBA-
NP), MDM samples were fixed, dehydrated, and washed, as described in 
section 2.3.11.  Steven Mitchell performed the next steps in this protocol.   




Samples were embedded in TAAB 812 resin.  Sections, 1μm thick, were cut 
on a Leica Ultracut UCT Ultramicrotome, stained with Toluidine Blue, and 
viewed in a light microscope to select suitable areas for investigation.  Ultrathin 
sections, 60 nm thick, were cut from selected areas, stained in Uranyl Acetate 
and Lead Citrate then viewed in a JEOL JEM-1400 Plus TEM.   Representative 
images were collected on a GATAN OneView camera with assistance from 
Steven Mitchell.   
 
These TEM experiments were repeated with the addition of an LPS pre-
treatment of MDM in order to prime the MDM to increase the chances of finding 
MBA-NP within the phagolysosomes.  In these experiments, MDM were 
treated with 10 ng/mL LPS (from P.aeruginosa 10) (Sigma) for one hour, after 
which wells were washed twice with DPBS, followed by MBA-NP incubation 
as before.   
  




Chapter 3: Neutrophil Extracellular Traps are 
Associated with Airways Inflammation 
 
Background 
NETs were initially described as an anti-bacterial defence mechanism(65) and 
subsequent studies have revealed that NETs have been conserved throughout 
evolution(25,61–64), intimating the importance of their antimicrobial function.  
However, NETs have also been described as the “double-edged swords of 
innate immunity”(96) because they have been associated with numerous 
diseases characterised by sterile inflammation, including autoimmune 
disease, venous thrombosis and cardiovascular disease(97,99,100), 
described more fully in Chapter 1, section 1.12.   
 
Within the context of CF lung disease, mounting evidence suggests that NETs 
are the principal source of the free DNA within the airways, which is found at 
higher levels in CF patients compared to HC(101).  Marcos et al. quantified 
NETs using the Quant-iT PicoGreen® assay, based on a green fluorescent dye 
that binds DNA, and visualised sputum NETs using confocal laser scanning 
microscopy (CLSM) and electron microscopy(94).  They concluded that the 
presence of NETs was associated with a decline in lung function in CF 
patients(94).  Dwyer et al. also used the PicoGreen® assay to quantify NETs 




then measured the NET-protein contents by liquid chromatography-mass 
spectroscopy (LC-MS/MS) and western blot analysis(180).  However, a recent 
review article by Nauseef and Kubes highlighted the importance of confirming 
co-localisation between NET-DNA, histones and constituent proteins such as 
NE in assays which quantify NETs, to avoid false-positive results(103).  Hence, 
during my PhD, a novel ELISA was used to quantify histone-bound 
calprotectin, as a measure of NET abundance. 
 
Several of the aforementioned NET-associated proteins, such as NE, MPO 
and calprotectin, have been used as biomarkers for CF lung disease.  For 
example, release of NE, an azurophilic granule protease, is known to degrade 
proteins including elastin and collagen in the airways(109).  NE is also found 
in high concentrations in CF sputum and BAL samples and levels correlate 
with lung function decline in CF(38,181,182).  Similarly, both sputum and 
serum calprotectin levels significantly decrease following treatment of CF 
exacerbations, and serum calprotectin is negatively correlated with FEV1 and 
can predict time to next exacerbation in adult CF patients(114).  Likewise, 
sputum MPO levels increase during CF exacerbations and have been 
associated with poorer outcomes(111–113).  Given these NET constituent 
proteins are associated with lung function decline in CF, this strengthens the 
emerging favoured hypothesis that NETs contribute to lung damage in CF.  
Furthermore, recombinant human DNase (rhDNase, also referred to 
generically as dornase alfa, trade name Pulmozyme®) is a medication given to 




CF patients, which may function through degradation of NETs.  This 
medication contains DNase – an enzyme that cleaves extracellular DNA.  It is 
administered to patients as a nebulised treatment, usually once daily.  It 
decreases sputum viscosity(183) but also reduces airway inflammation, 
improves patients’ lung function and reduces exacerbation rates in both 
children and adults with CF(146,147,184).  DNase I is known to block G-actin 
polymerisation to F-actin(185), which could function to reduce sputum viscosity 
in the context of CF lung disease.  It may be that the drug’s main mechanism 
of action is through the inhibition of NET formation and/or clearance of NET-
DNA and this is a hypothesis that was explored during my PhD.  
 
Airway inflammation is usually quantified through measurement of sputum or 
BAL proinflammatory cytokines, such as IL-6, TNF-α and IL-8.  IL-6 is an acute 
phase response protein released from immune cells in response to pathogen-
associated molecular patterns (PAMPs).  IL-6 regulates almost all aspects of 
the innate immune system but has been noted to be both pro- and anti-
inflammatory(186).  TNF-α is mainly produced by activated macrophages and 
is a potent chemoattractant for neutrophils.  Once bound to its receptors on 
immune cells, TNF-α induces activation of NF-κB, MAPK and Caspase 8 
pathways, which mediate apoptosis(187,188).  Lastly, macrophages and 
monocytes are the main source of IL-8 production(189).  This cytokine can 
also be released by other innate immune cells and epithelial cells, the latter of 
which may be a major source of IL-8 in CF lung disease(190).  Once released, 
IL-8 induces chemotaxis of neutrophils and other granulocytes towards the site 




of infection and stimulates phagocytosis.  This is particularly relevant within 
the context of CF lung disease, where there is an excess of neutrophils within 
the airways(191), as described more fully in Chapter One, Section 1.9.   
 
  





1. NETs are proinflammatory in CF and their presence in patients’ sputum 
is associated with increased severity of lung disease. 
2. Macrophages produce proinflammatory cytokines when exposed to 
NETs and these effects are more pronounced in CF myeloid cells.   
 
Aims 
1. To quantify sputum NETs (using an ELISA that measures histone-
bound calprotectin) and proinflammatory cytokine levels in CF and HC 
participants, in order to determine if the level of NETs is associated with 
more severe lung disease and inflammation. 
 
2. To investigate the response of human HC and CF macrophages to 
NETs in culture, using microscopy to investigate cell morphology and 
ELISA quantification of the cytokines IL-8, TNF-α, IL-6 and IL-10 
present within culture supernatants. 
  





3.1 Participant Demographics 
Sputum was collected from HC and CF participants, following an induced 
sputum protocol in the former and spontaneous sputum from the latter, as 
described in Chapter 2, sections 2.2.5 and 2.2.6.  Analysis of participant 
demographics showed that there were no significant differences in the sex, 
age or body mass index (BMI) between genotype groups (Table 3.1).  As 
expected, CF participants had significantly lower FEV1 and ppFEV1 than HC 
participants (Table 3.1).   
  




Demographic HC (n=15) 
(median ± 95% 
CI) 
CF (n=45) 






Female 8 (53.3%) 18 (40%) n/a 
Male 7 (46.7%) 27 (60%) n/a 




p = 0.404 







p = 0.110 









p < 0.0001 
Table 3.1: Participant demographics including sex, age, body mass index 
(BMI (kg/m2)) and lung function.  There was no significant difference in the 
groups’ median age.  BMI was similar between both groups.  CF participants 
had significantly reduced median forced expiratory volume in one second 
(FEV1) compared to HC participants and median percentage predicted FEV1 
(ppFEV1) was similarly significantly reduced.  Data represents median ± 95% 
confidence intervals (CI) for continuous variables.  Data analysed using Mann-
Whitney test, where p<0.05 is deemed statistically significant.   




3.2 Neutrophils represent the predominant cell type in CF sputum 
and contain cytoplasmic vacuolations containing bacteria 
Sputum cytology revealed differences between HC and CF sputum.  Firstly, 
CF sputum samples had significantly higher total cell counts per gram of 
sputum compared to HC sputum, CF 2.9x107 (7x106 – 7.7x107/g) and HC 
6.88x105 (2.32x105 – 1.26x106/g) (median ± 95% CI) (Figure 3.1).  Secondly, 
macrophages were the predominant cell type within induced sputum from HC 
participants whilst neutrophils were the principal cell type within spontaneous 
sputum from CF participants (Figure 3.1).  CF sputum contained significantly 
higher numbers of neutrophils per gram of sputum compared to HC sputum 
(Figure 3.2) and this negatively correlated with ppFEV1 in CF participants 
(Figure 3.3).   
 
The neutrophils from CF sputum samples were morphologically different from 
HC neutrophils, manifested by higher numbers of cytoplasmic vacuoles, many 
of which appeared to contain bacteria (Figures 3.4 and 3.5).  It is important to 
note that HC sputum was collected using an induced sputum protocol whilst 
CF participants were able to spontaneously expectorate sputum.  Previous 
studies specifically designed to contrast the two techniques in the context of 
CF show that cell differential counts (excluding squamous cells) from both 
collection methods were similar(192) but induced sputum gives rise to 
improved cell viability(170).  It is unknown whether vacuolation and autophagy 
are affected by the sampling method employed.  Future work could examine 




this phenomenon (see Chapter 6, section 6.2).  The percentage of neutrophils 
containing these cytoplasmic vacuolations was quantified.  This demonstrated 
that the number of cells containing vacuolations was significantly higher in CF 
sputum neutrophils when compared to HC sputum neutrophils (Figure 3.6).  
These data support the hypothesis that an association exists between NET 
formation and autophagy and this should be investigated in future research 
(see Chapter 6, section 6.2).        










Figure 3.1: Differential cell counts from healthy control (HC) (A&B) and Cystic Fibrosis (CF) (C&D) sputum.  (A) Within 
HC induced sputum, macrophages are the predominant cell type (40% (34.6 – 54.8%)), followed by neutrophils (18.8% (10.6 -
31.6%)), airway epithelial cells (AEC) (14.5% (10.8 - 28.3%)), squamous epithelial cells (squamous) (6.4% (5.6 - 20.2%)), 
lymphocytes (0.7% (0.3 - 1.1%)), then eosinophils (0.3% (0.01 - 2.1%)).  (B) Differential cell count of HC induced sputum 
expressed as cell count per gram of sputum.  (C) Neutrophils are the principal cell type in spontaneous sputum from CF 
participants (94.6% (90.8 - 95.6%)), followed by macrophages (2.4% (2.6 - 5.2%)), squamous (0.9% (1.2 - 4.3%)), eosinophils 
(0% (0.09 -0.5%)), lymphocytes (0% (0.01 - 0.13%)).  (D) Differential cell count of CF spontaneous sputum expressed as cell 
count per gram of sputum.  Note HC induced sputum contains significantly fewer total cells per g compared to CF spontaneous 
sputum: 6.88x105 (2.32x105 - 1.26x106) vs. 29x106 (7x106 - 77x106).  HC induced sputum has more variation in cell type (B) 
compared to CF spontaneous sputum (D), in which neutrophils dominate.  Data represents individual points and median with 
95% confidence intervals.   




 Figure 3.2  
 
Figure 3.2:  Cell counts of neutrophils per gram of sputum in Healthy 
Control (HC) and Cystic Fibrosis (CF) sputum.  HC induced sputum (shown 
in blue) contains significantly fewer neutrophils per gram compared to CF 
induced sputum (shown in pink).  Data represents individual points and median 
± 95% confidence intervals and was analysed by Mann-Whitney test.  HC 
n=15, CF n=45.  Note the logarithmic scale of the y-axis. 
 
  








Figure 3.3: Neutrophils per gram of sputum correlated with lung function 
in Cystic Fibrosis participants.  The number of neutrophils per gram within 
CF spontaneous sputum (neutrophils/g) was correlated with the percentage 
predicted forced expiratory volume in one second (ppFEV1).  This shows that 
a significant negative correlation exists between the two parameters, i.e. with 
increasing neutrophil numbers, lung function deteriorates, r = -0.43, p=0.0038.  
Data represents individual points with linear regression and 95% confidence 
bands.  Data analysed using Spearman rank correlation coefficient.   












Figure 3.4: Morphological appearance of cells present in Healthy Control 
(HC) and Cystic Fibrosis (CF) sputum.  Representative photomicrograph 
images of cytocentrifuge preparations of cells present in HC induced (A) and 
CF spontaneous (B) sputum (taken using a x20 objective lens) to illustrate 
morphological appearance of cells that were present and quantified.  Scale bar 
20 µm.  Neutrophils exhibit a distinctive multi-lobed nucleus (white arrows) with 
evidence of vacuolation in the cytoplasm of those within spontaneous sputum 
from CF participants (B) (see Figure 3.5 for further demonstration of this 
finding).  Macrophages (black arrows) are identified by their characteristic 
features: they are large, irregular cells with an eccentrically placed nuclei, 
numerous vesicles and vacuoles, and ruffled surface(193).  Squamous 
epithelial cells (clear black arrows) are wide, flat cells with relatively featureless 
cytoplasms and contrast nicely to the airway epithelial cell (grey arrow of (A)), 
which has a distinctive columnar shape (with height 2-3 times greater than its 
width) and a basal nucleus(194).      










Figure 3.5: Comparison of morphological appearance of neutrophils in Healthy Control (HC) and Cystic Fibrosis (CF) 
sputum.  Representative photomicrograph images of cytocentrifuge preparations of cells present in HC induced (A) and CF 
spontaneous (B) sputum (taken using a x100 objective lens) to illustrate morphological appearance of cells that were present.  
Scale bar 10 µm.  HC sputum neutrophils had few, if any, vacuoles present in their cytoplasm (white arrow, (A)).  This image 
(from left to right) shows a macrophage, an airway epithelial cell and a neutrophil.  In contrast, the cytoplasm of CF sputum 
neutrophils contains numerous vacuolations (black arrows, B) some of which appear to contain bacteria, suggesting these are 
phagosomes/phagolysosomes.   










Figure 3.6: Quantification of sputum neutrophil cytoplasmic vacuolation 
in Healthy Control (HC) and Cystic Fibrosis (CF) sputum.  HC data shown 
in blue, CF in pink.  Sputum NETs were quantified in terms of fold-change in 
optical density (OD) compared to the mean OD of healthy control samples.  A) 
Photomicrograph images of sputum cytocentrifuge preparations (taken using 
a x40 objective lens) were analysed to quantify the percentage of neutrophils 
containing cytoplasmic vacuolations.  CF spontaneous sputum had 
significantly increased neutrophil vacuolation percentages relative to HC 
induced sputum, p<0.0001.  B)  Within the CF samples, there was no 
significant correlation between the percentage of vacuolated and sputum 
NETs, r= -0.24.  C) With regard to CF samples, there was no significant 
correlation between the percentage of vacuolated neutrophils and the 
percentage predicted forced expiratory volume in one second (ppFEV1), r= -
0.01.  A) Data represents individual points, and mean ± SD.  B&C) Data 
represents individual points.  Data analysed a two-tailed, unpaired Student’s t-
test (A) and Pearson’s correlation coefficient (B&C).  HC n=14, CF n=43.           
  




3.3 CF sputum contains significantly higher levels of NETs than HC 
sputum  
Having established that the cohort of CF participants had excessive airway 
neutrophils, I next quantified the presence of NETs within the soluble phase of 
sputum samples using an in-house ELISA.  CF sputum contained significantly 
increased levels of NETs when compared to HC sputum (Figure 3.7).  
Furthermore, sub-analysis of the CF participant data revealed that those on 
once daily nebulised Pulmozyme® (rhDNase) treatment had significantly 
reduced levels of NETs relative to CF participants who were not treated with 
rhDNase (Figure 3.8).  Patients were not on rhDNase either because it was 
not indicated (i.e. their lung disease was not severe enough) or because they 
had not tolerated or were non-concordant with the treatment.  These factors 
may have contributed to confounding of the data.   
 
Sub-analysis was also performed to determine whether those CF participants 
with P.aeruginosa or A.fumigatus colonisation had higher levels of NETs in 
their sputum but this was found not to be the case (Figure 3.9).  Similarly, 
Azithromycin treatment did not affect NET levels in the CF cohort (Figure 3.9). 
 
CF sputum NET levels did not have a significant positive correlation with the 
number of neutrophils per gram of sputum – suggesting that an intrinsic 
abnormality in CF neutrophils accounts for enhanced NET formation, rather 
than there simply being more neutrophils present (Figure 3.10).  NET levels in 




CF sputum did not significantly correlate with lung function when analysed in 
isolation (Figure 3.11).  However, when multi-variate linear regression 
modelling was used to predict FEV1, it revealed that sputum NETs, the number 
of respiratory exacerbations in 12 months experienced by the participant prior 
to sputum sampling, sputum neutrophils per gram, age and sex were all 
significant predictors of FEV1, whereas DNase treatment was not (Table 3.2). 
 
In order to validate the results obtained using the in-house NET ELISA, they 
were compared to those from established indirect measures of NETs, namely 
MPO activity, PicoGreen® and HNE assays.  We hypothesised that the in-
house ELISA would be superior to these assays because it depends upon co-
localisation of calprotectin and histones (the latter of which are associated with 
NET-DNA).  This co-localisation of NET constituents is a key requirement of 
any NET quantification assay; it is no longer sufficient to measure only one 
constituent because they can occur independently of NETs(103).  Sputum 
MPO activity, dsDNA and NE were found to be significantly increased in CF 
compared to HC sputum (Figures 3.12A, 3.13A and 3.14A).  These parameters 
also all had significant positive correlations with NETs (Figure 3.12B, 3.13B 
and 3.14B) and significant negative correlations with ppFEV1 (Figures 3.12C, 
3.13C and 3.14C).  Interestingly, with regard to the multi-variate linear 
regression model used to predict FEV1, when sputum NETs was replaced with 
MPO, NE and dsDNA, the model was weaker overall in terms of adjusted 
r2=0.6 (versus 0.64 when modelled with sputum NETs) and none of those 




parameters were shown to be significant independent predictors of FEV1.  This 
suggests that sputum NETs, as measured by co-localisation of NET proteins 
and histones, could be an important biomarker for CF lung disease research.   
 
3.4 Proinflammatory cytokines are elevated in CF sputum 
Commercially available ELISA kits quantified the concentrations of key 
inflammatory cytokines present in sputum samples.  IL-6 concentrations were 
significantly lower in CF sputum compared to HC sputum (Figure 3.15A).  
Conversely, TNF-α, IL-8 and calprotectin concentrations were all significantly 
higher in CF sputum compared to HC sputum (Figure 3.15B-D).   
 
3.5 CF sputum proinflammatory cytokines are positively correlated 
with sputum NETs and negatively correlated with lung function 
To determine whether there were any associations between these 
inflammatory cytokines and decline in lung function in CF participants, 
correlations were performed (Figure 3.16 A-D). Interestingly, only sputum 
calprotectin concentrations were negatively correlated with ppFEV1 (Figure 
3.16D).  We next tested for correlations between the levels of inflammatory 
cytokines and sputum NETS.  Positive correlations existed between sputum 
NETs and IL-8 and calprotectin but not between NETs and IL-6 or TNF-α 
(Figure 3.17). 




3.6 Calprotectin levels were significantly increased in the serum of CF 
participants compared to HC serum. 
A commercially available ELISA kit was used to measure serum calprotectin.  
Calprotectin was found to be significantly higher in the serum of CF participants 
compared to HC participants (Figure 3.18A).  Serum calprotectin levels were 
demonstrated to have no significant correlation with the levels of sputum NETs 
(Figure 3.18B).  However, serum calprotectin was shown to significantly 
negatively correlate with lung function.  This was the case when HC and CF 
data were combined and when CF data were analysed in isolation (Figure 
3.19).     

























Figure 3.7: Quantification of NETs in the soluble phase of Healthy Control 
(HC) and Cystic Fibrosis (CF) sputum.  An in-house ELISA measured 
histone-bound calprotectin.  Sputum NETs = fold-change in mean optical 
density (OD) from mean HC OD.  A) CF sputum contains significantly more 




NETs than HC sputum.  Median HC sputum NETs was 0.74 (0.45-1.18) and 
CF sputum NETs 5.94 (5.1-6.29).  Data represents individual points and 
median ± 95% confidence intervals.  Data analysed by Mann-Whitney test.  HC 
n=15, CF n=44.   B) Differences in sputum NETs analysed by Kruskal-Wallis 
test with Dunn’s multiple comparisons test for CF data divided into three 
groups based on percentage predicted forced expiratory volume in one second 
(ppFEV1), i.e. into mild (i.e. > 80%), moderate (40% - 80%) and severe (< 
40%).  Analysis showed no statistically significant difference in sputum NET 
levels between the CF severity groups.   






Figure 3.8: The impact of nebulised Pulmozyme® (recombinant human 
DNase) treatment on the levels of NETs present in sputum was measured 
by ELISA.  Data shown are determinations of NET levels from different 
individuals.  Our CF cohort were divided into two groups based on whether or 
not they received nebulised rhDNase, a mucolytic therapy that functions to 
fragment DNA.  Analysis of sputum NETs present in untreated versus once 
daily by unpaired two-tailed Student’s t-test revealed significantly lower NETs 
in those treated with DNase (untreated 5.48 ± 1.56 vs. treated 7.12 ± 2.23, 
p=0.0096).  Data represents individual points and mean ± standard deviation.  
DNase treatment: none n=10, once daily n=33.  Sputum NETs = fold-change 
in mean optical density (OD) from mean HC OD. 











Figure 3.9: Sputum NET levels in CF participants with or without 
Pseudomonas aeruginosa (PA) and Aspergillus fumigatus (Aspergillus) 
colonisation and Azithromycin treatment.    A) Analysis of sputum NET 
levels by an unpaired, two-tailed Student’s t-test revealed no significant 
difference between those CF participants colonised with PA (n=29) versus 
those without PA (n=16)(p=0.193).  B) Analysis of sputum NET levels by an 
unpaired, two-tailed Student’s t-test revealed no significant difference between 
those CF participants colonised with Aspergillus (n=18) versus those without 
Aspergillus (n=27) (p=0.5982).  C) Analysis of sputum NET levels by an 
unpaired, two-tailed Student’s t-test revealed no significant difference between 
those CF participants taking azithromycin (n=20) versus those not on the drug 
(n=25) (p=0.235).  All data represents mean ± SD.  Sputum NETs = fold-
change in mean optical density (OD) from mean HC OD.   
  







Figure 3.10: Correlation between neutrophils per gram of sputum and 
sputum NETs in CF participants.  Analysis of the correlation between 
neutrophils per gram of sputum and the level of sputum NETs by Pearson rank 
correlation coefficient revealed no significant correlation between these two 
parameters (r=0.28, p=0.07).  Sputum NETs = fold-change in mean optical 
density (OD) from mean HC OD. 
 
  















Figure 3.11:  Healthy Control (HC) and Cystic Fibrosis (CF) sputum NETs 
correlated with lung function.  HC data represented by blue data points, CF 
data represented by pink data points.  With regard to the CF data, analysis of 
the correlation between sputum NETs and percentage predicted forced 
expiratory volume in one second (ppFEV1) by Spearman rank correlation 
coefficient revealed no significant correlation (r2=0.11, p=0.46).  Sputum NETs 
= fold change in optical density (OD) from mean healthy control OD.  




Variable β SE t value Significance 
Sputum NETs 1.23E-01 5.72E-02 2.151 0.038* 
DNase -9.24E-02 2.57E-01 -0.359 0.722 
Number of exacerbations in 12 months -3.37E-01 5.87E-02 -5.737 0.0001*** 
Sputum neutrophil count per gram -2.79E-09 1.32E-09 -2.112 0.042* 
Age -2.39E-02 9.14E-03 -2.616 0.013* 
Sex 3.868E-0.1 1.739E-0.1 2.224 0.032* 
 
Table 3.2: Predicting forced expiratory volume in one second (FEV1) using a multi-variate linear regression model.  When FEV1 
was predicted using multi-variate linear regression modelling, it was found that sputum NETs, the number of respiratory exacerbations 
experienced by the participant in 12 months prior to sputum sampling, sputum neutrophils per gram, age and sex were all independent 
significant predictors whereas DNase treatment was not.  The overall model fit was r2 = 0.6927.  Specifically, CF sputum NETs remains 
independently associated with FEV1, p=0.038.  Residual standard error: 0.5553 on 36 degrees of freedom.  Adjusted r2 = 0.6415.  F-statistic: 
13.53 on 6 and 36 DF, p-value = 5.702e-08.










Figure 3.12: Sputum MPO activity correlated with sputum NETs and lung 
function.  Healthy Control (HC) data represented in blue data points.  Cystic 
fibrosis (CF) data represented in by pink data points.  A) Differences in sputum 
MPO activity analysed by Kruskal-Wallis test with Dunn’s multiple comparisons 
test revealed a significant increase in MPO activity in CF sputum relative to HC 
sputum (p<0.0001).  CF data were divided into three groups based on 
percentage predicted forced expiratory volume in one second (ppFEV1), i.e. 
into mild (i.e. > 80%), moderate (40% - 80%) and severe (< 40%).  Analysis of 
differences in MPO activity between these groups showed a statistically 
significant increase in MPO activity in the severe group compared to the mild 
group (p=0.02).  B) Analysis of sputum MPO activity correlated with sputum 
NETs by Spearman rank correlation coefficient revealed a significant positive 
correlation (r=0.73, p<0.0001).  C) Analysis of sputum MPO activity correlated 
with ppFEV1 by Spearman rank correlation coefficient showed a significant 
negative correlation (r= -0.67, p<0.0001).  Data represents individual points 
and linear regression (solid black line) with 95% confidence bands (dotted 
lines).  MPO activity = fold change in optical density (OD) from mean HC OD.   
  










Figure 3.13: Sputum dsDNA correlated with sputum NETs and lung 
function. Healthy Control (HC) data represented in blue data points.  Cystic 
fibrosis (CF) data represented in by pink data points.  A) Differences in sputum 
dsDNA (ng/mL) analysed by two-tailed Mann-Whitney test revealed a 
significant increase in dsDNA concentrations in CF sputum relative to HC 
sputum (p<0.0001).  B) Analysis of sputum dsDNA levels correlated with 
sputum NETs by Pearson correlation coefficient revealed a significant positive 
correlation when HC and CF data were analysed together (r=0.73, p<0.0001) 
and when CF data were analysed alone (r=0.38, p=0.01).  C) Analysis of 
sputum dsDNA levels correlated with percentage predicted forced expiratory 
volume in one second (ppFEV1) by Pearson correlation coefficient showed a 
significant negative correlation when HC and CF data were analysed together 
(r= -0.68, p<0.0001) and when CF data were analysed alone (r= -0.45, 
p=0.0025).  Data represents individual points and linear regression (solid black 
line) with 95% confidence bands (dotted lines).  Sputum NETs = fold-change 
in optical density (OD) from mean HC OD.   
  























All:  r = 0.73, p<0.0001
CF: r = 0.38, p=0.01








All: r = -0.63, p<0.0001
CF: r = -0.36, p=0.01




Figure 3.14: Sputum Neutrophil Elastase (NE) protein level correlated 
with sputum NETs and lung function.   Healthy Control (HC) data 
represented in blue data points.  Cystic fibrosis (CF) data represented in by 
pink data points.  A) Differences in sputum NE concentrations (mU/mL) 
analysed by two-tailed Mann-Whitney test revealed a significant increase in 
NE concentrations in CF sputum relative to HC sputum (p<0.0001).  B) 
Analysis of sputum NE levels correlated with sputum NETs by Spearman rank 
correlation coefficient revealed a significant positive correlation when HC and 
CF data were analysed together (r=0.73, p<0.0001) and when CF data were 
analysed alone (r=0.38, p=0.01).  C) Analysis of sputum NE levels correlated 
with percentage predicted forced expiratory volume in one second (ppFEV1) 
by Spearman rank correlation coefficient showed a significant negative 
correlation when HC and CF data were analysed together (r= -0.68, p<0.0001) 
and when CF data were analysed alone (r= -0.36, p=0.01).  Sputum NETs = 
fold-change in optical density (OD) from mean HC OD.   
 
  










Figure 3.15: ELISA quantification of sputum inflammatory markers in healthy control (HC) and Cystic Fibrosis (CF) 
sputum.  A) Analysis of sputum IL-8 concentrations in CF vs. HC sputum revealed a statistically significant increase (p<0.0001).   
B) Analysis of sputum TNF-α concentrations in CF vs. HC sputum showed a statistically significant (p=0.01).  C) Analysis of 
sputum calprotectin concentrations in CF vs. HC sputum demonstrated a statistically significant increase (p<0.0001).  D) 
Analysis of sputum IL-6 concentrations in CF vs. HC sputum revealed a statistically significant decrease (p=0.01).  Data 
represents individual points and median ± 95% confidence intervals.  All data analysed using two-tailed Mann-Whitney test.  HC 
n=8-15, CF n=32-45. 
















































Figure 3.16: Cystic Fibrosis (CF) sputum inflammatory marker concentrations correlated with lung function.  A) Analysis 
of IL-6 concentrations present in CF sputum correlated with percentage predicted forced expiratory volume in one second 
(ppFEV1) revealed no significant correlation.  B) Analysis of TNF-α concentrations present in CF sputum correlated with ppFEV1 
showed no significant correlation.  C) Analysis of IL-8 concentrations present in CF sputum correlated with ppFEV1 demonstrated 
no significant correlation.  D) Analysis of sputum calprotectin concentrations present in CF sputum revealed a statistically 
significant negative correlation (r= -0.37, p=0.03).  Data represents individual data points and linear regression lines (solid black 
lines) with 95% confidence bands (dotted lines).  All data analysed by Spearman rank correlation coefficient, asides from IL-8 
data, which was analysed by Pearson correlation coefficient.   







Figure 3.17: Sputum NETs correlated with sputum IL-8 and calprotectin 
concentrations.  Healthy control (HC) data represented in blue, Cystic 
Fibrosis (CF) data represented in pink.  A) Analysis of sputum NETs correlated 




with sputum IL-8 concentrations by Spearman rank correlation coefficient 
revealed a significant positive correlation when HC and CF data were analysed 
together (r=0.67, p<0.0001) and when CF data were analysed alone (r=0.37, 
p=0.01).  B) Analysis of sputum NETs correlated with sputum calprotectin 
concentrations by Spearman rank correlation coefficient revealed a significant 
positive correlation when HC and CF data were analysed together (r=0.80, 
p<0.0001) and when CF data were analysed alone (r=0.55, p=0.001).  Sputum 
NETs = fold change in optical density (OD) from mean HC OD. 
 
  







Figure 3.18: Serum calprotectin levels in Healthy Control (HC) and Cystic 
Fibrosis (CF) participants and correlation with sputum NETs in CF 
participants.  A) Analysis of calprotectin concentrations in CF versus HC 
serum by two-tailed Mann-Whitney test revealed significantly higher 
calprotectin concentrations in CF serum (p<0.0001).  Data represents 
individual data points and median with 95% confidence intervals.  HC n=15, 
CF n=31.  B) Analysis of the correlation between sputum NET levels and 
serum calprotectin in CF participants by Pearson rank correlation coefficient 
revealed no significant correlation between these parameters (r=0.05, p=0.77).  
Sputum NETs = fold change in optical density (OD) from mean HC OD.   
  























Figure 3.19: Serum calprotectin correlated with percentage predicated 
forced expiratory volume in one second (ppFEV1).  When serum 
calprotectin concentrations were correlated with ppFEV1, a measure of lung 
function, using Pearson rank correlation coefficient, there was a significant 
negative correlation.  This was the case when Healthy Control (HC, shown in 
blue data points) data were combined with Cystic Fibrosis (CF, shown in pink 
data points) data (r=-0.42, p=0.0009), and when CF data were analysed alone 
(r= -0.34, p=0.03).  Data represents individual data points and linear regression 
(solid black line) with 95% confidence interval bands (dotted lines).     
  




3.7 Establishing a model for co-culture of monocyte-derived 
macrophages with NETs 
Having determined that sputum NETs were elevated in CF sputum and were 
positively associated with the levels of proinflammatory cytokines present in 
sputum, I sought to establish a cell culture model to investigate whether NETs 
exert proinflammatory effects, focussing on the interplay between neutrophils 
and macrophages.   
 
Preliminary experiments were designed to determine which pharmacological 
agents should be used to stimulate and inhibit NET formation in vitro.  PMA 
was chosen over ionomycin because it resulted in characteristic NET 
formation, with diffuse and spreading NETs evident and smaller standard 
deviations when quantified (Figure 3.20A and B, and Figure 3.21C).  The 
concentration of PMA for optimal stimulation of NETs was then determined by 
quantification of NET formation using a fluorescence microscopy kinetic plate 
reader assay.  100nM PMA was the most effective stimulator of NET formation 
(Figure 3.20C and 3.21), whilst DNase (100U/mL) was the most effective 
inhibitor of NET formation (Figure 3.22).  I next compared the extent of NET 
formation when neutrophils were exposed to PMA as either adherent cells (i.e. 
“plated culture”) or when cultured in suspension (i.e. “rolling culture”) (Figure 
3.20D).  This was done to quantify the percentage of cells which NETed in 
each condition to determine if they were comparable.  There was a significant 
reduction in the percentage of neutrophils undergoing NET formation when 




cells were cultured in suspension compared to adherent culture (20.3 ± 6.1% 
versus 53.7 ± 21.4%, respectively) (Figure 3.20D).  In the control experiments 
(i.e. those without PMA) there was no significant difference in the percentage 
of neutrophils undergoing NET formation when comparing cells cultured either 
in suspension or as adherent cells (0.37 ± 0.4% versus 0.5 ± 0.4%, 
respectively).  Despite there being fewer cells undergoing NET formation when 
cultured in suspension, this method allowed neutrophils to be washed, thus 
removing any residual PMA that might adversely affect MDM function prior to 
co-culture.  The control experiment data revealed that the mechanical forces 
involved when cells were cultured in suspension did not stimulate NET 
formation.         






Figure 3.20: Quantification of in vitro neutrophil extracellular trap 
formation (NET formation) by fluorescence microscopy using SYTOX® 









microscopy.  When neutrophils were treated with PMA, this resulted in 
characteristic NET formation, with both diffuse and spreading NETs evident 
(white arrows).  B) Ionomycin-induced NETs were smaller and well-
demarcated, with fewer spreading NETs, compared to those induced by PMA.  
C) Neutrophils were untreated (i.e. control) or treated with PMA (at 10, 50 and 
100 nM) and Ionomycin (Iono.) (at 1, 5 and 10 µM).  NET formation was then 
quantified using ImageJ software to count the percentage of neutrophils 
undergoing NET formation.  The percentage of NETed neutrophils present in 
each condition were: control wells 0.73 ± 1.0, PMA 10 nM 22.7 ± 7.6, PMA 50 
nM 24.4 ± 15, PMA 100 nM 26.1 ± 9, Ionomycin 1 µM 33.5 ± 46.3, Ionomycin 
5 µM 23.7 ± 17.5, Ionomycin 10 µM 44 ± 24.4.   D) Quantification of the extent 
of NET formation when neutrophils were exposed to PMA as either adherent 
cells (i.e. “plated”) or when cultured in suspension (i.e. “rolling”).  Control wells 
had no significant NET formation in either plated or rolling culture.  Analysis of 
the percentage of neutrophils undergoing NET formation in plated versus 
rolling culture by one-way ANOVA with Tukey’s multiple comparisons test 
revealed a significant decrease in NET formation with rolling culture (p=0.03).  
Data represents individual points and mean ± SD.  n=3 for all experiments.     
  


































Figure 3.21: Quantification of DNA release by kinetic plate reader assay 
as a surrogate indicator of neutrophil extracellular trap (NET) formation. 
A) Analysis of NET production in PMA treated cells versus control neutrophils 
by two-way ANOVA with Tukey’s multiple comparisons test revealed 
significantly increased NET formation with PMA treatment (PMA 10 nM 
p=0.0006, PMA 50 nM p=0.0022, and PMA 100 nM p=0.0003).  B) Analysis of 
NET production in ionomycin treated cells versus control neutrophils by two-
way ANOVA with Tukey’s multiple comparisons test showed significantly 
increased NET formation with ionomycin treatment (all concentrations, 
p<0.0001).  Data represents mean ± SD.  C) Neutrophils were stimulated with 
PMA 100 nM in vitro and NETs visualised using immunofluorescence.  Co-
localisation of Hoechst staining (blue) and antibodies against myeloperoxidase 
(green) implies NET formation.    
  









Figure 3.22: Pharmacological inhibition of NET formation in vitro.  
Neutrophils were cultured in suspension with PMA 100 nM and/or the inhibitors 
DPI, Ro-31-8220 and DNase, then plated and incubated for six hours.  NET 
formation was visualised using SYTOX® green staining with fluorescence 
microscopy.  ImageJ software was used to count the percentage of neutrophils 
undergoing NET formation.  Analysis of the percentage of neutrophils 
undergoing NET formation by one-way ANOVA and Sidak’s multiple 
comparisons test revealed that the most significant inhibition of NET formation 
was by DNase, p<0.0001.  Data represents individual points and mean ± SD, 
n=3 for all experiments.   




3.8 Scanning electron microscopy revealed morphological 
differences between control and NETed neutrophils in co-culture with 
MDM  
In order to investigate morphological differences between control neutrophils 
and NETing neutrophils, scanning electron microscopy was used alongside 
transmitted light microscopy during the co-culture experiments.  Neutrophils 
were rolled in suspension for 15 min – half were control neutrophils and so 
were suspended in HBSS-/- only, whilst half were suspended in HBSS-/- and 
PMA to stimulate NET formation.  These control/NETed neutrophils were 
subsequently co-cultured with MDM for 24 hours (in a ratio of 2:1 neutrophils 
to MDM).  For the wells designated for scanning electron microscopy, cells 
were adhered to plastic Thermanox™ cover slips in wells of a 6-well plate, 
whilst those wells designated for investigation of supernatant cytokine levels 
simply had cells adhered to the base of the plastic wells.  During the co-culture, 
cells were cultured in IMDM supplemented with 25mM HEPES and L-
glutamine, 5% FCS and 1% Penicillin/Streptomycin.  IMDM was selected 
because it is a highly enriched media suitable for rapidly proliferating, high-
density cell cultures.  The antibiotics were used to prevent bacterial infection 
of the MDM during their 7 days of culture.  5% FCS was used to maintain both 
neutrophils and MDM present and autologous serum was avoided for the co-
culture because exposure to foreign autologous serum may have affected cell 
phenotypes, confounding results.  Following co-culture of neutrophils/NETed 
neutrophils with MDM for 24 hours, in those cells destined for scanning 
electron microscopy experiments, Gluteraldehyde was applied as a fixative 




then samples were processed ready for microscopy (see Chapter 2, section 
2.3.11 for details of methodology).   
 
Inspection of cell morphology using scanning electron microscopy revealed 
morphological differences between control neutrophils and NETing neutrophils 
and this was evident even using transmitted light microscopy at x20 
magnification (Figure 3.23).  Therefore, light microscopy was used after each 
co-culture experiment to confirm the NETs had been produced, where 
appropriate.  Scanning electron microscopy revealed ultra-structures of the cell 
surfaces and NET-like extracellular strands were clearly visible (Figure 3.23C-
E and Figure 3.24).      
 
3.9 NETs were proinflammatory to MDM 
Following the 24-hour co-culture between neutrophils/NETed neutrophils with 
MDM, supernatants were harvested and cytokine concentrations were 
quantified by ELISA.  HC NETs were proinflammatory to CF MDM, causing an 
increase in IL-8 production after 24 hours of co-culture (Figure 3.25A).  There 
was a similar trend in HC MDM but this failed to reach statistical significance 
(Figure 3.25B).  Both HC and CF MDM had exaggerated IL-8 production in 
response to CF neutrophils/NETs, suggesting CF NETs are hyper-
inflammatory relative to HC NETs (Figure 3.25).  DNase treatment significantly 




reduced IL-8 production from MDM in all co-culture combinations (Figure 
3.25).   
 
With regard to TNF-α production, CF MDM released more overall relative to 
HC MDM.  However, sub-analysis of separate HC and CF MDM responses to 
co-culture with HC NETs revealed a trend for increased TNF-α production 
relative to those co-cultured with control neutrophils but this did not reach 
statistical significance (Figure 3.26A).  DNase treatment significantly increased 
TNF-α production by CF MDM in response to HC NETs (Figures 3.26A).  In 
the case of co-culturing with CF neutrophils/NETs, there was a trend for 
increased TNF-α production from MDM but this only reached statistical 
significance in the HC MDM group (Figure 3.26B). 
 
IL-6 concentrations were low in all co-culture supernatants.  However, a 
significant decrease in IL-6 production was noted when healthy MDM were co-
cultured with CF control and NETed neutrophils (Figure 3.27B). 
 
Finally, IL-10 was measured because it commonly functions as an anti-
inflammatory cytokine.  When HC and CF MDM were co-cultured with HC 
control neutrophils and NETs, there were significantly increased levels of IL-
10 produced from CF MDM (Figure 3.28A).  HC NETs were not, however, 
proinflammatory relative to control neutrophils (Figure 3.28A) to either HC or 




CF MDM.  Lastly, HC and CF MDM produced similar, albeit low levels, of IL-
10 in response to CF neutrophils and NETs, with no significant differences 
between co-culture conditions (Figure 3.28B). 
  










Figure 3.23: Scanning electron microscopy of the neutrophil/NETed 
neutrophil and monocyte-derived macrophage co-culture experiment.  A)  
Morphological differences exist between control and NETed neutrophils.  Light 
microscopy showing control neutrophils (white arrows): small, round, well-
demarcated cells, much smaller compared to adjacent MDM (clear black 
arrows).  B) Light microscopy of NETed neutrophils (black arrows): larger and 
irregularly shaped in comparison to their control counterparts.  C) scanning 
electron microscopy of a control neutrophil.  D) scanning electron microscopy 
of NETed neutrophils with extracellular strands (clear white arrows), in-keeping 
with NETs.  E) False-coloured image of the NET-MDM co-culture, showing a 
NETed neutrophil with an elongated extracellular strand.   










Figure 3.24: Scanning electron microscopy image of the co-culture between NETed neutrophils and monocyte-derived 
macrophages (MDM).  White arrows = NETed neutrophil; black arrows = MDM; clear white arrow = erythrocyte; clear black 
arrow = NET-like extracellular strand.  In the false coloured image (right), the NETed neutrophils are shown in green whilst the 
MDM are shown in blue.  Physical interactions between adjacent cells are evident and the cytoplasm of the MDM contains 
numerous, well demarcated rounded structures, which may be actin.     










Figure 3.25: Quantification of supernatant IL-8 concentrations from the 
neutrophil/NETed neutrophil and monocyte-derived macrophage (MDM) 
co-culture experiments.  HC = healthy control (shown in blue), CF = cystic 
fibrosis (shown in pink), Nø = control neutrophil.  Data represents individual 
data points and mean ± SD, n=5-6 per group.  Neutrophil extracellular traps 
(NETs) increase IL-8 production by MDM and CF NETs exaggerate this effect.  
A) Analysis of supernatant IL-8 levels, when HC neutrophils/NETed 
neutrophils were co-cultured with either HC MDM or CF MDM, was performed 
using two-way ANOVA with Tukey’s multiple comparisons test.  This analysis 
revealed a significant increase in IL-8 levels when CF MDM are cultured with 
HC NETs, compared to CF MDM in media alone or cultured with control 
neutrophils (p=0.005 and p=0.01, respectively).  Furthermore, DNase 
treatment caused a significant decrease in IL-8 levels where CF MDM were 
cultured with NETed neutrophils (p=0.004).  Similar trends were seen for HC 
MDM but these failed to reach statistical significance.  B) Analysis of 
supernatant IL-8 levels when CF neutrophils/NETed neutrophils were cultured 
with HC MDM, again by two-way ANOVA with Tukey’s multiple comparisons 
test, revealed a significant increase in IL-8 levels when HC MDM were cultured 
with CF NETs versus those cultured in media alone or with control neutrophils. 
(p=0.0006 and p<0.0001, respectively).  Similar, significant differences in 
supernatant IL-8 levels were found in CF neutrophil/NETed neutrophil and CF 
MDM co-culture.  DNase treatment once again caused a significant decrease 
in IL-8 levels in HC and CF MDM (p<0.0001 and p-0.007, respectively).   
  




















Figure 3.26: Quantification of supernatant TNF-α concentrations from the 
neutrophil/NETed neutrophil and monocyte-derived macrophage (MDM) 
co-culture experiments.  HC = healthy control (shown in blue), CF = cystic 
fibrosis (shown in pink), Nø = control neutrophil.  Data represents individual 
data points and mean ± SD, n=5-6 per group.  A)  Analysis of supernatant 
TNF-α levels produced by HC and CF MDM when co-cultured with HC 
neutrophils/NETed neutrophils by two-way ANOVA with Tukey’s multiple 
comparisons test revealed that CF MDM produce significantly increased levels 
of TNF-α relative to HC MDM (p=0.0493).  There were no significant 
differences in TNF-α levels from HC MDM between the different co-culture 
conditions.  However, TNF-α levels were increased in CF MDM co-cultured 
with HC NETs in the presence of DNase, relative to CF MDM cultured alone 
or with HC control neutrophils (p=0.001 in both conditions).  B)  Analysis of 
supernatant TNF-α levels produced by HC and CF MDM when co-cultured with 
CF neutrophils/NETed neutrophils by two-way ANOVA with Tukey’s multiple 
comparisons test revealed no significant difference in TNF-α production 
between genotypes.  There were no significant differences in TNF-α levels 
from CF MDM when the different co-culture conditions were compared.  With 
regard to TNF-α levels from HC MDM, statistical analysis revealed a significant 
increase in TNF-α levels when CF NETs were co-cultured with HC MDM 
versus control neutrophils (p=0.04).  A similar trend was seen for CF MDM but 
this did not reach statistical significance. 
 











Figure 3.27: Quantification of supernatant IL-6 concentrations from the 
neutrophil/NETed neutrophil and monocyte-derived macrophage (MDM) 
co-culture experiments.  HC = healthy control (shown in blue), CF = cystic 
fibrosis (shown in pink), Nø = control neutrophil.  Data represents individual 
data points and mean ± SD, n=5-6 per group.  NETS do not induce an IL-6 
response by either HC or CF MDM.  A) There was no IL-6 production by HC 
MDM when co-cultured with HC neutrophils and NETs.  The same was true for 
CF MDM, with the exception of one sample in which CF MDM were cultured 
in media alone.  B) HC MDM cultured alone produce low levels of IL-6 (mean 
37.9 pg/mL ± 41.3).  Analysis of IL-6 levels by two-way ANOVA with Tukey’s 
multiple comparisons test revealed a significant increase in IL-6 levels from 
HC MDM cultured alone versus those with CF control neutrophils or CF NETs 
(p=0.004 in both cases).  No such difference existed in the co-culture 
conditions between CF neutrophils/NETs and CF MDM.  DNase treatment did 
not affect IL-6 concentrations.   





















































Figure 3.28:  Quantification of supernatant IL-10 concentrations from the 
neutrophil/NETed neutrophil and monocyte-derived macrophage (MDM) 
co-culture experiments.  HC = healthy control (shown in blue), CF = cystic 
fibrosis (shown in pink), Nø = control neutrophil.  Data represents individual 
data points and mean ± SD, n=5-6 per group.  A) Analysis of IL-10 production 
by two-way ANOVA with Tukey’s multiple comparisons test revealed an overall 
significant increase in IL-10 levels from CF MDM versus HC MDM (p=0.0004) 
but no differences between co-culture conditions when each genotype of MDM 
were analysed separately.  B) There is no significant difference in IL-10 levels 
when HC and CF MDM were co-cultured with CF neutrophils/NETs.  DNase 
does not affect IL-10 concentrations.   
  





The data analysis in this chapter began with descriptive statistics of participant 
demographics.  Although CF participants had poor lung function, they were 
systemically well, as indicated by their normal BMI.  Indeed, the CF 
participants’ median BMI was 22.5 kg/m2 (where median male BMI was 23.2 
kg/m2 and female BMI was 21.4 kg/m2).  This suggests good practice by the 
participants’ multi-disciplinary care team because for adults with CF, better 
lung function is associated with higher BMI(195);  nutritional advice and 
interventions should be targeted at sustaining a BMI of 22 kg/m2 in women and 
23 kg/m2 in men(196).   
 
I next interrogated variations between HC and CF participants’ sputum cell 
pellet differential cell counts.  This was important to address the fundamental 
question of whether there might simply be more NETs in CF sputum than HC 
sputum because the former is characterised by neutrophilic infiltration of the 
airways.  In agreement with the existing literature(192), it was found that CF 
sputum contained predominantly neutrophils whereas HC sputum had a 
variety of cell types present, the most numerous of which being the 
macrophage.  Furthermore, light microscopy revealed that the CF sputum 
neutrophils differ morphologically when compared to HC counterparts, the 
former containing significantly more cytoplasmic vacuolations, many of which 
appeared to contain bacteria.  This abnormality may reflect impaired 
phagocytosis in CF neutrophils.  This would be in agreement with a previous 




study by Morris et al. who showed that pulmonary neutrophils from patients 
with CF had a reduced phagocytic capacity for C3bi-opsonised Zymosan(197).  
They suggested that impaired phagocytic capacity was due to abnormal lung 
environment in CF or dysfunctional priming on neutrophil migration into the 
airway, rather than it being an intrinsic defect due to absent/dysfunctional 
CFTR(197).  Investigation of whether phagocytosis is impaired in CF 
neutrophils was beyond the remit of this PhD but would be of interest for future 
research.  Airway neutrophils could be isolated from BAL and cultured with an 
enhanced green fluorescent bacteria, such as P.aeruginosa or S.aureus, then 
both phagocytic capacity and subsequent bacterial degradation could be 
assessed by flow cytometry(198).  Alternatively, or in addition to impaired 
phagocytosis, the vacuolations seen in CF neutrophils may be associated with 
abnormal autophagy.  This is the process whereby aged portions of the cytosol 
are appropriated and broken down within double-membrane-bound vesicles 
termed autophagosomes, which also plays an important role in the killing of 
microorganisms by innate immune cells and is impaired in CF(199).  
Fluorescence microscopy could be used in CF and non-CF airway neutrophils 
to image autophagy markers such as microtubule-associated proteins 1A/1B 
light chain 3B (LC3) and lysosomal markers (e.g. LAMP-1/2 or LIMP-II).   
 
In order to address the question of whether there are simply more NETs in CF 
sputum because it is a disease characterised by neutrophilic infiltration of the 
airways, I examined whether there was a correlation between neutrophils per 




gram of sputum and sputum NETs.  No significant correlation existed, which 
supports the suggestion that there is an intrinsic propensity for CF neutrophils 
to undergo NET formation, in agreement with recently-published data from our 
group(70). 
 
Indeed, the data in this chapter confirm that CF sputum contains significantly 
higher levels of NETs than HC sputum and NETs are significantly associated 
with airway inflammation and decline in lung function in CF lung disease, in 
agreement with previous studies(94,180).  Our ELISA was used to quantify 
NETs and it may be preferable to the PicoGreen® assay for two reasons.  
Firstly, because the ELISA detects histone-bound calprotectin it specifically 
enables measurement of NET-DNA as opposed to DNA from bacteria, which 
typically does not contain histones.  Secondly, the ELISA demonstrates co-
localisation between NET constituents, which is a key requirement of any in 
vitro assay measuring NETs(103).  Using the ELISA, it was found that sputum 
NET levels were significantly lower in those CF participants treated with once 
daily DNase (Pulmozyme®) compared to those not on this therapy, which 
strengthens the conviction that the assay is a measure of NETs, since they 
should be cleared from the airways by DNase.  Conversely, it is possible that 
DNase simply disrupts the association between histones and calprotectin.   
 
To confirm that our NET ELISA results were in line with other indirect measures 
of NETs, MPO activity, dsDNA and NE assays were performed.  Each of these 




outputs were significantly higher in CF sputum relative to HC sputum and had 
significant positive correlations with NETs and significant negative correlations 
with lung function.  Increased MPO and NE activity in the sputum implicates 
neutrophilic inflammation in the disease pathophysiology, as these can be 
released via degranulation and NET formation.  When FEV1 was predicted 
using the multivariate linear regression modelling, MPO activity, dsDNA levels 
and NE were not significant independent predictors of FEV1, whereas sputum 
NET levels were and strengthened the model overall, as shown by an increase 
in its modified R2 value.  We conclude that our assay, which measured co-
localisation between NET constituents, may be superior to these indirect 
measures of NETs.    
 
CF sputum had increased levels of IL-8, TNF-α and calprotectin, relative to HC 
sputum.  These cytokines are especially important for neutrophil chemotaxis 
and migration(109), which would occur during a CF exacerbation.  However, 
all sputum samples were taken from non-exacerbating CF participants and so 
results are reflective of stable disease.  These data suggest CF patients have 
chronic inflammation, even when not suffering infective exacerbations.  IL-8 
has previously been used as a biomarker for CF(200–202),but we found no 
significant negative correlation with ppFEV1.  This suggests sputum IL-8 is of 
limited use as a biomarker, in agreement with other studies which have shown 
that it does not always change during exacerbations(114,203).  Interestingly, 
IL-6 was significantly lower in CF sputum compared to HC sputum, which has 




been reported elsewhere(204); this altered regulation of IL-6 may contribute to 
the impaired resolution of the acute phase response and neutrophilia that 
typifies CF lung disease.  It also lends support to the hypothesis that in certain 
contexts, IL-6 functions as an anti-inflammatory cytokine(186).  When 
correlating these cytokines with sputum NETs, it was found that only IL-8 had 
a significant positive correlation with NETs, perhaps unsurprising since it plays 
a key role in neutrophil recruitment.  Calprotectin, a protein which is highly 
abundant in neutrophils and activates macrophages via TLR-4(205), has been 
proposed as a biomarker for CF by our group(114).  The data in this chapter 
support that viewpoint because calprotectin most strongly correlated with 
sputum NETs (more so than sputum IL-8 levels) and was the only 
proinflammatory protein measured which had a significant negative correlation 
with lung function.  Multi-variate linear regression was finally used to determine 
the interplay between NETs and lung function; when FEV1 was predicted, it 
was found that sputum NETs was an independent, significant predictor 
(alongside the number of exacerbations in 12 months, sputum neutrophils per 
gram, sex and age).  To conclude, the data in this chapter have confirmed that 
NETs are associated with airway inflammation and predict FEV1.  However, 
the underlying mechanisms have not been fully resolved. 
 
To investigate the antimicrobial association of sputum NETs, it was 
hypothesised that those CF participants colonised with P.aeruginosa would 
have higher levels of NETs in their sputum, since this organism is known to be 




a potent activator of NET formation(89), but this was not the case when data 
was analysed.  NETs are suited to degrading large microorganisms such as 
fungal hyphae which are too large to be phagocytosed and Marcos et al. found 
that airway NETs correlated with A.fumigatus colonisation(94).  However, in 
our CF cohort sputum NET levels were unaffected by A.fumigatus colonisation.  
These findings support the view that NETs are proinflammatory and damaging 
in CF, rather than acting as effective antimicrobial mediators.       
 
In order to try to elucidate mechanisms by which NETs were proinflammatory, 
an in vitro co-culture model was utilised, based on one previously used by our 
group(70).  Preliminary experiments were carried out to stimulate and quantify 
NET formation, which found that PMA was more effective than ionomycin at 
inducing NET formation.  Exposure of neutrophils to PMA resulted in NETs 
which were diffuse and spreading in appearance, characteristic features of in 
vitro NETs(61).  Ionomycin on the other hand produced small, well-demarcated 
cells when visualised using SYTOX® Green, more characteristic of apoptotic 
cells.  We did not assess neutrophil apoptosis rates; however, this could be 
addressed in future NET assay experiments by flow cytometry using annexin-
V in combination with propidium iodide (PI) and morphological assessment of 
apoptotic changes by light microscopy of H&E stained cytocentrifuged 
neutrophils.  Approximately 50% neutrophils NETed in response to culture with 
100 nM PMA and this dropped to ~20% after rolling culture.  However, the 
latter method was selected because it permitted washing of neutrophils to 




remove any residual PMA, which may have adversely affected the MDM in the 
co-culture model.  I did not investigate the potential effects PMA has on MDM.  
This is a question which could be addressed in future experiments by culturing 
them in IMDM supplemented with varying concentrations of PMA then 
assessing cell morphology and ability to secrete IL-8 in response to NETs and 
another inflammatory stimulus (e.g. LPS).   
 
HC and CF control neutrophils and NETed neutrophils were co-cultured with 
HC and CF MDM for 24 hours in various combinations (see Figures 3.23 – 
3.28).  HC NETs stimulated IL-8 production by CF MDM, in agreement with 
previous experiments(70) and CF NETs exaggerated this effect; indeed when 
CF NETs were used, HC MDM also produced significantly increased levels of 
IL-8.  This implies firstly that NETs produced by CF neutrophils are hyper-
inflammatory relative to HC NETs and secondly that CF MDM are hyper-
responsive relative to HC MDM.  The underlying reasons for this are unclear.  
Intrinsic abnormalities in CFTR-/- neutrophils and macrophages do exist, but 
none directly pertaining to NET formation(66), although the Gray group has 
previously shown that CF neutrophils form more NETs over time(70).  CF 
macrophages have significantly higher levels of TLR-4 on their plasma 
membranes(132) and so it may be that the calprotectin present on NETs 
activates macrophages to produce higher amounts of proinflammatory 
cytokines.  To address this suggestion, measurement of TLR-4 protein and 
RNA expression from co-culture cell lysates would be of interest for future 




research.  DNase treatment rescued the proinflammatory MDM phenotype, 
significantly reducing IL-8 production in all co-culture combinations and this 
might contribute to the drug’s anti-inflammatory properties(37).  It may be that 
degradation of NETs by DNase facilitated their uptake by MDM into 
phagolysosomes.  Phagocytosis of NETs is one mechanism by which NETs 
are cleared from the airways and does not result in proinflammatory cytokine 
secretion(206).   
 
Regarding TNF-α, CF MDM produced more of this proinflammatory cytokine 
compared to HC MDM overall and sub-analysis revealed increased levels in 
response to CF NETs versus control neutrophils in the HC MDM group.  
However, TNF-α concentration did not differ between co-culture conditions to 
the same extent as IL-8, suggesting different cell signalling pathways govern 
the production of these two cytokines in response to NETs.  DNase treatment 
increases TNF-α production by CF MDM, perhaps because fragmentation of 
the DNA increases the release of the NET constituent proinflammatory 
proteins.     
 
In agreement with the sputum cytokine data, MDM did not produce IL-6 in 
response to NETs, suggesting it does not play a key role in the mechanism by 
which NETs are proinflammatory in CF lung disease.   
 




Finally, IL-10 is a cytokine which has been described as anti-inflammatory in 
the context of CF(207,208).  CF MDM produced higher baseline IL-10 levels 
than HC MDM, but this effect was not increased due to co-culture with NETs.   
During the co-culture experiments, I only investigated the 24 hour time point.  
It may be that if supernatants had been harvested over a time course, the 
levels of proinflammatory cytokines would vary.  In addition, the model studied 
only the co-culture between neutrophils/NETs and MDM.  To mimic better the 
CF lung, in which inflammation is driven by infection with Gram-negative 
bacteria such as P.aeruginosa, the co-culture model could have a second 
stimulus added, such as LPS or live bacteria.  I hypothesise this would result 
in a further exaggeration of proinflammatory cytokine release by the MDM.  
Given that the macrophages used were monocyte-derived macrophages, it is 
unlikely that they had any exposure to bacteria (unlike alveolar macrophages) 
and so the hyper-activation of the CF macrophage is likely to be due to an 
intrinsic defect.   
 
The data in this chapter supports our hypothesis that NETs accumulate in CF 
airways and are associated with inflammation and increased severity of lung 
disease.  Furthermore, we have shown that NETs are proinflammatory to MDM 
and this response is exaggerated in CF MDM.   
 
  




Chapter 4: Examination of the acute 
inflammatory response in CFTR-/- mice 
Background 
The data discussed in the previous chapter suggest that the presence of NETs 
in the airways is associated with airways inflammation and increased severity 
of CF lung disease in our patient cohort.  These findings led to the question of 
whether a mouse model of CF could be utilised to elucidate further the 
mechanisms by which NETs cause inflammation in CF lung disease and 
assess whether clearing NETs from the airways reduces inflammation. 
 
The Cftrtm1UncTg(FABPCFTR)1Jaw/J mice (Charles River Laboratories Ltd., 
UK) were used in the CF mouse models in this chapter.  The characterisation 
of the mice have been described previously(172).  In brief, these bi-transgenic 
mice have both the FABP-hCFTR transgene (human fatty acid binding protein 
1 liver (FABP1) promoter directing expression of a human cystic fibrosis 
transmembrane conductance regulator (ATP-binding cassette sub-family C, 
member 7) (CFTR) gene) and a targeted mutation of the cystic fibrosis 
transmembrane conductance regulator homolog gene (Cftrtm1Unc).  The first 
transgene corrects the lethal gut phenotype typical of CFTR knockout mice 
(i.e. they usually die within 40 days due to intestinal obstruction, with or without 
perforation and resultant peritonitis(209)).  This bi-transgenic model allows 




mice to have normal gut function whilst ensuring little or no CFTR expression 
in the airways.  Various other CF mouse models have been used previously to 
investigate the pathophysiology of CF lung disease(210).  Of relevance to this 
thesis, previous studies by other groups have demonstrated that CF mice have 
an exaggerated response to both sterile and bacterial-induced inflammation.  
For example, Su et al. exposed CD1 wild-type (WT) and F508del-CF mice (the 
latter back-crossed into a CD1 genetic background (>eight generations)) to 
intratracheal LPS and culled the animals at 24 hours then performed BAL.  
Neutrophils within the BAL were positively stained by anti-CFTR antibody 
(showing that these activated neutrophils express CFTR).  The CFTR 
knockout mice had increased production of proinflammatory cytokines by 
activation of NF-κB, and worsened LPS-induced acute lung inflammation and 
damage 24 hours following LPS(211).  Similarly, Bonfield et al. subjected WT, 
whole body CFTR KO and myeloid-specific CFTR KO mice to infection using 
P.aeruginosa-laden agarose beads instilled into their right main bronchi with 
culls performed at three and 10 days.  Myeloid-specific CFTR KO was 
achieved crossing a LysM promoter-driven Cre recombinase transgene into a 
“floxed” CFTR line carrying a CFTR allele with LoxP sites flanking exon 10(19).  
Both whole-body and myeloid-specific CFTR KO resulted in increased lung 
damage at day 10 as demonstrated by increased erythema and nodularity on 
macroscopic examination, BAL neutrophilia, elevated BAL proinflammatory 
cytokines (including IL-1β, IL-6 and monocyte chemoattractant protein-1 
(MCP-1) at both days three and 10) and reduced survival(19).  The myeloid-
specific CFTR KO mice had an intermediate severity phenotype, indicating that 




myeloid-derived innate immune cells play a crucial role in the pathophysiology 
of CF lung disease.   
 
Existing literature therefore shows that CF mouse models are important tools 
with which to study dysfunctional innate immunity in the context of CF.  I chose 
to examine LPS-mediated acute lung injury throughout the animal experiments 
of this thesis.  Mice were nebulised with LPS from P.aeruginosa (serotype 10).  
LPS is a principal constituent of the outer membrane of gram-negative 
bacteria, it is an established TLR-4 agonist, induces neutrophil-driven 
inflammation and some groups report that it stimulates NET formation both in 
vitro and in vivo(108,212–214).  LPS is comprised of three principal structural 
parts: lipid A, a core domain containing an oligosaccharide component, and a 
repetitive polysaccharide, known as the O-antigen(215).  Pieterse et al. 
demonstrated that LPS induces NET formation and the type of NETs produced 
in vitro in response to LPS depends upon culture conditions and the bacterial 
source of LPS – in serum- and platelet-free culture, only LPS from E.coli 
O128:B12 and P.aeruginosa 10 induced “suicidal” NETs in an autophagy and 
ROS-dependent but TLR-4-independent manner(212).  The authors 
speculated that this was because these two bacteria are able to evade killing 
by phagocytosis, P.aeruginosa through the formation of biofilms and E.coli 
O128:B12 due to the sugar composition of its O-antigen(212) and therefore 
NET formation provided neutrophils with an alternative bactericidal 
mechanism.  Conversely, in the presence of platelets in vitro and in whole 




blood cultures ex vivo, all LPS serotypes stimulated “vital” NETosis, 
independent from ROS formation and autophagy but requiring platelet-TLR4 
and CD62P-dependent platelet–neutrophil interactions(212).  In agreement 
with Pieterse et al.’s findings, Clark et al. found that in vitro, NETs only formed 
in the presence of both LPS and platelets(216).  However, the molecular 
mechanisms responsible for CD62P-induced NET formation remain unknown.  
It follows that for our in vivo model, the use of LPS from P.aeruginosa (serotype 
10) should be appropriate to induce NET formation.  I chose to induce 
inflammation using LPS as opposed to an infection model because it allowed 
elucidation of any NET-associated phenotype, without the confounding factors 
of possible defects in bacterial killing caused by absence of CFTR in innate 
immune cells.  This model produces consistent and reproducible neutrophil-
dominated lung inflammation and so mimics the inflammation seen in early CF 
lung disease, prior to bacterial colonisation.  
 
Previous murine, pig and human CF models have implicated macrophages in 
the production of damaging proinflammatory cytokines in response to LPS. 
Bruscia et al. demonstrated that CFTR-/- murine macrophages have higher 
basal levels of macrophages in their BAL compared to WT mice at 0 hours 
following a nebulised LPS challenge(217).  CF murine macrophages also 
produced increased levels of IL-6, IL-1α, G-CSF and MCP-1 over 24 hours 
following stimulation with LPS in vitro whilst cytokine levels in heterozygote 
animals were intermediate between CF and WT values(217).  Furthermore, 




Paemka et al. used an ex vivo CF pig model to demonstrate that  macrophages 
from newborn CF pigs have an absence of functional CFTR and exhibit an 
increased inflammatory response to an LPS challenge(21).  In this study, 
PBMC were isolated from whole blood then adherent cells were differentiated 
in IMDM supplemented with foetal bovine serum, Pen/Strep and M-CSF for 6 
days.  Resultant CF pig MDM produced significantly more IL-8 and TNF-α in 
response to 200 ng/mL LPS relative to non-CF pigs(21).  The authors 
suggested that an intrinsic defect in the CF macrophage was responsible for 
the hyper-responsive phenotype, since it occurred in newborn animals, which 
were yet to develop inflammatory lung disease(21).  They speculated that M1 
macrophage polarisation might cause this intrinsic defect(21) but did not 
investigate this at a mechanistic level.  With regard to possible mechanisms 
underlying development of human disease, addition of NETs to HC and CF 
human MDM resulted in the induction of IL-8 and TNF-α production after 24 
hours’ co-culture and this cytokine response was heightened in CF MDM 
compared to HC MDM, although the method of control of cytokine production 
was not defined(70).  Data presented in Chapter 3, which details a co-culture 
experiment between HC and CF control/NETed neutrophils and MDM in 
various combinations, corroborates and builds upon these findings.  Therefore, 
to assess innate immune cell function (by which we infer this to be macrophage 
function) proinflammatory cytokine levels within BALF were measured at 24 
and 72 hours post-LPS challenge as the output for the CF mouse model 
experiments.  To investigate whether clearing NETs would reduce 
inflammation seen in the CF mouse, nebulised DNase therapy was 




administered at 12 hours’ post-LPS nebulisation to half of the animals of each 
genotype.  DNase was selected for two reasons: firstly, data from Chapter 3 
show that DNase was the most effective inhibitor of NET formation in vitro (see 
Figure 3.17).  Secondly, DNase is an established treatment for CF patients 
(see Chapter 1 and 3).  Experiments designed to assess the impact of DNase 
treatment on proinflammatory cytokine production would provide insight into 
potential anti-inflammatory mechanisms of actions.   
 
Hypotheses and Aims 
It was hypothesised that there would be increased levels of NETs in the CF 
mouse lung and consequently more severe inflammation compared to WT 
littermates.  Furthermore, DNase treatment would be predicted to normalise 
levels of NETs, BALF proinflammatory cytokine levels and lung inflammation 
scores in CF mice in line with levels seen in WT littermates.  The aims of these 
experiments were: 
1) To determine whether NET formation and associated inflammation are 
increased in Cftrtm1UncTg(FABPCFTR)1Jaw/J mice in comparison to WT 
littermates following a sterile inflammatory challenge using nebulised 
lipopolysaccharide from P.aeruginosa (serotype 10).   
2) To investigate whether nebulised DNase treatment clears NETs and 
reduces inflammatory indices in the Cftrtm1UncTg(FABPCFTR)1Jaw/J 
mice and WT littermates. 





4.1 Characterisation of LPS-induced acute lung inflammation in mice 
Preliminary experiments in C57BL/6 mice nebulised with PBS or LPS were 
used to determine when peak and resolution of inflammation occurred.  Peak 
inflammation was defined as the time point at which BAL neutrophil counts, 
BAL IL-6 levels (because it is a key cytokine in the acute phase response) and 
semi-quantitative scoring of acute lung injury (including inflammatory cell 
infiltration of the alveoli) on histology sections were at their maximum.  
Resolution of inflammation was defined as the time point at which these 
parameters returned to baseline levels (i.e. the levels observed in the zero 
hour time point mice).  These experiments revealed that peak inflammation 
occurs at 24 hours following LPS-mediated acute lung injury, with subsequent 
resolution after 72 hours.  This was assessed using three parameters: BALF 
differential cell counts, semi-quantitative scoring of acute lung inflammation on 
H&E stained lung sections, and quantification of BALF supernatant IL-6 levels.  
With regard to the semi-quantitative scoring of H&E stained lung sections, four 
parameters were scored: vascular congestion, thickness of the interalveolar 
septa (indicative of oedema), inflammatory cell infiltration, and haemorrhage.  
There was a significant increase in total cell count and neutrophil counts in 
BALF at 24, 48 and 72 hours post-LPS (Figure 4.1A and B).  Macrophage 
numbers did not differ between groups until 72 hours post-LPS (Figure 4.1C), 
which accounted for the differences seen in total cell count at that time-point, 
suggesting that macrophages play a key role in resolution of inflammation.  In 




agreement with these data, a semi-quantitative score of acute lung 
inflammation demonstrated peak damage at 24 hours post-LPS, largely 
resolved by 72 hours (Figures 4.2 and 4.3).  This may imply that damage is 
neutrophil dependent, since BALF neutrophils also peak at 24 hours post-LPS.  
Resolution of this neutrophil-driven inflammation begins by 48 hours post-LPS 
because neutrophil numbers and lung inflammation scores are falling by this 
time point.  In addition to the histological changes seen, analysis of the BALF 
supernatant revealed significantly elevated levels of IL-6 24 hours post-LPS, 
which had returned to baseline by 72 hours (Figure 4.4).  These data informed 
the CF mouse model experiments – samples were collected at 24 and 72 hours 
post-LPS in order to quantify levels of NETs and inflammatory parameters at 
peak and resolution of inflammation.  
 
  




Figure 4.1  
 




Figure 4.1:  Neutrophilic inflammation peaks 24 hours after lipopolysaccharide 
(LPS)-mediated lung injury.  C57BL/6 mice were treated with nebulised LPS or PBS.  
Bronchoalveolar lavage samples were analysed for total cell counts and macrophage 
and neutrophil counts.  Data represents mean ± SD.  Data analysed by multiple t-
tests with the Holm-Sidak adjustment for multiple comparisons to compare cell counts 
between PBS and LPS treated groups.  n=4 per group per time point.  *** p<0.001.  
** p<0.01, * p<0.05.  A) Total cell count/mL peaks 24 hours post-LPS and remains 
elevated even at 72 hours.  B)  Neutrophils/mL also peaks at 24 hours post-LPS and 
has almost normalised by 72 hours.  C) Macrophages/mL does not significantly differ 
between groups until 72 hours post-LPS.  PBS did not affect BALF cell counts (A-C).   
 
In order to compare cell counts obtained at the different time points, two-way ANOVA 
with Sidak’s multiple comparisons test was used.  There were no significant 
differences in the PBS group BALF total cell counts across the time course.  The LPS 
treated group had significantly higher total cell counts at 24, 48 and 72 hours post-
LPS vs. zero hours (p>0.0001, p=0.0002 and p=0.0001), and at 48 and 72 hours vs. 
24 hours (p=0.02 and p=0.04, respectively).  There was no significant difference in 
total cell count in the LPS treated group at 72 vs. 48 hours (p=0.997).  BALF 
neutrophils per mL did not significantly differ over time in the PBS treated group.  The 
LPS treated group had significantly increased neutrophils per mL at 24 vs. 0 hours 
(p<0.0001) 48 vs. 0 hours (p<0.0001) but not at 72 hours (p=0.12).  The LPS treated 
group had significantly increased neutrophils per mL at 48 vs. 24 hours (p=0.002), 72 
vs. 24 hours (p<0.0001) and 72 vs. 48 hours (p=0.01).  BALF macrophages per mL 
did not significantly differ over time in the PBS treated group.  The LPS treated group 
had significantly increased macrophages per mL at 72 vs. zero hours, 72 vs. 24 hours, 
and 72 vs. 48 hours (all p<0.0001).  There was no significant difference in the LPS 
treated group BALF macrophages per mL at 24 and 48 hours vs. zero hours (p=0.13 
and p=0.21, respectively) or at 48 vs. 24 hours (p>0.99).    











D) PBS-treated mice 
had no increase in 
vascular congestion 
(white arrows), 
thickening of the 
interalveolar septa 
(clear black arrow), 
inflammatory cell 
infiltration (solid black 
arrow) or haemorrhage (too small to see at this scale) over the time course experiment.  E-F) In contrast, lipopolysaccharide (LPS)-treated 
mice had inflammation peaking at 24 hours and mainly resolving by 72 hours.  All images at X 20 magnification.  




















Figure 4.3: Inflammation peaks at 24 hours and has resolved by 72 hours.  
The lungs of C57BL/6 mice were harvested at 0, 24, 48 and 72 hours following 
nebulised PBS or lipopolysaccharide (LPS) treatment.  A) Haematoxylin & 
Eosin stained sections were scored using a semi-quantitative score for acute 
lung inflammation.  B) Inflammatory cell infiltration (percentage of lung 
parenchyma (i.e. excluding blood vessels) within which inflammatory cells 
were evident) was also quantified.  Data reveals peak inflammation at 24 hours 
and resolution by 72 hours in the LPS-treated group.  n=2 per group per time 
point. 







Figure 4.4:  Bronchoalveolar lavage (BAL) IL-6 levels peak at 24 hours 
following lipopolysaccharide (LPS)-mediated acute lung injury.  C57BL/6 
mice were treated with nebulised PBS or LPS then BAL fluid was collected at 
0, 24, 48 and 72 hours.  There was a significant increase in IL-6 concentration 
with LPS treatment (standardised for BAL volume) compared to PBS at 24 
hours (p=0.02).  Data represents individual values, mean ± SD.  Data analysed 
using multiple t-tests with the Holm-Sidak adjustment for multiple comparisons.  
n=4 per group per time point. 
 
 




4.2 CFTR-/- mice have an exaggerated acute inflammatory response to 
LPS-mediated lung injury 
Based on the preliminary results of LPS-induced acute lung inflammation in 
C57BL/6 mice, I next examined the development and resolution of acute lung 
inflammation in Cftrtm1UncTg(FABPCFTR)1Jaw/J mice (CFTR-/-) and C57BL/6 
WT littermate mice, examining samples taken at 24 and 72 hours following 
LPS administration.  These time points were selected in order to investigate 
potential differences in the time of peak inflammation and subsequent 
resolution of inflammation.  Analysis of BALF cell differential counts revealed 
that following LPS challenge, the cell composition changed from alveolar 
macrophages at baseline (i.e. within the time course experiment) to 
predominantly neutrophils at 24 hours, but neither genotype nor DNase 
treatment had a significant impact on cell counts (Figure 4.5).  However, CFTR-
/- mice had a statistically significant increase in acute inflammation 
(characterised histologically by the presence of pulmonary oedema, 
inflammatory cell infiltration, vascular congestion and haemorrhage) relative to 
their WT littermates at 24 hours post-LPS (Figures 4.6 and 4.7).  Of note, the 
histopathological semi-quantitative scores at 72 hours were not as low as that 
seen at baseline in the time course experiment, suggesting a degree of 
inflammation was still present at 72 hours in both genotypes.  With regard to 
BAL cell counts and histology scores, inflammation had decreased to the same 
extent in both genotypes by 72 hours post-LPS, suggesting there was no 
problem with resolution of inflammation in CFTR-/- mice (Figures 4.5 and 4.7).  
Given the difference in estimation of inflammation based on BAL cell count and 




histology at 24 hours’ post-LPS, it was hypothesised that inflammatory cells 
present in the BALF of CFTR-/- mice may exhibit exaggerated proinflammatory 
responses to give rise to increased inflammation.  This hypothesis was further 
examined by measuring cytokine levels in BALF supernatants using a 
multiplex array.  CFTR-/- mice were noted to have significantly increased levels 
of IL-6, TNF-α, IL-17 and IL-10 at the 24 hour time point relative to their WT 
littermates (Figure 4.8).  In contrast, levels of IFN-ɣ, IL-23, KC, IL-1β, MIP-2 
and MCP-1 did not significantly differ with genotype or DNase treatment (see 
Appendix 8).  By 72 hours, all cytokine levels had decreased to almost 
undetectable levels, with no significant differences between genotype and 
treatment groups (see Appendix 8).   
 
Finally, to provide a potential quantitative method for scoring lung inflammation 
24 hours’ post-LPS, a [3H]-PK11195 radiotracer, which binds TSPO 
(mitochondrial translocator protein, a protein demonstrating increased 
expression in immune cells during inflammatory responses), was used 
together with autoradiography (work performed in collaboration with Dr 
Adriana Tavares, who directly supervised my experiments).  Unfortunately, a 
common problem with PK11195 is high non-specific binding in vivo and this 
was also the case in this ex vivo experiment, as shown by the high uptake in 
“non-specific binding” radiotracer control lung sections (Figure 4.9B).  This 
meant that when the “non-specific binding” ROI mean pixel intensity was 
subtracted from “total binding” ROI mean pixel intensity, resultant values sat 




too low on the calibration curve and so extrapolation of nCi/mg (i.e. the non-SI 
unit of radioactivity) would have been inaccurate.  Therefore, results were 
expressed in terms of percentage specific binding.  These data failed to reveal 
a significant difference in lung PK11195 levels between groups (Figure 4.9C).  
The data also exhibited a wide standard deviation and it may be that in these 
assays the PK11195 was too non-specific to discriminate reliably inflammatory 
cells (since TSPO is expressed on haematopoietic and lymphatic cells).  
Future studies should therefore have increased sample sizes and/or utilise a 
more specific, second generation TSPO radiotracer – such as 18F-LW223, 
currently under development by Dr Adriana Tavares’ group.  
  




Figure 4.5      
 
Figure 4.5: Genotype and DNase treatment did not affect BALF cell counts at 24 
or 72 hours post-LPS.  BALF differential cell counts from CFTR-/- (Hom) and WT 
mice, at 24 and 72 hours post-LPS were analysed for A) total cell count, B) neutrophil 
count and C) macrophage count.  Data represent mean ± SD.  Data analysed by two-
way ANOVA with Sidak’s multiple comparisons test.  n=4-7 per group.     






Figure 4.6: Histology sections of WT and CFTR-/- (Hom) murine lung sections at 
24 hours post-LPS.  The semi-quantitative score measured the extent of pulmonary 
oedema (thickening of the alveolar interstitium), inflammatory cell infiltration (white 
arrow), vascular congestion and pulmonary haemorrhage.  Inflammatory cell 
infiltrates are seen in (B) as purple, nucleated cells (black arrows).       







Figure 4.7:  Histopathological scoring of acute lung inflammation 
following LPS-mediated acute lung injury.  CFTR-/- mice have excessive 
acute sterile lung inflammation relative to WT littermates 24 hours following 
LPS administration.  By 72 hours, this inflammation has resolved to near 
baseline (mean scores of 2 were obtained in baseline samples in the time 
course experiments) in both genotypes.  H&E stained lung sections were 
analysed using a semi-quantitative score for acute lung inflammation.  Data 
represents individual points and mean ± SD.  24-hour and 72-hour data 
analysed separately using two-way ANOVA, then combined data analysed 
using two-way ANOVA to compare time points.  n=4-6 per group.        






Figure 4.8: Murine 
bronchoalveolar lavage fluid 
(BALF) cytokine levels 24 
hours post-LPS in WT and 
CFTR-/- mice.  Filled bars = WT, 
non-filled = CFTR-/-.  CFTR-/- 
mice have significantly higher 
levels of IL-6 (A), TNF-α (B), IL-
17 (C) and IL-10 (D) in their 
BALF at 24 hours post-LPS 
relative to C57BL/6 WT 
littermates.  DNase does not 
affect cytokine levels.  Data 
analysed by two-way ANOVA 
with Tukey’s multiple 
comparisons test.  Data 
represents individual points and 
mean ± SD.  n=4-5 per group.  p-
values refer to two-way ANOVA 
analysis determining whether 
there was a statistically 
significant difference in cytokine 
levels between genotypes. 






Figure 4.9: Autoradiography of ex vivo murine lung sections for translocator 
protein (TSPO) quantification.  A) Regions of interest (ROI) were drawn round 
Tritium standards [3H] to generate a calibration curve.  B) ROI were then drawn round 
consecutive lung sections (see purple outlines) for total and non-specific binding, 
mean pixel intensities extracted and calibrated against the standard curve generated 
from (A).  C) WT = filled bars, CFTR-/- = non-filled bars.  There were no significant 
differences between groups for percentage specific binding of [3H]-PK11195 to 
TSPO. In addition, possible differences in TSPO binding may have been obscured by 
large SD values. The translocator protein (TSPO) [3H]-PK11195 radiotracer assay is 
too insensitive to measure murine lung inflammation ex vivo 24 hours post-LPS.  Data 
represent individual points and mean ± SD.  Data analysed using two-way ANOVA.  
n=5 per group. 
  




4.3 Airway NETs do not differ between genotypes but significantly 
reduce on resolution of inflammation 
Having determined that CFTR-/- mice have heightened inflammation at 24 
hours in response to LPS, the role that NETs play in this phenomenon was 
interrogated.  NETs were quantified in BALF supernatants using an in-house 
ELISA using an anti-histone primary antibody from a cell death detection kit, 
followed by a mouse S100A9 ELISA kit for the detection antibody.  Data show 
that no significant differences in the level of BALF NETs were present in WT 
or CFTR-/- mice either at peak inflammation (24 hours) or during subsequent 
resolution (72 hours) (Figure 4.10).  However, there was a statistically 
significant decrease in BALF NETs at 72 hours post-LPS relative to 24 hours 
post-LPS for both genotypes (Figure 4.10).  Furthermore, there was a trend for 
reduced levels of NETs with DNase treatment, although this failed to reach 
statistical significance.  It may be that more mouse numbers would make the 
data significant.  Alternatively, one possible explanation for the lack of 
difference between levels of NETs between WT and CFTR-/- would be that the 
BAL fails to sample airway NETs effectively. I therefore used 
immunohistochemistry to image neutrophils and NETed neutrophils within ex 
vivo murine lung sections (Figure 4.11).  Whilst total neutrophil count did not 
differ between groups, the CFTR-/- mice had a significant increase in neutrophil 
recruitment into the alveolar compartments, relative to their WT littermates 
(Figure 4.12B).  Neutrophils were deemed NETing if 1) they were triple positive 
for Hoechst DNA staining and antibodies against MPO and S100A9 with co-
localisation of MPO and S100A9 revealed by the presence of yellow pixelation 




(Figure 4.11).  Quantification of NETs by counting triple-positive cells support 
the BALF NET ELISA results. There were no significant differences in NETs 
between genotype or treatment groups at 24 hours post-LPS.  Similar to the 
ELISA-based findings, there was a trend for decreased NETs with DNase 
treatment (Figure 4.12B & C).  It is likely that additional experiments (to 
increase the sample size) would be required to confirm or refute the trends 
seen in the data with regard to DNase treatment.  The 72 hour time point was 
not examined using immunohistochemistry because it was predicted that 
numbers of NETing neutrophils would be too low to provide a reliable estimate 
of NETing cells.  C57BL/6 mice treated with nebulised PBS served as a 
negative control for this experiment (Figure 4.12A-C).  Since only a few studies 
have been published which describe how to  image murine NETs in lung 
sections ex vivo using immunohistochemistry(108,214), the approach used 
here could be added to the repertoire of methods for quantification of the 
presence of NETs in vivo.   
  




Figure 4.10  
 
 
Figure 4.10: Quantification of bronchoalveolar lavage fluid (BALF) NET 
levels by ELISA.  BALF NETs significantly decrease on resolution of 
inflammation but do not differ between genotypes at individual time points.  At 
24 hours’ post-LPS, there is no significant difference in BALF NETs between 
groups.  At 72 hours’ post-LPS, there is a trend for decreased NETs with 
DNase treatment in both genotypes, but this did not reach statistical 
significance.  BALF NETs significantly decrease at 72 hours relative to 24 
hours (p=0.03).  NETs quantified using fold-change in optical density from WT 
+ LPS readouts.  Data represents individual points and mean ± SD.  24 hour 
and 72 hour data analysed separately using two-way ANOVA with Sidak’s 
multiple comparisons test, then time points compared using two-way ANOVA.  
n=4-7 per group. 










Figure 4.11: Immunohistochemistry of NETs in ex vivo murine lung sections following LPS-mediated acute lung injury.  
NETs can be imaged using immunohistochemistry and quantified through detection of co-localisation of constituent proteins.  
Representative confocal microscopy images of lung sections from a C57BL/6 WT mouse 24 hours following LPS-mediated acute 
lung injury.  The zoomed-in image (right) shows co-localisation of MPO (green) and S100A9 (red), i.e. yellow pixelation.  The 
number of cells triple positive for Hoechst (blue), MPO and S100A9 and with yellow pixels, were deemed NETed neutrophils 
(white arrows). 












































Figure 4.12:  Quantification of ex vivo murine lung neutrophil numbers 
and NETs by examination of immunohistochemistry images.  WT 
littermates = filled bars with triangle symbols, CFTR-/- =clear bars with round 
symbols, C57BL/6 controls = clear bars with square symbols.   CFTR-/- mice 
have higher numbers of neutrophils in the alveolar compartment compared to 
WT littermates 24 hours following LPS.  A) The total number of neutrophils in 
lung sections per six fields-of-view on CLSM did not differ between genotype 
groups or with DNase treatment.  B) CFTR-/- mice have increased recruitment 
of neutrophils into the alveolar compartments compared to WT littermates 
(p=0.02).  C) The percentage of neutrophils deemed NETing (see Figure 4.11 
for criteria) did not differ between genotypes but there was a trend for reduction 
in NETs with DNase treatment.  Parameters were compared to PBS-treated 
control C57BL/6 mice lung sections (A-C).  Data represents individual points 
and mean ± SD.  Data for LPS-treated mice analysed by two-way ANOVA with 
Sidak’s multiple comparisons test.  n=4-6 per group.   
  




4.4 Surrogate markers of NETs corroborated the NET ELISA results 
As a comparison to ELISA-based NET quantification, BALF supernatant was 
collected from mice at 24 and 72 hours’ post-LPS induced acute lung injury 
and MPO activity, PicoGreen® and Pierce® BCA assays were assessed.  There 
were significant reductions in both protein and dsDNA concentrations at 
resolution of inflammation (72 h) compared to peak inflammation (24 h) (Figure 
4.13C-F).  At 24 hours post-LPS, there was no significant difference in MPO 
activity within BALF of WT and CFTR-/- mice and DNase treatment did not 
affect MPO activity (Figure 4.13A).  At 72 hours’ post-LPS, however, CFTR-/- 
mice had higher MPO activity when treated with DNase, relative to WT 
littermates (Figure 4.13B).  BALF supernatant protein concentrations were 
significantly elevated in CFTR-/- mice relative to WT littermates at peak 
inflammation (Figure 4.13C). There was no significant difference in BALF 
dsDNA concentrations between genotypes and treatment groups at either 
peak or resolution of inflammation (Figure 4.13E&F).  Taken together 
alongside the NET results, these findings suggest that in the CF mouse model 
of LPS-induced acute lung inflammation, NETs are not the main cause of the 
exaggerated inflammatory response seen in CFTR-/- mice.  Alternatively, 
repeated challenge would be needed to replicate human CF lung disease 
where there is no resolution, as was the case in this mouse model.     
  




Figure 4.13      
 
Figure 4.13: MPO activity, Pierce® BCA, and PicoGreen® assays on 
murine bronchoalveolar lavage fluid 24 and 72 hours following LPS-
induced acute lung inflammation.  WT = filled bars.  CFTR-/- = non-filled 
bars.  LPS-induced acute lung injury causes significant increases in airway 
protein and dsDNA concentrations at peak inflammation.  BALF supernatant 




24 hours 72 hours




MPO activity, C&D) protein concentration and E&F) dsDNA concentration.  B) 
There was a significant increase in MPO activity in CFTR-/- mice treated with 
LPS + DNase relative to WT littermates at 72 hours.  MPO activity was 
expressed as fold-change from mean WT+ LPS optical density.  C) CFTR-/- 
mice have significant elevation in BALF protein concentration at 24 hours post-
LPS relative to WT.  C&D) Protein concentrations fall significantly with 
resolution of inflammation.  E&F) There was no significant difference in BALF 
dsDNA concentrations between genotypes and treatment groups but levels 
significantly fall upon resolution of inflammation.  Data represent individual 
points and mean ± SD.  The 24 and 72 hour data were analysed separately 
using two-way ANOVA with Sidak’s multiple comparisons tests.  Thereafter, 
time points were compared to one another using two-way ANOVA.  n=4-7 per 
group.   




4.5 DNase is effectively delivered to the lung via nebulisation 
Two experiments were carried out to demonstrate that DNase is active, even 
when administered by nebulisation to the mice.  Firstly, in vitro DNA digestion 
was shown using DNA gel electrophoresis experiments, in which calf thymus 
DNA was loaded onto the gels alone or in combination with increasing 
concentrations of DNase (625 U – 2500 U).  These experiments revealed that 
DNase fragmented calf thymus DNA at all of the concentrations (Figure 
4.14A).  Having confirmed that the drug was active in vitro, I designed an 
experiment to demonstrate effective delivery of DNase to the airways via 
nebulisation.  I treated heterozygote mice (CFTR-/+) with 2.5mL DPBS or 
DNase 2500 U (they did not receive LPS) for ~ 10 min, prior to animals being 
culled and BALF harvested.  BALF was then incubated with 1µg/mL calf 
thymus DNA then dsDNA concentrations quantified using the PicoGreen® 
assay.  Incubation with BALF from DNase-treated mice resulted in a significant 
decrease in dsDNA levels relative to PBS control BALF (Figure 4.14B).  These 
two experiments confirmed that DNase was active and nebulisation effectively 
delivered the drug to the airways sampled by BAL. 
 
With regard to the CF mouse model of LPS-induced acute lung inflammation, 
I decided to treat CFTR-/- mice and WT littermates with 2500 U DNase 12 hours 
after the administration of LPS, and once daily thereafter in the case of the 
mice culled at 72 hours post-LPS.  The maximum DNase dose was selected 
so that it increased the likelihood of active drug being in the airways when 
NETs were formed.  With regard to the assays measuring murine airway NETs, 
a trend was noted for decreased levels of NETs when mice were treated with 




DNase (Figures 4.10 and 4.12C).  Moreover, MPO activity in BALF 
supernatant was increased with DNase treatment (Figure 4.13A&B).  
Conversely, DNase did not significantly affect other parameters such as semi-
quantitative scoring of lung damage (Figure 4.7) and BALF proinflammatory 
cytokine concentrations (Figure 4.8).  It is likely that further experiments to 
increase the sample sizes would be required to confirm or refute the trends 
seen in the NET quantification data.  Moreover, it may be that DNase 
administered at the same time as LPS, as well as once daily thereafter, would 
have been more effective.   
                                                                                                                                                
 
  






Figure 4.14: Nebulisation delivers active DNase to murine airways.  A) DNA gel electrophoresis with 1kb DNA ladder (lane 1), calf thymus DNA 
1µg/mL only (lane 2) and calf thymus DNA 1µg/mL incubated with increasing doses of DNase (625 U – 2500 U in lanes 3 - 10, each dose in duplicate).  
The drug actively fragments DNA at all doses.  Representative gel of n=3 experiments.  B) CFTR+/- mice were nebulised with 2.5 mL 2500U DNase or 
PBS control then BALF harvested.  Resultant supernatant was incubated with calf thymus DNA then dsDNA was quantified using a PicoGreen® assay 
kit.  There is a significant decrease in dsDNA when calf thymus DNA was incubated with BALF supernatant from mice treated with DNase in comparison 
to PBS control.  Data represents individual points and mean ± SD.  Data analysed by two-tailed student’s t-test.  n=4 per group over two separate 
experiments.  




4.6 The exaggerated acute inflammatory response of CFTR-/- mice is 
associated with increased expression of RAGE 
Data in this chapter thus far have shown that CFTR-/- mice have a heightened 
inflammatory response to acute LPS-induced lung injury.  To investigate 
whether NET constituents are critical players in the causative mechanisms, 
RT-PCR and western blot techniques were performed on whole lung lysates 
from mice culled 24 hours following LPS.  The 24 hour time point was selected 
to assess parameters when inflammation was at its peak.  Whole lung lysates 
were used instead of BALF because the latter would also sample anything 
produced by AEC (which may confound results) and because lysates permit 
sampling of the lung interstitium, which may also contain immune cells.  Gene 
expression for PRR and receptors which have NET constituents as ligands 
were assessed by RT-PCR, namely TLR-2, -4, -9 and RAGE.  This revealed 
no alteration in TLR-2, -4 or -9 mRNA expression between genotypes and 
treatment groups (Figure 4.15A-C).  However, RAGE mRNA expression was 
significantly upregulated in CFTR-/- mice (Figure 4.15D).  Western blot analysis 
revealed no difference in whole lung RAGE protein expression in CFTR-/- mice 
relative to WT littermates (Figure 4.16).  These data suggest that RAGE may 
have altered intracellular processing or location between genotypes, a 
suggestion that requires further detailed examination.   
  




Figure 4.15 Figure 4.15: Relative RAGE mRNA 
expression is upregulated in CFTR-/- 
mice relative to WT littermates 24 
hours post-LPS (D).  Expression of 
innate immune cells’ pattern recognition 
receptor genes was analysed by RT-PCR 
analysis of murine whole lung lysates.  
Data is expression relative to β-actin gene 
expression.  Data represents individual 
values and mean ± SD.  n=3-6.   A–C) 
Relative expression of TLR-2, -4 and -9 
mRNA is unaffected by genotype or 
DNase treatment.  D) Relative RAGE 
mRNA expression is affected significantly 
by genotype (p=0.04) (with significant 
elevation in expression in Hom + LPS 
compared to WT + LPS (p=0.02)) but 
unaffected by DNase.  Data analysed by 
two-way ANOVA with Sidak’s multiple 
comparisons test. 







Figure 4.16: Expression of RAGE protein in lung lysates from WT and 
CFTR-/- (Hom) mice at 24 hours following LPS administration as assessed 
by western blot analysis.  WT = filled bars.  CFTR-/- = non-filled bars.  n=3-
5.  Representative immunoblot shown for RAGE with expression of GAPDH 
used as a protein loading control.  Data in graph represents individual values 
for expression of RAGE relative to GAPDH shown as mean ± SD.  Data were 
analysed by two-way ANOVA.   
  





Previous studies have demonstrated that innate immune cells including 
neutrophils and macrophages express CFTR mRNA at low levels(19) and 
express functional CFTR protein both intracellularly(218) and at the cell 
membrane(21,124,219).  In human and murine neutrophils, the protein is 
present in secretory vesicles and phagolysosomes, inferring that CFTR is a 
critical regulator of neutrophil phagocytosis(83,211).  Specifically, Painter et al. 
suggest that CFTR-containing secretory vesicles merge with phagosomes 
during the formation of phagolysosomes(83).  Furthermore, using 
immunofluorescent staining of murine neutrophils they found that CFTR was 
associated with phagocytic vacuoles containing green fluorescent protein-
expressing P.aeruginosa and lack of CFTR on phagolysosomes resulted in 
defective chlorination (and therefore degradation) of bacterial proteins within 
this organelle(83).  The role of CFTR in macrophage function will be discussed 
fully in Chapter 5.   
 
Data presented in this chapter confirm that CFTR-/- mice have an abnormal 
acute inflammatory response to LPS in their lungs, in agreement with findings 
by Su et al.(211).  The CFTR-/- mice used in this study did not have an increase 
in BAL neutrophil counts at 24 hours post-LPS administration when compared 
with WT littermates.  One possibility is that the lavage method used did not 
dislodge all of the cells present within the lower airway compartments, which 
had yet to migrate up into the airways for clearance following migration into the 




alveoli.  Moreover, the 24 hour time point may have been too late to see any 
difference in BAL neutrophil counts, since Su et al. demonstrated higher 
neutrophil counts at 4 hours post-LPS(211).  In spite of this, the CFTR-/- mice 
used in our experiments had increased levels of the proinflammatory cytokines 
IL-6, TNF-α and IL-17 in their BAL at 24 hours post-LPS.  TNF-α is a prolific 
inflammatory cytokine made by activated macrophages and signals to both 
macrophages and neutrophils in the acute phase response and throughout the 
inflammation time course.  It can prime neutrophil effector function (which 
augments their response to secondary stimuli such as LPS), induces oxygen 
radical generation and degranulation(220), and acts upon the endothelium to 
increase expression of adhesion molecules such as ICAM-1 and VCAM-1 to 
aid neutrophil adhesion(221).  It is likely that elevated levels of BAL TNF-α 
contribute to the acute lung injury seen in the CFTR-/- mice.  Elevated TNF-α 
levels were also found in the sputum of non-exacerbating CF participants when 
compared to healthy controls (Chapter 3, Figure 3.15).  Conversely, IL-6 levels 
were significantly elevated in the CFTR-/- mice but significantly reduced in CF 
participants’ sputum relative to HC.  These data raise the possibility that IL-6 
may have pleiotropic effects which are context-dependent – it may be 
proinflammatory by driving macrophage proinflammatory cytokine production, 
or anti-inflammatory to aid resolution of inflammation(186).  IL-17 was 
increased in CFTR-/- mice BAL 24 hours post-LPS compared to WT littermates.  
IL-17 is a proinflammatory cytokine produced by Th17 cells, neutrophils, 
gamma-delta T cells and natural killer cells(222) that regulates 
granulopoiesis(41) and neutrophil recruitment(223).  IL-17 levels are elevated 




in the sputum of adult CF patients during exacerbations and decrease with 
antibiotic therapy(222).  Finally, increased levels of IL-10 in murine BAL at 24 
hours post-LPS mirrored data from the human MDM-neutrophil/NET co-culture 
experiment in Chapter 3.7, in which CF human MDM produced significantly 
increased levels of IL-10 at 24 hours relative to HC MDM.  Other studies have 
shown IL-10 to be reduced in the context of CF(207,208), suggesting an 
imbalance which drives inflammation.  It may be that the chronic inflammation 
and infection of CF lung disease is not fully represented by the CF mouse 
model of LPS-induced acute lung but we would suggest that it is nevertheless 
useful for the study of dysfunctional innate immune cell responses to 
inflammation in CF and the acute lung injury setting.   
 
Elevated levels of proinflammatory cytokines may have contributed to the 
significant increase in neutrophil recruitment to the alveolar compartments 
seen on IHC of CFTR-/- murine lung sections.  Histological scoring of acute 
lung inflammation using a modified, validated score(173,174,224) also 
supported these results: CFTR-/- mice had evidence of exaggerated lung 
damage in response to LPS, in agreement with Su et al.(211).  BAL protein 
levels were also significantly higher in CFTR-/- mice 24 hours post-LPS, which 
could be due to increased albumin due to endothelial damage and pulmonary 
oedema.  To test the hypothesis that elevated proinflammatory cytokines 
contribute to increased neutrophil recruitment, the experiments could be 
repeated with CFTR-/- mice being treated with commercially available 




antibodies, e.g. tocilizumab (anti-IL-6 receptor(225)), infliximab (anti-
TNF(226)) and secukinumab (anti-IL-17A(227)).  Alternatively, double 
knockout mouse models could be set up (i.e. IL-6, TNF-α, or IL-17a/IL17ra 
knockout mice could be crossed with CFTR knockout mice) and animals 
challenged with LPS, although the time it would take to breed such animals 
may make such models impractical and whether or not such double knockouts 
would be viable is uncertain. 
 
Data in this chapter support the suggestion that NETs, airway proteins and 
dsDNA all accumulate at peak inflammation and clear at subsequent resolution 
in both genotypes.  One might have expected delayed resolution or 
persistence of NETs in the CFTR-/- mice given the fact NETs accumulate in CF 
participants’ airways (see Chapter 3) but the acute nature of the experiment 
likely accounts for this discrepancy.  It appears that airway NETs are not solely 
responsible for the heightened inflammation seen in the CFTR-/- mice because 
there was no increase in BAL NETs in these mice relative to WT littermates at 
24 hours post-LPS.  However, sample sizes were small (owing to the slow 
breeding of CF mice) and SD large and so inferences drawn from these 
findings are limited.  It could be that there is a difference between genotypes 
undetected due to insufficient group size; additional experimentation is 
required to confirm or refute our conclusions regarding airway NETs in the CF 
mouse model.  Other intrinsic defects of the CF neutrophil, such as enhanced 




recruitment to the alveoli and a propensity to degranulate and produce reactive 
oxygen species, may account for the lung damage demonstrated(109).   
 
When ELISA and IHC quantified NETs, there was a trend for decreased NETs 
in mice treated with DNase.  Whilst further experiments (to increase the sample 
size) are likely needed to confirm or refute these results, they may suggest that 
DNase was active and targets NETs.  This is in agreement with the human 
data, which show that CF participants taking DNase had significantly lower 
levels of sputum NETs compared to those not on the medication.  Overall, 
DNase treatment did not significantly affect LPS-mediated inflammation.  In 
contrast, Liu et al. report that DNase I treatment significantly reduced NET-
DNA levels in BALF and reduced LPS-induced lung injury (as assessed by 
histological lung injury scores, pulmonary wet/dry weights and total proteins in 
BALF)(108).  In their experiment, mice were treated with DNase I at 0 hours 
and 10 hours post-LPS administration and so with regard to our experiments, 
it is possible that inflammation would have been reduced if DNase had been 
given at the time of LPS administration, instead of at 12 hours following LPS 
treatment.  Furthermore, the DNase doses may not have been comparable as 
they were delivered by different routes (i.e. nebulised vs. intratracheal 
instillation).   
 




Our data does suggest that DNase releases NET-bound MPO from the 
inhibitory effect of interactions with negatively charged DNA; BAL MPO activity 
was significantly higher in CFTR-/- mice treated with the DNase once daily for 
72 hours.  Extrapolating this result to human patients with CF, the implication 
is that DNase treatment might result in increased MPO activity in the airways.  
Given that this peroxidase is a principal contributor to CF lung 
damage(228,229), it may be that some patients clinically deteriorate when 
taking DNase because MPO activity is increased.  Further studies – including 
in vitro study of NETs and clinical studies of CF patient airway samples would 
be required to investigate this hypothesis.  These data are in line with results 
from Dubois et al. regarding human NE, which shows increased activity in vitro 
in the presence of DNase(102).  However, the same pattern was not seen in 
WT mice and so future work should re-examine this finding.  
 
To investigate potential mechanisms by which NET constituents could 
contribute to heightened LPS-mediated inflammation in CFTR-/- mice, 
expression of RAGE and three key TLR were studied using RT-PCR.  The 
TLRs are transmembrane PRR, which recognise and bind PAMPs or DAMPs 
(see Table 4.1).  The former are microbial-derived whilst the latter are host-
derived factors.  The interaction between these ligands and the TLRs induce 
proinflammatory gene expression via activation of NF-κB, AP1 and interferon-
regulatory factors(230).  NET constituents (see Introduction for full descriptions 
of each) may function as DAMP ligands upon TLR:  








viruses, porins of 
bacteria such as 
H.influenzae, Zymosan 
of fungi, as well as 
endogenous ligands 
such as hyaluronan.  
Histones and HMGB1 




shock proteins  
Histones, S100 
proteins, HMGB1 
TLR-9 unmethylated CpG 




Table 4.1: Toll-like receptors (TLR), their classic ligands(230) and NET 
constituents that activate respective TLR. 
 
LPS was used to induce lung inflammation in mice and it is a well-known PAMP 
ligand for TLR-4. The intracellular processing of TLR4 is abnormal in CFTR-/- 
mice, with retention of TLR4 within the early endosome and reduced 
translocation to lysosomes(132). This ultimately leads to increased LPS-
induced inflammation by inhibiting the downregulation of proinflammatory gene 
transcription.  RAGE is a PRR for glycoproteins, HMGB1 and S100 
proteins(231).  Both serum and sputum HMBG1 are strong risk markers for 
lung function decline in CF patients(232) and so it is possible NETs drive 
inflammation via HMGB1 and calprotectin interactions with RAGE. 




The RT-PCR data did not reveal any differences in TLR-2, -4, and -9 mRNA 
expression in our murine whole lung lysates.  This technique has limitations 
however because it does not specifically study the airway innate immune cells.  
Future experiments could isolate these cells from BAL by flow sorting (using 
Ly6G for neutrophils and Siglec-F for macrophages) prior to cell pellet RNA 
extraction and RT-PCR.  However, this would require higher numbers of 
animals (which should be avoided where possible when designing such 
experiments) and so in vitro models could be designed instead.  For example, 
CFTR-/- and WT littermate mice could be culled then isolation of bone marrow-
derived neutrophils and differentiation of bone marrow-derived macrophages 
performed (i.e. bone marrow cells would be differentiated into macrophages 
using macrophage colony-stimulating factor).  These cells would then be 
challenged with LPS prior to cell pellet RNA extraction and RT-PCR.  
Alternatively, single cell RNA sequencing could be performed on isolated 
airway innate immune cells and so cell numbers obtained might not be so 
critical.       
 
My data suggest that CFTR-/- mice had increased RAGE mRNA expression 
but normal protein expression in lung lysates in response to LPS-induced lung 
inflammation.  This observation raises the possibility that CFTR mutation 
causes RAGE up-regulation and/or intracellular trafficking perturbations, which 
may contribute to increased ligand binding and subsequent proinflammatory 
gene expression in CF lung disease.  There is evidence that RAGE signalling 




is involved in autophagy: activation of adenosine 5′-monophosphate-activated 
protein kinase (AMPK) is RAGE-dependent(231) and could therefore regulate 
autophagosome formation.  Thus, if CF cells have upregulation of RAGE, this 
may lead to enhanced activation of AMPK and increased autophagosome 
formation, which would account for the increased vacuolations seen in human 
CF neutrophils in Chapter 3.  That said I did not see evidence for vacuolation 
in the mouse BAL neutrophils.  The study of RAGE-dependent AMPK 
activation and subsequent autophagosome formation was beyond the scope 
of this thesis but could provide another avenue of future research. 
 
  




Chapter 5: Exploring Macrophage Acidification 
in Cystic Fibrosis using Optical Nanosensors  
 
Background 
“Macrophage” is derived from the Greek μακρός (makrós) = large and φαγείν 
(phageín) = to eat, and so macrophages are literally the “big eaters” of the 
innate immune system.  They have been shown to express CFTR mRNA at 
low levels(19) and express functional CFTR protein intracellularly(20) and at 
the cell membrane(21,124,219).  In a process called phagocytosis (see 
Chapter 1: Introduction), macrophages engulf microbes, cellular debris and 
foreign material into phagosomes, which are plasma membrane-derived 
vacuoles within the cytoplasm.  These in turn fuse with lysosomes, which are 
organelles containing numerous enzymes that break down biological polymers 
including proteins, carbohydrate and nucleic acids(233).  When a phagosome 
fuses with a lysosome they form a membrane-bound organelle called a 
phagolysosome (see Figure 5.2).  The resultant phagolysosome has an acidic 
pH, which facilitates bacterial killing(126,234).  Mature phagolysosomes reach 
pH 4.5 - 5.0(8,9), principally regulated by the vacuolar proton ATPase(236).  
However, CFTR has been suggested as an extra and important mediator of 
organelle pH(237) and faulty macrophage phagolysosomal acidification has 
been incriminated in pathophysiology of bacterial infectious diseases by 
organisms such as Mycobacterium tuberculosis and S.aureus (13,14).   
 




Previous studies investigating the role of CFTR in regulating changes to 
organelle pH have had conflicting results.  A seminal paper by Di et al. reported 
that alveolar macrophages from CFTR-deficient mice had defective 
phagolysosomal acidification and therefore sub-optimal killing of internalised 
P.aeruginosa(20).   Furthermore, it has been shown that these cells have 
alkalinised pH of intracellular vesicles (presumed to be lysosomes) relative to 
WT macrophages(240).  It has been proposed that this pH change affects the 
action of enzymes involved in ceramide metabolism, ultimately resulting in 
defective acute response of alveolar macrophages to P.aeruginosa.  On the 
other hand, some authors suggest CFTR-deficient macrophage cell lines and 
primary mouse and human alveolar macrophages have no change in the pH 
of phagosomes (241–243).   
 
Such discrepancies in reported phagolysosomal pH may be due to different 
methods used to measure pH.  To date, pH quantification has been limited to 
the use of pH-sensitive fluorescence spectroscopy.  If single wavelength or 
dual-dye pseudo-ratiometric protocols are followed, insensitive quantification 
may result.  This is due to issues such as laser drift, shifts in focus, irregular 
labelling and photobleaching of the fluorophores(244).  In addition to these 
issues is the problem encountered with the use of non-ratiometric fluorescence 
spectroscopy - fluorescence changes depending upon fluorophore 
concentration.  Hence, results may be insensitive due to simple differences in 
the quantity of dye molecules taken up by the cells, rather than there being 
actual differences in pH.  However, fluorescence spectroscopy quantification 




of phagolysosomal pH, with careful and appropriate experimental design, 
could produce accurate pH readouts. 
 
Surface-enhanced Raman spectroscopy (SERS)-based nanosensors are a 
potentially superior alternative to analyse pH within living systems.  The 
scientific theory behind Raman spectroscopy is eloquently summarised 
elsewhere(245) but shall be described here in brief because in order to 
understand the results of this chapter, a basic understanding of the 
underpinning physics is required.  Raman spectroscopy is a technique that 
uses an inelastic scattering interaction between light and matter to obtain 
chemical information.  Monochromatic light – the incident light – strikes a 
surface and excites briefly a molecule within that surface into its “virtual” state 
(i.e. above the vibrational state but not reaching the electronic state, see Figure 
5.1).  Following this, several light scattering possibilities may occur.  Elastic 
scattering is where scattered light has the same frequency as the incident light 
(Rayleigh scattering).  Alternatively, inelastic scattering – where the scattered 
light has either a lower (Stokes Raman) or higher (Anti-Stokes Raman) 
frequency than the incident light – may occur.  Raman scattering is named 
after the Indian scientist Sir Chandrashekhara Venkata Raman, who first 
observed the phenomenon in 1928(246).  He received the Nobel Prize for 
Physics for his work on the Raman effect (i.e. inelastic scattering) in 1930 and 
in the same year, received an LL.D. from the University of Glasgow(246).  
However, it was not until the 1960s, after the invention of the laser, that Raman 
spectroscopes were widely developed for use in analytical chemistry.     
 




Using Raman spectroscopy, Raman scattered light is collected by a 
spectrometer and the energy difference of scattered light relative to the 
incident light (i.e. Raman shift) is calculated.  This energy difference equates 
to the energy of the bond vibrations of the molecule.  When the energy of the 
bond vibrations are plotted against the intensity, a unique fingerprint spectrum 
is acquired for the molecule.  This spectrum may change in appearance if 
factors such as molecular structure and confirmation and chemical 
environment are altered, as these affect the vibrational energy of each bond 
within the molecule.  Hence, chemists have designed molecules that reliably 
and predictably change structure in response to an analyte in order to measure 
the amount of analyte present in a system (by detecting changes in the 
fingerprint spectra).  That said the interaction between incident light and a 
molecule normally results in Rayleigh scattering rather than Raman (by a 
factor of 107).  To overcome this problem and increase the propensity with 
which light Raman scatters, surface-enhancing techniques are employed, 
usually functionalising the molecules to high conductivity metals like silver and 
gold.  In doing so, the molecule interacts with surface plasmons (i.e. rapid 
oscillations of the electron density) on the nanoparticle surface, which creates 
an electromagnetic field to enhance Raman scattering(247).  Furthermore, 
functionalisation to nanoparticles results in charge transfer between the 
substrate and the probed molecules.  These effects result in significantly 
stronger Raman scattering(247), which can be detected on a spectrometer.  
Chemists have engineered nanoparticles to provide optimal surface 
enhancement of the Raman signal when excited by the relevant incident light, 
coining the term SERS.   
 




In this proof-of-concept study, which was a collaboration between Samuel J 
Stanfield (a Chemistry PhD student, Supervisor Professor Colin Campbell) and 
me, the Raman spectrum of para-mercaptobenzoic acid (p-MBA) was used to 
provide information about the pH of the macrophage phagolysosome.  pMBA 
- illustrated in Figure 5.2 - contains a carboxylic acid moiety that can be 
deprotonated to yield the carboxylate anion, resulting in anticipated and 
dependable changes to the Raman spectrum.  Hence, a relationship between 
pH and Raman signal was established and calibrated.  The specifically 
designed nanosensors (MBA-NP) therefore comprise 150 nm gold 
nanoparticles functionalised using p-MBA.  When excited at their plasmon 
resonance frequency using a 785 nm laser, the gold nanoparticles enhance 
the spectroscopic response of p-MBA molecules.  MBA-NP has been shown 
to accurately quantify pH within the physiological range(178,248–250).   
 
Hypothesis and Aims 
It was hypothesised that MBA-NP could be used to measure phagolysosomal 
pH in macrophages and would be more sensitive than non-ratiometric 
fluorescence spectroscopy.  The aims of the chapter were: 
 
1) Demonstrate nanoparticle uptake into MDM phagolysosomes using 
transmission electron microscopy. 
 
2) Develop a new in vitro experimental technique using optical 
nanosensors to quantify macrophage phagolysosomal pH. 







Figure 5.1: Jablonski diagram illustrating infrared, Rayleigh, Raman and 
fluorescence energy level transitions, modified from(251).  Within this 
diagram, the absorbance of a photon of a particular energy (i.e. the incident 
light) by a molecule of interest is indicated by the arrows pointing 
up.  Absorbance is the method by which an electron is excited from a lower 
energy level to a higher energy level using the energy transferred from the 
photon.  Incident light strikes a surface and excites briefly a molecule within 
that surface into its “virtual” state (a very short-lived, unobservable quantum 
state(251)).  Following this, several scattering possibilities may occur.  Elastic 
scattering is where light has the same frequency as the incident light (Rayleigh 
scattering) and so returns to the ground state.  Alternatively, inelastic 
scattering – where the scattered light has either a lower (Stokes Raman) or 
higher (Anti-Stokes Raman) frequency than the incident light – may occur.  In 
contrast, fluorescence involves the emission of a photon by a molecule as a 
means of dealing with the energy received from the incident light.  The energy 
of the fluorescent photon is always less than that of the incident photon.   
 







Figure 5.2: Phagocytosis of functionalised gold nanoparticles by a 
macrophage.  Gold nanoparticles are functionalised with para-
mercaptobenzoic acid to form our pH-sensitive nanoparticles, MBA-NP.  They 
are engulfed by the cell’s plasma membrane, forming an intracellular 
phagosome.  The phagosome fuses with a lysosome, containing proteolytic 
enzymes, to form an acidic phagolysosome.  The right-hand-side 
demonstrates the structure of MBA-NP (not to scale).  Note the alteration of 
the carboxyl group in response to hydrogen ion concentration within the 
environment.  This structural change gives rise to changes in the Raman 
spectrum acquired when excited with monochromatic light at 785 nm. 
 
 





5.1 Participant demographics reveal no significant differences 
between groups 
Demographic data were analysed and showed that age and sex demographics 
did not differ between groups (see Table 5.1).  This is important because 
macrophage functions, including phagocytosis, are impaired with increasing 
age(252,253).  CF participant demographics included genotype and ppFEV1 
(as detailed in Table 5.2).  Experiments were performed on cells from CF 
participants with F508del mutation (heterozygous and homozygous) to ensure 
maximal impairment of CFTR function within the CF groups.  Lung function 
varied in the CF participants, with ppFEV1 ranging from 34.1 – 102.1% (mean 















































































F = 3 






Table 5.1: Participant group demographics, specifically age and sex.  
There are no significant differences in participant demographics, analysed 
using one-way analysis of variance (ANOVA).  SD, standard deviation; F, 
female; M, male; n/a, not applicable.  Sample sizes in parentheses.  Data 
summarised as mean ± SD where appropriate. 
  










Age Sex Genotype Percentage 
predicted 
FEV1 
1 29 F DF508/1717-1G>A 74.1 
2 28 F DF508/G493x 68.3 
3 38 M DF508/DF508 50.1 
4 18 M DF508/DF508 70.7 
5 34 M DF508/DF508 41.5 
6 18 F DF508/G493x 55.0 
7 24 F DF508/DF508 102.1 
8 29 M DF508/DF508 34.1 
9 22 M DF508/G542x 57.3 
10 27 F DF508/G542x 71.6 
11 23 F DF508/p67L 82.9 
12 19 M DF508/G551d 79.9 
Mean ± SD 25.8 (± 6.3) n/a n/a 65.6 (± 19) 
Table 5.2: CF participant demographics, including age, sex, genotype 
and spirometry with data summarised as mean ± SD where appropriate.    F, 
female; M, male; % predicted FEV1 = Percentage Predicted Forced Expiratory 
Volume in one second; n/a, not applicable; SD, standard deviation.
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5.2 Transmission electron microscopy confirmed localisation of MBA-
NP to phagolysosomes 
Firstly, TEM confirmed that following one-hour co-incubation of MDM and 
MBA-NP, MBA-NP were present within the cellular organelle of interest (see 
Figure 5.3).  Figure 5.3D demonstrates a 150 nm diameter MBA-NP within an 
electron-dense, single-membrane endosome, which is characteristic of a 
phagolysosome(193).  Due to the nature of TEM, it was difficult to find 
phagolysosomes containing MBA-NP and so in some experiments, MDM were 
pre-treated with LPS to prime them for phagocytosis.  Figure 5.4 shows several 
MBA-NP within a phagolysosome following LPS pre-treatment of MDM.  This 
LPS pre-treatment was not used for the experiments in which Raman spectra 
were acquired from samples, because the clumping of MBA-NP gave signal 
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Figure 5.3: Transmission electron 
microscopy images of monocyte-derived 
macrophages (MDM) and functionalised 
nanoparticles (MBA-NP).  Note the difference 
in scale between A (2 µm scale bar) and B-D 
(150 nm scale bar).  A) MDM without any MBA-
NP.  Note the characteristic features: it is a 
large, irregular cell with an eccentrically placed 
nucleus (clear white arrow), numerous vesicles 
and vacuoles, and ruffled surface(31).  There 
are electron-dense, membrane-bound 
endosomes throughout the cytoplasm (solid 
white arrows).  B) MBA-NP: note their 
characteristic well-circumscribed, electron-
dense appearance and 150 nm diameter.  C) 
MBA-NP being engulfed by the MDM cell 
membrane (black arrow).  D) MBA-NP within a 
phagolysosome, an electron-dense, 
membrane-bound organelle (solid black 
arrow).  Note endosomes throughout the 
cytoplasm (solid white arrows) and the nucleus 
(clear white arrow). Representative images of 
n=3 experiments.   





Figure 5.4: Transmission electron microscopy image of a 
lipopolysaccharide-treated monocyte-derived macrophage (MDM) 
containing several functionalised nanoparticles (MBA-NP) clumped 
together in a membrane-bound organelle, taken to be a phagolysosome 
(solid black arrow).  Also visible is the ruffled surface of the cell membrane 
(clear black arrow), electron-dense lysosomes (clear white arrows) and a 
mitochondrion (solid white arrow).  The scale bar is set to 150 nm, which is the 
diameter of a MBA-NP. 
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5.3 The percentage of MDM performing MBA-NP phagocytosis in 
healthy and CF MDM are the same and equally inhibited by cytochalasin 
D.  
Next, the study sought to evaluate whether both CF and HC MDM were 
capable of efficient phagocytosis of MBA-NP.  Whilst there is evidence that 
bacterial phagocytosis is impaired in CF macrophages(124), it was found that 
the percentage of MDM that had taken up MBA-NP by phagocytosis did not 
differ between HC and CF (see Figure 5.5A).  Phagocytosis is dependent upon 
actin polymerisation and so to provide evidence that MBA-NP were being 
taken up via phagocytosis, MDM were pre-treated with cytochalasin D, an actin 
polymerisation inhibitor (see Figure 5.5).  The percentage of MDM that had 
taken up MBA-NP decreased significantly by cytochalasin D treatment equally 
in both genotypes.  These results suggest that MBA-NP uptake is unaffected 
by loss of CFTR function. 
 
Cytochalasin D treatment also affected MDM morphology with treated cells 
displaying decreased diameter, rounding up and loss of pseudopods (Figure 
5.6).  These changes occurred consistently in both genotypes.     
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Figure 5.5: Photomicrograph images used to quantify phagocytosis of 
functionalised nanoparticles (MBA-NP) by monocyte-derived 
macrophages (MDM), with and without cytochalasin D (Cyto.D) 
treatment.  Representative photomicrograph images of MDM from healthy 
control (HC) and Cystic Fibrosis (CF) donors (all images were photographed 
using a x60 magnification lens).  A) No significant difference in MBA-NP 
phagocytosis was found between genotypes when quantified by light 
microscopy: HC 90 ± 6% vs. CF 90 ± 3%, p>0.9999.  Cytochalasin D treatment 
(10 μg/mL) was found to significantly inhibit phagocytosis in both genotypes 
(HC 30.8 ± 10.6% and CF 26.2 ± 5.93%), p<0.0001.  Data analysed using one-
way ANOVA with Tukey’s multiple comparisons test.  Summary data 
expressed as mean ± SD (n=6 HC and n=5 CF).  B-E are representative 
photomicrograph images used to quantify phagocytosis (scale bar = 30μm): B) 
MDM (solid black arrows); C) MDM with intracellular MBA-NP (clear black 
arrows); D) Light microscopy of MDM treated with cytochalasin D; and E) MDM 
with mostly extracellular MBA-NP (solid white arrows) when treated with 
cytochalasin D.   
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Figure 5.6: Photomicrograph images illustrate Cystic Fibrosis (CF) monocyte-derived macrophage (MDM) morphology in the 
presence and absence of cytochalasin D (Cyto. D) (all images were photographed using a x60 magnification lens).  MDM were 
differentiated from peripheral blood mononuclear cells over seven days then incubated with functionalised nanoparticles (MBA-NP) for one 
hour.  Where MDM were treated with cytochalasin D, this actin polymerisation inhibitor was present during a one hour pre-treatment and 
during MDM-MBA-NP incubation.  MDM morphology changes in the presence of cytochalasin D.  CF MDM (A) were spread out on the 
glass coverslip and numerous pseudopods were present (solid black arrows).  Intracellular MBA-NP are evident (clear black arrows).  In 
contrast, with cytochalasin D (B), MDM have decreased diameter and have rounded up, with loss of pseudopods.  As in Figure 5.5, 
cytochalasin D inhibits MBA-NP uptake, with the majority remaining extracellularly (white arrows).  This was a consistent finding in all 
experiments and was present in both genotypes.  Representative images of n = 10 experiments.   
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5.4 SERS-based nanosensors accurately quantify pH  
Preceding data demonstrated that MBA-NP uptake rates do not differ between 
HC and CF MDM.  We next determined whether the Raman shift resulting from 
inelastic scattering of 785 nm photons off internalised MBA-NP could be 
measured to quantify accurately the pH of the phagolysosome.  A calibration 
curve was formulated from data collected by my collaborator Samuel J 
Stanfield (Figure 5.7C) by plotting pH measurements of IMDM titrated with 
NaOH/HCl using a Mettler-Toledo InLab Ultra-Micro-ISM pH electrode and 
against spectra from the MBA-NP collected on a Raman spectrometer (Figure 
5.7A&B).  The calibration curve R2 = 0.9895 (see Materials and Methods, 
section 2.5.3 for details of the line equation) and permits accurate 
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Figure 5.7: Surface enhanced Raman spectroscopy (SERS) spectra obtained from gold nanoparticles functionalised with para-
mercaptobenzoic acid (MBA-NP) at pH values 4.0 – 9.0 and subsequent generation of a pH calibration curve.  A) SERS spectra of 
para-mercaptobenzoic acid (p-MBA) at pH values 4 to 9.  The spectra were baseline corrected and normalised to a reference Raman-shift 
position (1580 cm-1) (grey arrow), the intensity of which was invariant to pH.  With increasing acidity, there was a decrease in the COO- 
peak at ~1420 cm-1(white arrow) and a corresponding increase in the CO peak at ~1700 cm-1 (black arrow) - see panel B) for close-up 
image of relevant spectra.  C) Nanosensor pH calibration curve, formulated by plotting pH measurements of IMDM titrated with NaOH/HCl 
using a Mettler-Toledo InLab Ultra-Micro-ISM pH electrode against band ratios of spectra from the MBA-NP collected on a Raman 
spectrometer (Intensity1420cm-1/Intensity1580cm-1 (I1420cm-1/I1580cm-1)).   
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5.5 Preliminary experiments generated Raman heat maps from 
extracellular and intracellular MBA-NP 
Preliminary experiments were conducted in which MDM and MBA-NP were 
incubated together for 60 min before acquisition of spectra.  Raman heat maps 
were collected with a Renishaw streamline 785 nm laser at 0.875 mW and a 
30 s acquisition time.  Raman heat map acquisition was possible because the 
microscope had a motorised XY stage and the software enabled us to acquire 
a complete spectrum at each pixel of the image.  The software interrogates 
these spectra to generate false colour images to highlight where Raman peak 
intensity occurs.  In effect, this permits visualisation of where the MBA-NP are 
within the field-of-view.  Specifically, the data were processed using WIRE™ 
2.0 software, to produce heat maps of Raman intensity based on the peak at 
1580 cm-1, in which any pixels with a relative Raman intensity at 1580 cm-1 are 
highlighted in green.  The SERS spectra obtained at those areas clearly 
demonstrate alkaline conditions extracellularly and acidic conditions 
intracellularly after 60 min MDM-MBA-NP incubation (Figure 5.8).     
  





Figure 5.8: Acquisition of Raman heat maps.  Representative 
photomicrograph image showing functionalised nanoparticles (MBA-NP) both 
inside and outside of a healthy control MDM, imaged following 60 min co-
incubation.  Superimposed green areas (false-coloured using WIRE™ 2.0 
software) show relative Raman intensity at 1580 cm-1 and therefore the 
position of MBA-NP within the field-of-view.  Focussed SERS spectra were 
acquired from both of these MBA-NP.  The resultant inset spectra show 
alkaline conditions extracellularly (purple spectra), with a clear increase in the 
COO- peak at ~ 1420 cm-1 (solid grey arrow) and acidic conditions 
intracellularly (blue spectra), with an increase in the CO peak at ~ 1700 cm-1 
(clear black arrow).  Representative image of n=3 experiments.   
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5.6 Sequential SERS measurements demonstrate the rate of 
phagolysosome acidification is equal between HC and CF MDM 
Having optimised the spectral acquisition technique, subsequent live cell 
Raman microscopy enabled targeting of a single MBA-NP for acquisition of 
spectra, allowing spatially defined ratiometric measurement.  To obtain 
temporally resolved pH measurements, Raman spectra were acquired from 
the same MBA-NP at least every five min from 10 min of incubation with MDM 
through to two hours from n=3 from each genotype (see Figure 5.9).  To do 
this, light microscopy was used to identify an extracellular MBA-NP in contact 
with the cell membrane, which was then followed it as it was taken up by the 
cell and processed through the phagocytosis apparatus.  Raman spectra were 
acquired over time, which demonstrated spectral change from basic to acidic 
appearances (see Figure 5.7) as the MBA-NP was processed into acidic 
compartments.  To avoid possible laser damage to the cells and MBA-NP 
during these two hour-long experiments, the laser power was reduced to 
0.0875 mW (from 0.875 mW for the other acquisitions, which gave optimal 
spectra in terms of signal/noise ratio).  This laser power of 0.0875mW is far 
below that which has been shown to be safe to use within living cells(254) but 
still gave satisfactory spectra.  Visual inspection of the macrophage 
morphology, as well as of the Raman spectra, confirmed that the laser 
damaged neither the cells nor the nanosensors during our experiments. 
 
The results confirm that as the individual MBA-NP were internalised and 
processed through the cells’ phagocytosis apparatus, the pH progressively 
decreases at a similar rate in both genotypes, with most if not all pH decrease 
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occurring over ~15-20 minutes and stabilising after 60 min incubation (see 
Figure 5.9) to between pH 4.5-5.5.  These data are consistent with previous 
studies, which suggest maximal acidification is reached within 5-15 min of 
particle ingestion(241,242,255) and our monitoring of pH over time revealed 
that pH had stabilised within 60 min incubation of MBA-NP with MDM (Figure 
5.9), suggesting full maturation of the phagolysosome.  Hence, the 60-minute 
time point was selected to acquire spectra from MBA-NP within multiple cells, 
to provide accurate comparison of mature phagolysosomal pH between CF 
and HC MDM.   
  





Figure 5.9: Sequential SERS measurements from individual 
functionalised nanoparticles (MBA-NP) quantify pH as the MBA-NP are 
phagocytosed by monocyte-derived macrophages.  Healthy control (HC) 
data shown in blue and Cystic Fibrosis (CF) in pink.  SERS measurements 
quantify the pH of MDM phagocytosis organelles as MBA-NP were processed 
from the extracellular environment into a mature phagolysosome.  MDM were 
incubated with MBA-NP for 10 min prior to acquisition of Raman spectra from 
an MBA-NP, which was taken up by the MDM and processed through the 
phagocytosis apparatus over two hours.  MDM phagolysosomal acidification 
occurs at a similar rate in both genotypes with most of the pH decrease 
occurring in ~15-20 minutes and pH was stable at ~4.5-5.5 by 60 min.  n=3 for 
each genotype.    
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5.7 SERS measurements reveal no difference in phagolysosomal pH 
between CF and HC MDM 
We finally went on to address whether there was an acidification defect in CF 
MDM phagolysosomes.  All these experiments had spectral acquisition 
performed following 60 minutes’ incubation of MDM with MBA-NP.  To confirm 
that MBA-NP were sensitive to pH changes, phagolysosomal pH was 
measured following incubation of MDM with Bafilomycin A1, a vacuolar 
ATPase inhibitor required for macrophage phagosomal acidification(256).  We 
anticipated alkaline SERS spectra from MBA-NP in Bafilomycin A1-treated 
cells, which would strengthen our conviction that the MBA-NP were within 
phagolysosomes.  In addition, we interrogated the role of CFTR protein in 
phagolysosomal acidification by treating HC MDM with CFTRinh-172 in some 
experiments.  We hypothesised that pharmacological inhibition of the CFTR 
protein would result in pH readouts similar to those obtained from MBA-NP 
within CF MDM.   
 
As shown in Figure 5.10A, there was no statistically significant difference 
between phagolysosomal pH of HC and CF MDM.  Furthermore, 
pharmacological inhibition of CFTR by CFTRinh-172 treatment did not alter 
phagolysosomal pH in HC MDM (Figure 5.10A).  As hypothesised, when both 
HC and CF MDM were treated with Bafilomycin A1, phagolysosomes failed to 
acidify, reaching pH of 7.74 and 7.48 for HC and CF MDM, respectively, in 
agreement with existing literature(242). 
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Figure 5.10: Quantification of monocyte-derived macrophage (MDM) phagolysosomal pH using surface enhanced 
Raman spectroscopy (SERS)-based nanosensors.  A) MBA-NP quantify pH of MDM phagolysosomes.  There was no 
statistically significant difference between phagolysosomal pH of HC and CF MDM: 5.41 ± 0.11 vs. 5.41 ± 0.20, p>0.9999.  
Pharmacological inhibition of Cystic Fibrosis Transmembrane conductance Regulator (CFTR) by CFTRinh-172 treatment did 
not alter phagolysosomal pH in HC MDM, which measured 5.33 ± 0.13, p=0.999.  There was a statistically significant increase 
in pH from nanosensors within the media compared to within MDM phagolysosomes, media pH measuring 8.34 ± 0.49, 
p<0.0001.  Bafilomycin A1 treatment equally inhibits phagolysosomal acidification in both genotypes (p<0.0001); pH 
measured 7.74 ± 0.46 and 7.48 ± 0.38 for HC and CF, respectively.  B)  Averaged spectra from each group showing a clear 
difference spectra from intracellular MBA-NP vs. those within media and those treated with Bafilomycin A1.  Summary data 
expressed as mean ± SD and analysed using one-way ANOVA with Sidak’s multiple comparisons test.  Sample sizes: HC, 
n=4 (comprising 13 technical replicates from different cells); CF, n=6 (comprising 18 technical replicates); CFTRinh-172, n=6 
(comprising 18 technical replicates); media, n=7 (comprising 10 technical replicates); HC + Bafilomycin A1 n=5 (comprising 
18 technical replicates); and CF + Bafilomycin A1 n=5 (comprising 20 technical replicates).  
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5.8 Comparison between SERS-based nanosensors and pHrodo™ 
Green Zymosan Bioparticles® Conjugates revealed MBA-NP were 
superior in quantification of MDM phagolysosomal pH  
As a comparison to our novel technique, we also measured MDM 
phagolysosomal acidification using pHrodo™ Green Zymosan Bioparticles® 
Conjugates.  pHrodo™ is a fluorogenic dye that significantly increases its 
fluorescence emission with decreasing environmental pH.  There was no 
statistically significant difference in mean fluorescence intensity (MFI) between 
genotypes (see Figure 5.11), in agreement with our nanosensor data.   
 
In addition, both cytochalasin D and Bafilomycin A1 treatment significantly 
decreased fold change in MFI.  The reduced fluorescence in the presence of 
cytochalasin D was likely due to less Zymosan Bioparticles® being trafficked 
into the phagolysosomes.  Bafilomycin A1 on the other hand functions to inhibit 
vacuolar ATPase and so it is likely that the Bioparticles® reached an alkaline 
phagolysosome.   
 
These data also demonstrate pHrodo™ measurement is highly variable with a 
high coefficient of variation (CV) in both HC and CF (15.6% and 13.5% 
respectively) when compared with MBA-NP (2 and 4% respectively), 
underlining the superior accuracy of measuring pH with nanosensors.  
 






Figure 5.11: Measurement of monocyte-derived macrophage (MDM) 
phagolysosomal acidification using pHrodo™ Green Zymosan Bioparticles® 
Conjugates fluorescence spectroscopy.  MDM were incubated with pHrodo™ 
Green Zymosan Bioparticles® Conjugates for one hour.  In some experiments, cells 
were treated with the actin polymerisation inhibitor, cytochalasin D (Cyto. D) or the 
vacuolar ATPase inhibitor, Bafilomycin A1 (Baf.) as a pre-treatment and during 
incubation with the Zymosan.  Fluorescence was then measured using a digital plate 
reader.  Mean Fluorescence Intensity (MFI) increases with increasing acidification 
and was expressed as a fold change from Zymosan-only control wells.  There are 
statistically significant decreases in fold-change in MFI from MDM treated with 
cytochalasin D and Bafilomycin A1, p=0.003 and p=0.006, respectively.  Genotype 
did not significantly affect fold change in MFI.  Summary data expressed as mean ± 
SD and analysed using two-way ANOVA and Tukey’s multiple comparisons test.   
Sample sizes: HC n=9, CF n=7, HC + Cyto.D n=8, CF + Cyto.D n=7, HC + Bafilomycin 
A1 n=5, CF = Bafilomycin A1 n=6.    
  




This chapter aimed to examine whether SERS-based nanosensors could be 
used to measure the pH of macrophage phagolysosomes with greater 
accuracy than fluorescence spectroscopy techniques.  This is an important 
question because a debate exists in the literature around whether defective 
phagolysosomal acidification contributes to bacterial colonisation and infection 
and therefore the pathogenesis of CF lung disease.   
 
The first step in addressing this question was to provide evidence that the 
MBA-NP are trafficked into the phagolysosome.  Phagocytosis has been 
defined as “the uptake of large particles (>0.5 µm) into cells” and “occurs by 
an actin-dependent mechanism and is usually independent of clathrin”(257).  
Professional phagocytes such as macrophages, neutrophils and dendritic cells 
internalise particulate matter with high efficiency.  However, as described in 
this review article by Aderem and Underhill(257), phagocytosis has had to 
evolve into an extremely complex process, so as to deal with the wide array of 
microbes and self-debris requiring clearance.  Importantly, there are diverse 
receptor structures that play a role in phagocytosis, including receptors for 
immunoglobulin (FcR), complement (CR1 and CR3), lipids 
(phosphatidylserine and oxidised lipids), and scavenger receptors.  Indeed, 
scavenger receptors have been directly implicated in the uptake of gold 
nanoparticles with diameters < 100 nm(258) and nanoparticles of various 
sizes, including those ≤ 0.5 µM, have been taken up by macrophages via size-
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independent phagocytosis(259).  In agreement, we used TEM to demonstrate 
that 150 nm diameter MBA-NP are taken up into membrane-bound, electron-
dense organelles, the appearance of which were in keeping with 
phagolysosomes(193).  Our images are remarkably similar to those published 
by Chithrani et al.(260) and support our assertion that MBA-NP are 
phagocytosed.  Furthermore, the measured pH falls as low as pH 4.4 - 5.0 
when spectra were acquired over two hours, suggesting that MBA-NP are in a 
phagolysosome, as late endosomes usually do not acidify to that extent(127). 
 
Having established that MBA-NP nanosensors were indeed transported into 
the organelle of interest, we then asked whether uptake was affected by CFTR 
function.  Previous studies have suggested that CF macrophage phagocytosis 
is impaired.  This may be due to numerous factors, for example the high levels 
of NE present in CF airways may result in cleavage of CR1(261) and so 
bacterial recognition will be impaired.  Furthermore, in a study of human 
macrophages from HC and CF participants, macrophages from the CF sputum 
had significantly reduced expression of scavenger receptors and CD206 at 
both the mRNA and protein levels, the former was shown to impair 
phagocytosis of non-opsonised particles as well as microbes(262).  Analysis 
of photomicrograph images (Figure 5.5) taken using the Raman microscope 
permitted effective quantification of nanosensor uptake in our model.  There 
was no difference in nanosensor uptake between genotypes, indicating MBA-
NP uptake is CFTR independent.   
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MDM were treated with cytochalasin D as a pharmacological means by which 
to interrogate underlying endocytic pathways.  Cytochalasin D inhibits 
nanosensor uptake equally in both genotypes, demonstrating an active 
involvement of the actin cytoskeleton in uptake of nanosensors.  Reassuringly, 
photomicrograph images such as those represented in Figure 5.6 reveal that 
cytochalasin D modulates MDM morphology, in agreement with published 
literature(263,264) and provide further evidence that the inhibitor was 
pharmacologically active in our model.  Whilst these results do not answer 
whether uptake was via phagocytosis or macropinocytosis, both of which are 
actin-dependent endocytic pathways, this question has been addressed in 
other studies:  França et al. used pharmacological inhibitors of mediators of 
macropinocytosis and clathrin-mediated endocytosis to confirm that 150 nm 
gold NP uptake was likely via phagocytosis(258).  Regardless of the endocytic 
pathway used by MDM, the TEM images of MBA-NP within membrane-bound 
organelles coupled with SERS pH readouts of 4.0 - 5.0 strongly suggest that 
MBA-NP end up in a phagolysosome.   
 
After establishing that MBA-NP were located in the phagolysosome after 60 
minutes of incubation with MDM, we next measured the organelle’s pH.  
SERS-based nanosensors are a novel means of quantifying the 
phagolysosomal pH environment of macrophages and this data suggests they 
are superior to conventional fluorescence spectroscopy for several reasons.  
Firstly, a general limitation of fluorescence-based pH measurements is the 
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concentration range the sensor covers.  This range is dependent upon the acid 
dissociation constant (Ka) of the fluorophore, which gives a sigmoidal 
calibration curve with a non-linear association between fluorescence and pH, 
meaning that pH quantification may be insensitive at the sensor’s range 
limit(235).  It is therefore important to have a sensor with a wide range, 
especially when interrogating the endosomal-lysosomal system in which the 
pH can alter by at least 2.5 units from baseline(235).  In contrast to pH-
sensitive fluorophores, MBA-NP are excited using a single wavelength and use 
the ratio of vibrational modes from a single reporter molecule to measure pH 
in a range that is determined by the reporter’s pKa.  Thus, MBA-NP are 
concentration independent, i.e. pH measurement is independent of the number 
of particles phagocytosed.  Whilst ratiometric, dual-dye fluorescence 
spectroscopy protocols such as that performed by Haggie and Verkman(242) 
may address this problem to an extent, there remains the limitations of 
differential bleaching and laser drift, to which nanosensors are insensitive.  
Hence, MBA-NP nanosensors exhibit superiority over fluorescence 
spectroscopy in terms of sensitivity, ratiometric quantification, and both spatial 
and temporal resolution.   
 
Raman spectroscopy also enabled real-time monitoring of reductions in pH as 
the MBA-NP were processed through the phagocytosis apparatus with 
excellent spatial resolution.  Numerous other studies have investigated the 
kinetics of phagolysosomal acidification and suggest acidification begins within 
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two to three minutes of fluorescent probe binding and is completed within 5-15 
min(20,241,242,255,265–267).  In contrast, the data in this chapter 
demonstrates that it took up to 60 min for phagolysosomal maturation to occur, 
potentially because our MBA-NP are processed differently to Zymosan or 
bacteria.         
 
The key question addressed in this chapter was whether macrophage 
phagolysosomal acidification was CFTR dependent.  Using SERS-based 
nanosensors we found no significant difference in phagolysosomal 
acidification between human CF and HC MDM; this observation was further 
confirmed by pharmacological inhibition of CFTR using CFTRinh-172.  Taken 
together, these findings suggest CFTR has no direct role in phagolysosomal 
acidification.  Our comparative analysis of phagolysosomal pH measurement 
using conventional fluorescence spectroscopy also demonstrated no 
difference between HC and CF macrophages, but with a higher degree of 
uncertainty.  Phagolysosomal acidification was found to be sensitive to the 
vacuolar ATPase inhibitor, Bafilomycin A1, suggesting that the phagosome 
formed around MBA-NP both contains and is acidified by this crucial regulator 
of acidification, similar to the phagosomes formed around bacteria(256,265).  
The data in this chapter imply that the well-established bacterial killing defect 
of CF macrophages(20,268–270) may not be solely due to failure of 
phagolysosomal acidification.  We suggest that future experiments utilising a 
SERS-based approach would permit the measurement of other sub-cellular 
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processes, such as intracellular redox potential(271), which may contribute to 
the impaired bacterial killing noted in CF macrophages.   
 
Earlier studies of CF macrophage phagolysosomal acidification used murine 
macrophages in which CFTR has been deleted (20,242,243,272).  In spite of 
this, and in contrast to humans, CF mice do not develop spontaneous lung 
disease and thus the relevance of these studies’ observations to human 
disease remains questionable.  Conversely, a strength of this study is that it 
investigated acidification of phagolysosomes in primary human HC and CF 
MDM and our data underline the importance of undertaking such studies in 
humans.   
 
There were two key limitations to our experimental model.  The first was the 
use of MDM because we were unable to obtain HC and CF alveolar 
macrophages (from bronchoalveolar lavage or sputum).  We acknowledge that 
MDM are unlikely to function identically to alveolar macrophages, which 
acquire an activated phenotype in the context of the CF lung, which has an 
inflammatory milieu(273,274).  Measurement of the phagolysosomal pH of 
alveolar macrophages, ideally from human participants, using SERS-based 
nanosensors would be an important goal for further research.  The second key 
limitation of our model is that macrophage endocytosis and phagolysosomal 
acidification are adaptive processes and so there may be differences in 
macrophage phagolysosomal maturation for MBA-NP compared to bacteria.  
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Future experiments, in which alveolar macrophages uptake bacteria such as 
H.influenzae, S.aureus and P.aeruginosa alongside MBA-NP would be of 
interest to address this limitation and to mimic more accurately the CF lung 
environment.    
 
With regard to additional directions for future work, it would be interesting and 
important to investigate the precise mechanisms by which MBA-NP were 
endocytosed by macrophages, perhaps through antibody-mediated inhibition 
of the various cell surface receptors  that may be responsible, or through use 
of a cell line in which receptor expression has been inhibited using small 
interfering RNA(258).  Confocal microscopy could potentially be used to show 
co-localisation of nanosensors with phagolysosomal markers such as 
lysosomal-associated membrane proteins 1 and 2 (LAMP-1, -2) and lysosomal 
integral membrane protein (LIMP-II)(239).  Furthermore, probes of this general 
design (i.e. a sensing molecule attached to a metal nanoparticle) have the 
potential to be utilised in other areas of innate immune cell study.  For example, 
nanosensors could be used to measure the pH of the neutrophil phagosome, 
which does not acidify(275).  Whilst the focus of these proof-of-concept 
experiments was on CF, our technique could have widespread application to 
a wide range of respiratory diseases associated with airway infection and 
inflammation such as pneumonia, Tuberculosis, Chronic Obstructive 
Pulmonary Disease and non-CF bronchiectasis.   
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In conclusion, we have developed a novel and highly accurate technique with 
which to measure phagolysosomal acidification, compatible with real-time 
analysis of phagocytosis.  Using SERS-based nanosensors, we demonstrate 
that MDM phagolysosomal acidification is CFTR-independent and may not be 
critical in the pathophysiology of CF.   
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Chapter 6: General Discussion, Therapeutic 
Implications and Future Directions 
 
Summary of Key Findings 
The absence of functional CFTR protein in neutrophils and macrophages from 
CF patients causes impaired innate immune responses and contributes to the 
pathophysiology of CF lung disease. 
 
There were two main aims of this project: firstly, to determine whether 
increased production of NETs was associated with airways inflammation and 
lung function decline in CF and secondly, to determine whether CF 
macrophages display impaired phagolysosomal acidification using 
nanosensor-based measurements.   
 
NETs are associated with airways inflammation and increased severity 
of CF lung disease 
In Chapter 3, I confirmed that NETs, defined based on histone-associated 
calprotectin, accumulate in CF airways.  CF participants were free of recent 
respiratory tract infection (i.e. >two weeks), demonstrating that NETs are 
abundant in CF airways even with stable disease.  Furthermore, sub-analysis 
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of the CF cohort showed no difference in levels of sputum NETs in patients 
with or without colonisation with P.aeruginosa or A.fumigatus, suggesting that 
NETs do not play a significant antimicrobial role in CF lung disease.  However, 
sputum NETs were associated with airways inflammation as measured by 
levels of proinflammatory cytokines and represent a significant independent 
predictor of lung function.    
 
CF participants treated with once daily nebulised rhDNase (recombinant 
human deoxyribonuclease; dornase alfa) had a significant reduction in sputum 
NETs compared to CF participants not taking the drug, suggesting that DNase 
eithers inhibits NET formation or facilitates lysis of NETs and their removal via 
the mucociliary clearance escalator.   
 
There are two therapeutic implications of our findings.  Firstly, disrupting NETs 
likely represents an important therapeutic target in the treatment of CF lung 
disease.  Dornase alfa (rhDNase) is a mucolytic treatment that breaks down 
polymerised DNA and is indicated in CF patients over five years of age with 
an FVC of greater than 40% predicted to improve lung function(144,276,277).  
This nebulised therapy has been shown to reduce neutrophilic inflammation, 
possibly due to improved mucociliary clearance of fragmented DNA(149,278).  
Our data implies that rhDNase also functions to inhibit NET formation or clear 
NETs once they are formed, suggesting that early use of rhDNase therapy 
represents a prophylactic measure against airways inflammation.  I therefore 
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suggest that future longitudinal clinical studies should investigate whether the 
introduction of rhDNase in patients younger than five years of age would 
protect patients from lung function decline.  Furthermore, proinflammatory 
NET-associated proteins, including NE, MPO and calprotectin, may represent 
therapeutic targets to counter the unrelenting neutrophilic inflammation of CF 
lung disease.    
 
NETs are proinflammatory to MDM and this effect is enhanced in CF 
The in vitro co-culture model used in Chapter 3 demonstrated that NETs were 
proinflammatory via stimulation of proinflammatory cytokine release from 
MDM.  This effect was enhanced in CF MDM and when the NETs were CF 
neutrophil-derived.  Using blood-derived innate immune cells instead of airway 
samples meant that intrinsic defects could be delineated, without confounding 
effects from microbial colonisation in the lung environment.  These 
observations suggest that blood-derived neutrophils and MDM have intrinsic 
defects in function due to CFTR mutation.  Furthermore, DNase treatment 
abrogated MDM IL-8 production, hinting at an anti-inflammatory mechanism of 
action.   
 
CF mice have an exaggerated acute inflammatory response to LPS 
In chapter 4, a mouse model of acute sterile lung inflammation was used to 
determine that CF mice have an exaggerated inflammatory response to LPS 
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relative to WT littermates, both in terms of BALF proinflammatory cytokine 
concentrations and histological acute lung injury scores.  RT-PCR experiments 
revealed that CF mice have increased RAGE mRNA expression.  This 
observation requires further research to determine whether RAGE 
upregulation is linked to the chronic inflammation characterising CF lung 
disease.  BALF NETs increase at peak inflammation and fall during resolution 
of inflammation.  Going against our hypothesis and human study data, 
however, the CF mice did not produce more NETs in comparison to WT 
littermates.  In addition, although there were consistent trends suggesting 
DNase was targeting NETs, the difference between groups did not reach 
statistical significance.  We conclude that the CF mouse model is useful in 
investigating dysfunctional innate immune cells but does not fully mimic NET 
formation of human disease.   
   
SERS-based nanosensors accurately quantify MDM phagolysosomal pH 
Chapter 5 demonstrated that SERS-based nanosensors are a sensitive tool 
with which to quantify MDM phagolysosomal pH using ex vivo live cell imaging 
of HC and CF cells.  To our knowledge, this is the first time these nanosensors 
have been used in this context.  TEM confirmed nanosensor localisation to the 
phagolysosomes.  We revealed that SERS-based nanosensors are superior 
to non-ratiometric fluorescence spectroscopy in pH quantification and that 
phagolysosomal acidification is CFTR-independent, which agrees with 
previous studies(135,241,243). 
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The therapeutic implications of these results are limited because the 
experiment was a proof-of-concept study to confirm a new utility of nanosensor 
technology.  If future experiments confirm that human alveolar macrophage 
phagolysosomal acidification is similarly CFTR-independent, this would 
suggest that pharmacological manipulation of phagolysosomal pH might not 
be an important therapeutic strategy for CF drug development. 
 
Future Directions 
The most striking and unexplored finding of Chapter 3 was that CF sputum 
neutrophils contain numerous cytoplasmic vacuolations, not present in HC 
sputum neutrophils.  One might expect these vacuolations to represent 
phagosomes or phagolysosomes, given the microbial colonisation of the lungs 
from which the cells originated, and yet the majority of these vacuolations did 
not contain bacteria.  At the time of literature review, this increase in sputum 
neutrophil vacuolation in CF relative to HC is a previously unpublished finding.   
 
There is one paper by Mihalache et al. investigating autophagy-related 
necrotic cell death of neutrophils in the context of several inflammatory 
conditions(279).  Ex vivo lung tissue sections from cystic fibrosis patients (n=3) 
were fixed then stained with H&E and light microscopy examination to reveal 
cytoplasmic vacuolation of neutrophils (presumed to be within the alveolar 
compartments, although this is not specified)(279).  The authors did not 
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expand upon this finding in the context of CF airway neutrophils but concluded 
that inflammatory neutrophils have a propensity for autophagy-related necrotic 
cell death(279).   
 
In a study by Luciani et al., mechanisms linking CFTR and autophagy have 
been interrogated using mouse and human epithelial cell culture and in vivo 
mouse experiments(280,281).  Defective CFTR up-regulates ROS and 
transglutaminase 2 (TG2), the latter an enzyme which catalyses calcium-
dependent post-translational modifications of proteins(280).  TG2 drives the 
sequestration of the beclin 1 interactome (a complex of proteins critical for 
autophagosome formation), into aggresomes.  Intervention by overexpression 
of beclin 1, inhibition of TG2 using cystamine, and treatment with anti-oxidants 
rescued autophagy and restored CFTR trafficking to the plasma membrane in 
mouse and human CF epithelial cells.  IP anti-oxidant treatment of mice 
similarly restored autophagy and decreased lung inflammation (shown by an 
increase in LC3-positive vesicles and decreased macrophage infiltration and 
MPO activity in the lungs, respectively) of mice homozygous for F508del 
mutation in CFTR(281).     
 
Data in Chapter 3 shows increased cytoplasmic vacuolation in CF neutrophils 
when compared to HC neutrophils, suggesting defective CFTR in these innate 
immune cells is associated with abnormal autophagy.  We hypothesise 
autophagy is increased in CF and may contribute to the increased airway NET 
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formation seen in our CF cohort(14,76)(76)(76).  Hence, it may be beneficial 
to inhibit autophagy in CF.  This hypothesis would be in-keeping with a recent 
study by Tang et al. who investigated associations between autophagy and 
NET formation in the context of anti-neutrophil cytoplasmic antibody (ANCA)-
associated vasculitis(76).  In this study, they show that LAMP-2 (the receptor 
for chaperone-mediated autophagy, which directly translocates cytosolic 
proteins across the lysosomal membrane for degradation within the 
lysosomes(282)) is an antigen for auto-antibodies and is incorporated into 
NETs during NET formation(76).  Additionally, anti-LAMP-2 antibody-
stimulated neutrophils displayed increased NET formation and 
autophagosome formation and decreased apoptosis(76).  They showed that 
the non-specific autophagy inhibitors 3MA and LY294002 significantly inhibited 
this NET formation(76) via impaired chromatin decondensation, although 
underlying signalling pathways remain unknown.  Additionally, Junkins et al. 
compared bacterial clearance of P.aeruginosa in normal human16HBE14o- 
bronchial epithelial cells, and CFTR DF508 homozygous CFBE41o-  epithelial 
cells(283).  The CFBE41o- cells had defective killing of internalised bacteria, 
which was abrogated by rapamycin, which induces autophagy(283).   
 
Considering these studies’ conclusions alongside my findings in Chapter 3, 
which show CF sputum neutrophils to have increased cytoplasmic 
vacuolations, I hypothesise that CF sputum neutrophils have abnormalities in 
autophagy regulation, causing increased autophagy, which in turn contributes 
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to excessive NET formation.  This should be investigated using a combination 
of TEM and immunofluorescence microscopy to a) look for double membrane 
vesicles and b) identify the presence of autolysosomes within both HC and CF 
neutrophils.  Autolysosomes could be identified by co-localisation of 
microtubule-associated proteins 1A/1B light chain 3B (LC3) and lysosomal 
markers (e.g. LAMP-1/2 or LIMP-II) by fluorescence microscopy.  Possible 
associations between NET formation and autophagy in HC and CF blood 
neutrophils would be further interrogated by quantification of PMA-induced 
NET formation in the presence or absence of autophagy inhibitors (e.g. using 
one of the selective Vps34 
inhibitors(284))(285)(285)(284)(284)(283)(283)(282)(282)(282)(18)(18).  
Vps34 (vacuolar protein sorting) is a Class III phosphatidylinositol 3-kinase 
(PI3K).  The PI3K family of enzymes are a family of lipid kinases capable of 
phosphorylating the 3rd hydroxyl on phosphoinositides in cell 
membranes(284).  Vps34 signalling plays a role in membrane trafficking and 
protein sorting pathways.  It is therefore critical for autophagosome formation 
and so pharmacological inhibitors of Vps34 would be permit more specific for 
study of autophagy than other non-specific PI3K inhibitors such as 
Wortmannin and LY294002, which have been used in previous autophagy 
studies but may cause abnormalities in NET formation through the induction 
of apoptosis, rather than by direct affecting autophagy(76,285,286).  
Fluorescence microscopy will also be utilised to image autophagy markers in 
this model.  I hypothesise CF neutrophils will undergo NET formation more 
readily and have increased autophagy, relative to HC neutrophils, and that 
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autophagy inhibitors will inhibit NET formation.  If this hypothesis was 
confirmed, subsequent studies could investigate the potential role of Vps34 
inhibitors in the treatment of the chronic inflammation contributing to CF lung 
disease pathogenesis.  Ultimately, this may lead to a new class of anti-
inflammatory drugs for CF patients.       
 
With regard to the in vitro MDM-neutrophil co-culture model described in 
Chapter 3, there are several ways in which the experimental model could be 
improved.  I only sampled supernatants at 24 hours’ post-co-culture and it may 
be that proinflammatory cytokine production peaks earlier than this(211) and 
so supernatants could be harvested at 0, 6, 12, 18 and 24 hours post co-
culture.  Furthermore, I used a neutrophil:MDM ratio of 2:1 based on our 
group’s previous work(70).  This may not mimic in vivo conditions and so the 
ratio of cells within sputum sample differential cell counts could be calculated 
to inform future experiments.  It might also be worth introducing human 
bronchial epithelial cells into the model, again to better mimic the airway 
environment.  TRIzol-treated co-culture samples could be interrogated using 
RNA sequencing in an attempt to discover which cell signalling pathways are 
responsible for the NET-induced exaggerated inflammatory response seen in 
CF.  I hypothesise that these experiments would reveal upregulation of genes 
involved in the proinflammatory pathways such as NF-κB and MAPK.  This 
would be in agreement with the recently published, elegant study by Carmona-
Rivera et al., who investigated adenosine-induced NET formation and NET-
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macrophage interactions in the context of a genetic, systemic vasculitis called 
Deficiency of adenosine deaminase 2 (DADA2)(287).  The authors carried out 
in vitro co-culture experiments, similar to those performed in Chapter 3, 
between NETs and macrophages; contact of NETs with macrophages 
activated NF-κB translocation to nuclei of the macrophages and led to their 
production and release of proinflammatory cytokines, including TNF-α(287).  
Given that NETs have at least 24 associated proteins incorporated onto their 
chromatin backbone, it is probable that numerous pathways will be implicated 
in the CF MDM hyper-inflammatory phenotype.  To determine which of these 
NET proteins are the most inflammatory to MDM, experiments in which the 
major protein constituents of NETs (e.g. histones, NE, MPO, calprotectin, and 
LL37) were blocked with neutralising antibodies in the NETs/MDM co-culture 
model would be informative, measuring proinflammatory cytokine production 
to characterise responses.  
 
Regarding the CF mouse model used in Chapter 4, the LPS-mediated acute 
lung injury (ALI) experiments require a PBS control experiment in which BAL 
fluid NETs are quantified using our in-house ELISA.  I would hypothesise that 
the airway neutrophils from PBS-treated animals would not undergo NET 
formation, which when contrasted to results from the LPS-mediated ALI 
experiments, would confirm or refute our hypothesis that LPS induces in vivo 
NET formation in a murine CF model.  Admittedly, the CF mouse model has 
its limitations because the mice do not develop spontaneous post-natal lung 
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disease and so do not closely model the human disease.  However, such 
experiments remain an important adjunct to clinical studies, in which drug 
treatments, in particular, can be tested prior to being introduced to human 
participants.   
 
Going forward, a chronic inflammation model could be established, using 
CFTR-/- and WT mice, to better represent human CF lung disease.  In view of 
my findings, the focus will likely shift away from NET formation and towards 
whether RAGE-dependent AMPK activation and subsequent autophagosome 
formation is the driving mechanism underlying the exaggerated inflammatory 
response seen in CF mice.  Western blot and RT-PCR could be used to study 
the protein and gene expression of relevant proteins (e.g. RAGE, AMPK, 
Vps34, and LC3) in in vitro mouse and human bronchial epithelial cell lines, as 
well as ex vivo mouse airway innate immune cells from CFTR-/- and WT mice.  
Such studies could also be performed on ex vivo human lung tissue to provide 
further evidence that autophagy is implicated in the inflammation 
characterising CF lung disease(199).      
 
Murine alveolar macrophages from WT and CF murine BAL fluid could also be 
used to extend the SERS-based nanosensor experiments in the future.  
Alveolar macrophages could be isolated by flow sorting (using Siglec-F as a 
macrophage marker) from BAL samples.  The isolated alveolar macrophages 
would be incubated with MBA-NP as described in Chapter 5 to permit 
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quantification of their phagolysosomal pH using Raman spectroscopy.  We 
hypothesise that, in line with the data from human MDM phagolysosomal pH 
experiments, there will be no acidification defect in CF murine alveolar 
macrophages.  This would have implications for CF patients because it might 
highlight that macrophage phagolysosomal acidification should not be a target 
for new therapies in CF.     
 
Ultimately, to permit extrapolation of results to our CF population, we need to 
perform the SERS-based nanosensor experiments using human alveolar 
macrophages from HC and CF participants obtained via BAL.  With regard to 
the CF cohort, this would permit the study of cells that are likely to have 
ingested bacteria, which may have an effect upon phagolysosomal maturation.  
In addition to this, HC alveolar macrophages could be cultured with SERS-
based nanosensors alone or in combination with nanosensors in addition to 
bacteria that which commonly colonise/infect the lungs of CF patients (e.g. 
P.aeruginosa, H.influenzae, S.aureus, B.cepacia) then Raman spectroscopy 
used to quantify pH.  It may be that the presence of bacteria affects 
phagolysosomal pH.  It has been shown that bacteria have numerous 
mechanisms by which to evade phagocytosis-mediated degradation via 
inhibition of acidification (e.g. Mycobacterium tuberculosis prevents 
accumulation of vacuolar ATPase on phagolysosomal membranes(239,288)).  
Thus, I hypothesise that in the presence of internalised bacteria, the alveolar 
macrophage phagolysosomes will not fully acidify or will do so more slowly. 




It would also be important to confirm whether CFTR is present in these human 
alveolar macrophages and expressed on their phagolysosomal membranes; 
we cannot surmise that acidification is CFTR-dependent/-independent if we 
have not shown the protein to be present within the system.  CFTR 
identification could be done by total cellular protein extraction from alveolar 
macrophages then using an anti-CFTR antibody for subsequent western blot 
analysis.  Fluorescence microscopy using anti-CFTR antibodies, as used by 
Su et al.(211), would also permit imaging of CFTR localisation to the 
phagolysosomal membrane.  I would predict that CFTR is present within 
macrophages, in line with previous reports(19–21,124,219) and located to the 
phagolysosomal and plasma membranes.  These future experiments would 
provide further evidence that SERS-based nanosensors represent a new tool 
with which to investigate phagolysosomal acidification in live cell systems. 
 
Conclusions 
The data presented in this thesis show that neutrophils and NETs are key 
regulators of airways inflammation in CF lung disease.  Within the CF airways, 
neutrophils accumulate and undergo NET formation, which is associated with 
inflammation and subsequent lung function decline.  These data suggest that 
DNase either inhibits NET formation or aids in the clearance of NETs through 
their fragmentation and thus could represent a prophylactic therapy for 
paediatric patients, rather than being introduced only once lung disease is 
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established.  Furthermore, the data suggests that macrophage 
phagolysosomal acidification is CFTR independent and so other factors must 
be responsible for the bacterial killing defect of CF macrophages.  Future 
research will focus on 1) whether there is enhanced autophagy in CF 
neutrophils and whether this affects NET formation, and 2) whether SERS-
based nanosensors can be used to measure alveolar macrophage 
phagolysosomal pH, in both the presence and absence of bacteria.  Ultimately, 
we hope our research will contribute to the discovery of new drug targets in CF 
lung disease, with the overall aim of improving the quality of life and increasing 
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Appendix 1: Genotyping of Murine Ear Clippings by qPCR for 
Cftrtm1UncTg(FABPCFTR)1Jaw/J. 




ddH20 - 4.00 
PCR buffer 6.00 x 1.00 
dNTP 0.20 mM 0.96 
Primer CF common (E00246F11 (F11)) 100 µM 0.25    
Primer CF Mutant (E00246F12 (F12)) 
 
100 µM 0.25 
Primer Transgene (FABPCFTR) Forward 
(E00246G02 (G02)) 
100 µM 0.25 
Primer Transgene (FABPCFTR) Reverse 
(E00246G03 (G03)) 
100 µM 0.25 
gDNA - 1 
Taq polymerase - 6.25 
Table A1: PCR screening reagents for murine 
Cftrtm1UncTg(FABPCFTR)1Jaw/J genotyping.  Primers (Invitrogen (USA), 





Step Temperature (˚C) Time 
1 95 2 min 
2 95 30 sec 
3 52 45 sec 
4 72 45 sec 
5 Repeat steps 2-4 for 30 
cycles – more for 
backcrossed animals as 
transgene is lost at ~ 50
- 
6 72 10 min 
Table A2: PCR reaction conditions for murine 
Cftrtm1UncTg(FABPCFTR)1Jaw/J genotyping.  Lauren Melrose conducted 
PCRs.  They were conducted using a C1000 Touch™ cycler (Bio Rad, UK).  
Products were subsequently run on a 1.0% agarose (SLS, UK) gel.  Expected 
weights using the above primers: CF Mutant 357 bp; CF Het 357 bp and 562 





Appendix 2: U-PLEX® Biomarker Group 1 (Mouse) Analyte 
concentrations 









Calibrator (vol. = 






IFN-ɣ 3600 14 400 2880 
IL-1β 16 250 65 000 13 000 
IL-17A 2 650 10 600 2120 
IL-23 23 875 95 500 19 100 
MCP-1 1625 6500 1300 
MIP-2 2550 10 200 2040 
IL-6 20 000 80 000  16 000 
IL-10 28 500 114 000 2 800 
TNF-α 7688 30 750 3150 
KC 2800 11 200 2240 





Appendix 3: Murine Lung NET Immunohistochemistry 
Sodium Citrate Buffer for Murine Lung Immunohistochemistry Antigen 
Retrieval  
10 mM Sodium Citrate Buffer and 0.05% Tween, pH 6 
Tri-sodium citrate dehydrate 2.94 g 
dH2O 1000 mL 
HCl add until pH 6 
Tween-20 0.5 mL 
 
Primary Antibodies 
Target Description Dilution Manufacturer 
S100A9 Rat anti-mouse 
monoclonal (MAB2065) 
1:100 R&D Systems 










Alexa Fluor 568 
Goat anti-rat IgG 
(A11077) 




Alexa Fluor 488 
Goat anti-rabbit IgG 
(A11034) 
1:300 Invitrogen, Thermo Fisher 
Scientific 
Goat Serum Dilutions 
25% goat serum for blocking slides: made by mixing 500 µL goat serum with 1500 µL 
DPBS.  10% goat serum for antibody dilution: made by mixing 1700 µL 25% goat 




Appendix 4: [3H]-PK11195 Autoradiography Reagents 
 
50 mM Tris-Base buffer (pH 7.4) 
1) MW Trizma Base = 121.14 
2) Volume H₂O: 5L 
3) Weight of compound: 30.285g 
4) Adjusted pH (HCl): ~17.6 mL 
 
10µM PK11195 Displacer preparation 
1) MW PK11195 = 352.86 
2) Stock 15mM = 2.65 mg + 500 µL 100% Ethanol 
3) Stock 800µM = 53.3µL of 15mM stock + 946.7 µL 100% Ethanol 
4) 10µM PK11195 = 625µL of 800µM stock + ~50mL Tris-Base Buffer 
( 1.25% total Ethanol content) 
 
[3H]-PK11195 solution: 
5mL stock [3H]PK (PerkinElmer) added to 300 mL buffer and mixed well then 
20 µL of this diluted stock was further diluted in 2.5 mL Scintillation Cocktail in 
a PicoPrias glass vial to check concentration using a Hidex Scintillation 






Appendix 5: cDNA generation and RT-PCR Analysis 
 
2X Reverse Transcription Master Mix 
Reagent Volume per sample (µL) 
Buffer 2 
dNTP Mix (100 mM) 0.8 
10X random primers 2 
Multiscribe™ Reverse transcriptase 1 
RNase inhibitor 1 
Nuclease-free water 3.2 
 
Primer Probes – PrimeTime® qPCR Assays 











Appendix 6: Murine Lung Lysis Buffers  
Laemmli Buffer   
0.5 M Tris HCl pH 6.8 250 µL 1.25 mL 
100% Glycerol 200 µL 1 mL 
10% SDS 400 µL 2 mL 
Complete inhibitors (Roche 04693159001) 1 tablet in 
2mL 
400 µL 2 mL 
Phosphatase inhibitors (Roche 04906845001) 1 tablet in 
500 µL 
100 µL 500 µL 
H2O 650 µL 3.25 mL 
Final volume 2 mL  10 mL 
The additional protease inhibitor Phenylmethylsulfonyl fluoride (PMSF) was 
added to complete Laemmli buffer to a final concentration of 1 mM. 
 
SDS Lysis Buffer    
Stock Concentration Target Concentration To Add 
 Molarity %  
DTT 1 M 0.2  308.5 mg 
SDS 20%  4 2 mL 
Glycerol 100%  20 2 mL 
Tris-HCl pH 6.8 0.1  2 mL 
Bromophenol Blue 2%  0.04 0.1 mL 
Protease inhibitor cocktail   0.2 mL 
H2O   3.7 mL 







Appendix 7:  Immunoblot for Protein Expression: Gels, Buffers 
and Primary Antibody Dilutions 
 
SDS-PAGE gels: for 1.5 mm gel plates 
Stacking Gel Volume to be added for two gels 
Water 6 mL 
40% Acrylamide 1240 µL 
0.5 M Tris pH 6.8 2520 µL 
20% SDS 50 µL 
20% APS 100 µL 
TEMED 10 µL 
 
Resolving Gel Volume to be added for 10% gel 
Water 7.2 mL 
40% Acrylamide 3.8 mL 
1.5 M Tris pH 6.8 3.8 mL 
20% SDS 75 µL 
20% APS 150 µL 
TEMED 6 µL 
 
Running Buffer 
10X Running Buffer  
Glycine 190 g 
Tris Base 30.3 g 
20% SDS 50 mL 
dH2O to final volume of one litre 





10X Transfer Buffer  
Glycine 145 g 
Tris Base 29 g 
dH2O to a final volume of 800 mL 




10X TBS-Tween   
Tris-HCl 1M pH 8.0 100 mL 
NaCl 97.3 g 
dH2O to a final volume of 1000 mL 
Tween-20 5 mL 







Description Dilution Manufacturer 
RAGE 43 Rabbit monoclonal 
(ab181293) 
1:5000 Abcam 








Appendix 8: Supplementary murine BALF cytokine results 
 
Figure A8a: Murine BALF cytokine concentrations 24 hours’ post-LPS in WT 
and CFTR-/- mice.  Filled bars = WT, non-filled = CFTR-/-.  There were no significant 
differences in either genotype or treatment group in the levels of  IFN-ɣ (A), IL-23 (B), 
KC (C), IL-1β (D), MIP-2 (E) and MCP-1 (F).  Data analysed by two-way ANOVA with 
Tukey’s multiple comparisons test.  Data represents individual points and mean ± SD.  





Figure A8b: Murine BALF cytokine levels at 24 and 72 hours’ post-LPS in 
WT and CFTR-/- mice.  (A-D) IL-6, TNF-α, IL-17 and IL-10 concentrations were 
all significantly higher in CF mice compared to WT littermates at 24 hours’ post 
LPS.  DNase did not affect cytokine levels.  However, by 72 hours’ post-LPS, 
all of these cytokines had fallen to near undetectable levels.  P-values shown 
are for time point differences analysed by two-way ANOVA with Tukey’s 
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Neutrophil extracellular traps 
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